Logo Jan Blom
Login

Oncologisch onderzoek.nl

rss icon

Nieuws


TitelCommentaren Datum Auteur
Fase 1-studie van gedatolisib met paclitaxel en carboplatine voor gevorderde solide tumoren (0)2021-07-16 14:00
Evenwichtsstoornis, vestibulaire dysfunctie, en overleving van maligniteiten (0)2021-07-16 13:01
Overall survival resultaten van LOTUS-studie van eerstelijns ipatasertib plus paclitaxel voor gevorderd TNBC (0)2021-07-16 12:01
Gerandomiseerde fase 2-studie van toevoegen van CMB305 aan atezoluzimab voor STS met expressie van NY-ESO-1 (0)2021-07-15 15:00
Impact van eerdere ICI-behandeling op werkzaamheid van dacarbazine voor metastatisch melanoom (0)2021-07-15 14:00
Impact van leeftijd op uitkomsten van hoge-dosering chemotherapie en transplantatie voor recidiverende GCTs (0)2021-07-15 13:00
Intention-to-treat profijt van levende-donor levertransplantatie voor levercelcarcinoom in wachtlijstpatiënten (0)2021-07-15 12:00
Bevolkings-gebaseerde studie van wereldwijde aan alcoholgebruik toe te schrijven maligniteiten in 2020 (0)2021-07-14 15:00
Intellectueel functioneren van kinderen na protonen- of fotonenradiotherapie voor standaard-risico medulloblastoom (0)2021-07-14 14:00
Associatie tussen vermoeidheid en uitkomsten van gevorderde maligniteiten: analyse van vier SWOG-studies (0)2021-07-14 13:00
Multinationale fase 2-studie van eerstelijns bempegaldesleukine plus nivolumab voor metastatisch melanoom (0)2021-07-14 12:00
Model voor identificeren van patiënten met mogelijke verandering van behandelkeuze na 21-gene recurrence score testing (0)2021-07-13 15:00
Gecombineerde analyse van twee fase 1-studies van romidepsine- en lenalidomide-gebaseerde regimes voor R/R lymfoom (0)2021-07-13 14:00
CEA-toename als marker van ziekteprogressie na eerstelijns inductietherapie voor metastatisch colorectaalcarcinoom (0)2021-07-13 13:00
Fase 2-studie van perioperatief durvalumab plus neoadjuvante chemotherapie voor stadium IIIA(N2) NSCLC (0)2021-07-13 12:00

Tags

'gunstig hoog-risico'  “one thousand HER2 patients” project  (chemo)endocrine therapy  [11C] docetaxel  [18F]paclitaxel  %FT  1-day multidisciplinary clinic  1-year versus shorter duration of adjuvant trastuzumab  10-year outcomes  10-year recurrence  15-hydroxyprostaglandinedehydrogenase  15-PGDH  16K PRIL  16q23  1703-studie  18F-FDG opname  18F-fluciclovine-PET CT  1975-2016  1980-2017  1988-2017  1990 to 2017  1990-2017  1997-2016  1p 19q co-deleted oligodendroglioma  1p 19q codeleted oligodendroglioma  1p 19q non-co-deleted anaplastic glioma  20-year follow-up  2003-2007 versus 2013-2017  2006-2016  2006-2019  2008-2018  2010-2016  2018 FIGO stage IIIC SCC of the cervix  2020 UK post-polypectomy surveillance guidelines  2021 cancer mortality prediction in EU and UK  21-gen recurrence score assay  21-gene assay and breast cancer mortality  21-gene assay recurrence score  21-gene expression assay  21-gene recurrence score  21-gene recurrence score and BCSS  21-gene RS and response to neoadjuvant chemotherapy  25-hydroxyvitamin D  25-OH-D level at time of diagnosis  27-hydroxycholesterol  28-year risk of lung cancer  3 versus 1 year adjuvant imatinib  3 versus 6 months adjuvant chemotherapy  3 vs. 6 months oxaliplatin-based adjuvant chemotherapy  321GO  3D brachytherapy  3DCRT  4 Gy versus 24 Gy radiotherapy  45 and Up Study  4EVER trial  4L lymph node dissection  5-ARIs  5-fraction whole-breast radiotherapy  5-FU  5α-reductase inhibitors  6-MP plus methotrexate  70-GS  8-OHdG  90101 CREATE-studie  90YIT  91-maands update van CALGB 100104-studie  A.R.R.O.W-studie  A041202 study  AAC  AACR  AACR 2015  AACR Academy  AAML0531 trial  AAML1421 study  AAP  AB12005 study  abatacept for prevention of acute GVHD  ABC-06 trial  ABCB1 genetic variants  ABCSG 8A trial  ABCSG-18 study  abdominal and gluteofemoral size  abdominal radiation for childhood cancer; subsequent risk of diabetes  abemaciclib  abemaciclib plus fulvestrant for MBC  Abi Race studie  abirateron  abiraterone  abiraterone for prostate cancer  ablatieve behandeling  ablative radiation therapy  ablative therapy after TACE for HCC  abnormale peritoneale cytologie  ABOUND.2L+ study  ABP plus gemcitabine  abscopal effect  ABSI  ABSOLUTE  absolute dense area  absolute lymphocyte count  absolute lymphocyte count at diagnosis  absoluut neutrofielgetal  ABT-199  ABTC  ABVD  ABVD versus BEACOPP-escalated  acalabrutinib  acalabrutinib monotherapy  acalabrutinib versus ibrutinib  ACC  accelerated cellular senescence after chemotherapy  accelerated partial breast irradiation  ACCENT database analysis  access to anticancer medicines for children and adolescents in Europe  ACCRU study SC-1603  accrual  ACE  ACE inhibitors versus ARBs  ACE study  ACE-LY-004 studie  ACES  acetaminophen  ACHIEVE study  acid-suppressive medication  acne  ACOSOG Z0011  ACP statement  acquired resistance to osimertinib  acraal melanoom  ACRIN 6686-studie  acromegaly  AcSé phase 2 study  AcSé study  ACT  ACT-2 trial  Act.In.Sarc study  actieve surveillance  ACTIM  actinic keratosis  actinisch carcinoom  actionability  active cancer  active melanoma brain metastases  ACTIVE study  active surveillance  active surveillance for low-risk prostate cancer  active surveillance for prostate cancer  activering immuunsysteem  ACTs  acupuncture  acupuncture for aromatase inhibitor-related joint pain  acute cancer-associated venous thromboembolism  acute care use after initiation of systemic cancer therapy  acute graft-versus-host disease  acute GVHD  acute kidney injury  acute leukemia  acute leukemie  acute lymfoblastische leukemie  acute lymphoblastic leukemia  acute myeloid leukemia  acute myeloïde leukemie  acute promyelocytische leukemie  acute promyeolcytische leukemie  acute toxicity  AD-risico  adagrasib  ADAM-studie  ADAM8  ADAMTS-mutaties  ADAPT-studie  adaptive immune resistance  adaptive randomization  ADAURA study  adavosertib  ADC as response marker  ADC versus SCC  ADCs  adding durvalumab and olaparib to chemotherapy  adding gemcitabine to adjuvant chemotherapy  adding MRI and biomarkers  adding OFS to tamoxifen  addition of adjuvant capecitabine to standard chemotherapy  addition of androgen deprivation therapy or brachytherapy boost  addition of arsenic trioxide to frontline treatment  addition of bortezomib to melphalan and dexamethasone  addition of carboplatin to neoadjuvant chemotherapy  addition of celecoxib to adjuvant FOLFOX for stage III colon cancer  addition of chemotherapy to local therapy  addition of chemotherapy to neoadjuvant radiotherapy  addition of concurrent hypo-fractionated RT to failing anti-PD-1 therapy  addition of COX inhibition to immune checkpoint blockade  addition of daratumumab to lenalidomide plus dexamethasone  addition of lenalidomide to R-CHOP  addition of ramucirumab to docetaxel  additional cytogenetic abnormalities  additional immune modulators  ADEBAR  ademanalyse  ademtest  adenocarcinoma of the small intestine  adenocarcinoom  adenoma detection rate  ADH  adherence  adherene to adjuvant endocrine therapy  adherentie  adherentie AET  adherentie orale chemotherapie  adipose tissue distribution  adipositas  adiposity and survival  adjuvant abemaciclib plus endocrine treatment  adjuvant and concurrent TMZ  adjuvant anti-PD-1 therapy  adjuvant aromatase inhibitor  adjuvant aspirin for cancer  adjuvant bevacizumab  adjuvant capecitabine  adjuvant carboplatin plus taxanes versus EC followed by taxanes  adjuvant care  adjuvant chemotherapy  adjuvant chemotherapy after pCR to neoadjuvant CRT  adjuvant chemotherapy for breast cancer  adjuvant chemotherapy regimens  adjuvant CRT  adjuvant dabrafenib plus trametinib for stage III melanoma  adjuvant dabrafenib plus trametinib versus placebo for BRAF V600-mutated stage III melanoma  adjuvant denosumab  adjuvant docetaxel-based chemotherapy for early breast cancer  adjuvant endocrine therapy  adjuvant erlotinib for early-stage NSCLC  adjuvant ET ± CT  adjuvant ET with or without abemaciclib  adjuvant etoposide plus cisplatin  adjuvant FOLFIRINOX versus gemcitabine  adjuvant FOLFOX FLOX  adjuvant gefitinib versus chemotherapy  adjuvant icotinib versus chemotherapy  adjuvant imatinib  adjuvant ipilimumab  adjuvant ipilimumab versus IFNα-2b  adjuvant metronomic capecitabine  adjuvant multimodality therapy  adjuvant nivolumab versus placebo  adjuvant nivolumab vs ipilimumab  adjuvant olaparib  adjuvant osimertinib  adjuvant paclitaxel and carboplatin versus CEF-T  adjuvant pembrolizumab  adjuvant pemetrexed plus cisplatin versus vinorelbine plus cisplatin  adjuvant radiation  adjuvant radiation therapy  adjuvant radiotherapy  adjuvant RT  adjuvant RT for breast cancer  adjuvant S-1  adjuvant S-1 plus endocrine therapy  adjuvant S-1 with or without docetaxel  adjuvant SCRT versus CCRT or RT alone  adjuvant sorafenib  adjuvant therapy  adjuvant TLPLDC vaccine  adjuvant transarterial FOLFOX infusion  adjuvant trastuzumab  adjuvant trastuzumab duration  adjuvant trastuzumab for HER2-positive breast cancer  adjuvant treatment  adjuvant treatment for breast cancer  adjuvant treatments  adjuvant versus early salvage radiotherapy after prostatectomy for prostate cancer  adjuvant versus salvage radiotherapy  adjuvant weekly docetaxel plus radiotherapy  adjuvant XT-XEC versus T-FEC  ADJUVANT-studie  adjuvante chemotherapie  adjuvante CRT  adjuvante HER2-remming  adjuvante hormoontherapie  adjuvante systemische therapie  adjvant trastuzumab with or without chemotherapy  adjvuant chemotherapy versus chemoradiotherapy  ADMIRAL study  ADMIRAL trial  ADNEX  ado-trastuzumab emtansine  adolescent and young adult  adolescent and young adult cancer survivors  adolescent and young adult HL  adolescent overweigh or obesity  adolescents and young adults  adoptive T-cell therapy  ADORE trial  ADR  adrenal metastases  adrenocortical carcinoma  ADRRAD study  ADT  ADT for prostate cancer  ADT plus pelvic RT plus radium-223  ADT risk of depression  adult alternative donor HCT  adult cancers  adult glioma  adult glioma risk  adult height  adult survivors of childhood ALL  adult survivors of childhood cancer  adult survivors of childhood cancer diagnosed between 1970 and 1999  adult survivors of neuroblastoma  adult T-cell leukemia lymphoma  adult type granulosa cell tumors of the ovary  adult weight gain  advanced adrenocortical carcinoma  advanced ALK-positive NSCLC  advanced ALK-positive or ROS1-positive NSCLC  advanced anal cancer  advanced anal squamous cell carcinoma  advanced anthracycline-naive sarcoma  advanced B-RAF- or K-RAS N-RAS-mutated solid tumors  advanced biliary tract cancer  advanced biliary tract cancers  advanced BRAF-mutated melanoma  advanced BRAF-V600 mutated melanoma  advanced breast cancer  advanced BTC  advanced cancer  advanced cancer-related chronic nausea and vomiting  advanced cancers  advanced carcinoid or pancreatic neuroendocrine tumor  advanced ccRCC  advanced chondrosarcoma  advanced chordoma  advanced CLDN18.2 positive gastric cancer  advanced clear cell RCC  advanced colorectal liver metastases  advanced CRPC  advanced EGFR T790M mutated non-small cell lung cancer  advanced EGFR-mutant NSCLC  advanced EGFR-positive non-squamous NSCLC  advanced endometrial cancer  advanced epithelial ovarian cancer  advanced epithelioid sarcoma with loss of INI1 SMARCB1  advanced esophageal cancer  advanced esophageal squamous cell carcinoma  advanced esophagogastric cancer  advanced extraskeletal myxoid chondrosarcoma  advanced G GEJ cancer  advanced gastric cancer  advanced gastric or colorectal cancer  advanced gastric or gastroesophageal junction adenocarcinoma  advanced gastric or gastroesophageal junction cancer  advanced gastroesophageal cancer  advanced gastrointestinal cancer  advanced gastrointestinal stromal tumors  advanced germ cell tumors  advanced GIST with KIT or PDGFRA mutation  advanced HCC  advanced hepatocellu;ar carcinoma  advanced hepatocellular carcinoma  advanced hepatocellular carcinoma after progression on anti-PD-(L)1  advanced hepatocellular carcinoma with MET overexpression  advanced HL with large nodal mass  advanced HN CSCC  advanced HNSCC  advanced Hodgkin lymphoma  advanced HR-positive breast cancer  advanced indolent lymphoma  advanced leiomyosarcoma liposarcoma  advanced liver cancer  advanced lung cancer  advanced MDS in elderly patients  advanced melanoma  advanced melanoma in patients not represented in phase 3 trials  advanced Merkel cell carcinoma  advanced metastatic medullary thyroid carcinoma  advanced microsatellite instability-high cancers  advanced MPM  advanced mucosal melanoma  advanced non-clear cell RCC  advanced non-clear cell renal cell carcinoma  advanced non-clear-cell RCC  advanced non-small cell lung cancer  advanced non-squamous non-small cell lung cancer  advanced non-squamous NSCLC  advanced nonsquamous non-small cell lung cancer  advanced nonsquamous NSCLC  advanced nonsquamous NSCLC in elderly patients  advanced NSCLC  advanced NSCLC harboring KRAS G12C mutation  advanced NSCLC in special populations  advanced NSCLC or CRC  advanced NSCLC with T790M mutated EGFR  advanced or metaastatic colorectal cancer  advanced or metastatic colorectal cancer  advanced or metastatic CRC  advanced or metastatic thymic carcinoma  advanced or metastatic urothelial carcinoma  advanced or recurrent endometrioid endometrial cancer  advanced or refractory desmoid tumors  advanced ovarian cancer  advanced ovarian cancer in patients with BRCA-mutation  advanced ovarian carcinoma  advanced ovarium neoplasms  advanced pancreas cancer  advanced pancreatic cancer  advanced papillary renal cell carcinoma  advanced PDAC  advanced prostate cancer  advanced pulmonary sarcomatoid carcinoma  advanced rare cancers  advanced rare genitourinary malignancies  advanced RCC  advanced recurrent ovarian cancer  advanced refractory biliary tract cancer  advanced refractory CRC  advanced refractory esophageal squamous cell carcinoma  advanced renal cell carcinoma  advanced renal-cell carcinoma  advanced ROS1 fusion-positive non-small cell lung cancer  advanced salivary gland carcinoma  advanced sarcoma  advanced soft-tissue sarcoma  advanced solid cancers  advanced solid HER2-positive tumors  advanced solid malignancies  advanced solid tumors  advanced solid tumors with KRAS-G12C mutation  advanced squamous non-small cell lung cancer  advanced squamous NSCLC  advanced stage iNHL  advanced stage serous borderline ovarian tumor  advanced STS  advanced systemic mastocytosis  advanced thymoma  advanced triple-negative breast cancer  advanced UC  advanced urological cancers with pre-existing autoimmune disorders  advanced urothelial cancer  advanced urothelial carcinoma  advanced USC with HER2 overexpression  advanced wild-type BRAF melanoma  advanced-stage cancer  advanced-stage Hodgkin lymphoma  advanced-stage Hodgkin’s lymphoma  advanced-stage orophryngeal squamous cell carcinoma  Adventist cohort compared with a US Census popiulation  adverse events  adverse mental health outcomes  ADVL1412 study  aerobe inspanning  aerobic and resistance exercise  aerobic exercise during chemotherapy  afami-cel  afatinib  afatinib versus methotrexaat  AFFIRM  AFFIRM-studie  aflibercept  AFUGEM GERCOR  AGC  age  age at diagnosis  age at diagnosis of colorectal cancer  age at menarche  age at onset of lung adenocarcinoma  age dependence of modern clinical risk groups  age disparities  age-specific BMI  agent orange  AGES-Reykjavik study  aggressive lymphoma  aggressive prostate cancer  aggressive versus non-aggressive prostate cancer  AGITG MAX study  AGO-OVAR 16-studie  agressieve fibromatose  agressive squamous cell carcinoma  AGRICAN-studie  aGVHD  aHCC  AHELP study  AHEP0731 study  AHL2011 study  AHOD1221 study  AI  AI-induced arthralgia  AI-therapie  AIC  AIO-FLOT3 studie  airport-related ultrafine particles  AJCC 8th edition stage III melanoma  AJCC CSM-8  AJCC eighth edition staging  AL amyloidosis  AL-amyloïdose  ALBI  ALCANZA-studie  ALCL  aLCNEC  alcohol  alcohol and tobacco consumption  alcohol consumption  alcohol consumption and cancer risk in Australia  alcohol intake  alcoholconsumptie  alcoholgebruik  ALCYONE trial OS analysis  ALCYONE-studie  aldoxorubicine  alectinib  alectinib for crizotinib-resistant ALK-positive NSCLC  alectinib versus crizotinib  ALEX study  ALEX study PRO analysis  ALEX-studie  ALFA-0701 trial  ALFA0701 trial  ALiCCS studie  ALiCCS study  ALiCCS-studie  alisertib  alisertib plus induction chemotherapy  ALK inhibitors  ALK inhibitors for NSCLC with ALK-rearrangement  ALK rearranged or ROS1 rearranged NSCLC  ALK-positive non-small cell lung cancer  ALK-positive NSCLC  ALK-rearranged nonlung solid tumors  ALK-rearranged NSCLC  ALK-remmer  ALK(+) and ROS1(+) NSCLC  ALK1  alkaline phosphatase  alkylerende chemotherapie  ALL  all-cause and cancer-specific death  all-cause and cardiovascular disease mortality  Alliance A091401-studie  Alliance N0572-studie  ALLIVE-studie  allo-BMT  allo-HSCT  allo-HST  allogene hematopoïetische stamceltransplantatie  allogene stamceltransplantatie  allogeneic BMT in childhood  allogeneic hematopietic cell transplantation  allogeneic hematopoietic cell transplant  allogeneic hematopoietic cell transplantation  allogeneic hematopoietic cell transplantation outcomes  allogeneic HSCT  allogeneic stem cell transplantation for AML or ALL  allogeneic stem cell transplantion  allogeneic transplantation for myelodysplastic syndrome  allogenic transplant for NHL  alloHCT  alloHCT after PD-1 blockade  alloHCT for myelofibrosis  alloHCT recipients  alloHCT with CB versus MMUD with PTCy  alloHSCT  alloHSCT for myelofibrosis  alloHSCT for pediatric ALL  alloHSCT in women  alloSCT  almonertinib  ALND  alopecie  alpelisib  alpelisib plus fulvestrant  alpelisib plus nab-paclitaxel  alpha-fetoprotein  ALTA-1L  ALTA-1L second interim analysis  ALTA-studie  ALTER 01031 study  ALTER 0303 study  alternative cisplatin schedule  ALTERNATIVE study updated results  ALTERNATIVE-studie  ALTTO study sub-analysis  ALUR-studie  alveolar soft-part sarcoma  alvleesklierkanker  AM  Amara West  AMATERASU trial subgroup analysis  ambulatory function and mortality among cancer survivors  aMCC  AMD  American Association for Cancer Research  American Cancer Society richtljnen  AMG 337  AMH  AML  AML in elderly nonfit patients  AML in older adults  AML MDS  AML MDS in older patients  AML or high-risk MDS  AML or MDS  AML with FLT3-ITD mutation  AML with genomic evidence of residual disease  AML with internal tandem duplication of Fms-like tyrosine kinase 3  AML-relapse after allo-HCT  AML-risico  AML17-studie  AMLSG 09-09 study  aMM  AMPK variant  AMPK-route  AMPLCaRE study  AMPLE-2 study  amrubicine  analgesic use  analgesics  analgetica  analyse AZURE-studie  analyse binnen PICCOLO-studie  analyse CheckMate 205-studie  analyse COG AAML 1031  analyse CROSS-studie  analyse fase 3-studie CALGB 40503  analyse fase 3-studie GeparQuinto  analyse MA.27-studie  analyse NORDIC-VII studie  analyse STAMPEDE-studie  Analyse van CheckMate 066 en CheckMate 067  analyse van fase 3-studie CAO ARO AIO-04  analyse van STAMPEDE-studie  anamorelin  anaplastic astrocytoma or glioblastoma  anaplastic large-cell lymphoma  anaplastic thyroid carcinoma  anaplastisch grootcellig lymfoom  anaplastisch schildkliercarcinoom  anastrazole with or without fulvestrant  anastrozol  anastrozole  and HIV infection  and rituximab  and time already survived  androgeendeprivatie  androgeenreceptor  androgeensuppressie  androgen concentrations in prepubertal girls  androgen deprivation for FIR versus UIR prostate cancer  androgen deprivation therapy  androgen deprivation therapy for prostate cancer  androgen receptor expression  androgen receptor signaling inhibitor  anesthesia  anesthesiologist volume  anetumab ravtansine  aneuploïdie  ANG1005  angiogenese  angiosarcomen  angiosarcoom  angiotensin converting enzyme inhibitors  angiotensin II receptor blockers  ANGPT2  ANGPT2 and NOS3 polymorphisms  animal and plant protein intake  anlotinib  anlotinib versus placebo as third- or further-line treatment  anlotinib versus sunitinib  ANNOUNCE trial  anoikis-resistentie  anorexia nervosa  anorexie  anosmin-1  aNSCLC  aNSCLC with PD-L1 at least 50%  antacida  anterior temporal lobotomy  anthracycline chemotherapie  anthracyclines  anthracylcines  anti-angiogene middelen  anti-angiogenese  anti-B-cell maturation antigen BiTE molecule AMG 420  anti-CD19 and anti-BCMA CAR T-cells  anti-CD19 CAR T-cell therapy  anti-CD19 CAR T-cells  anti-CD22 CAR T-cells  anti-CD30 CAR-T cell therapy  anti-CTLA-4 plus anti-PD-1 blockade  anti-diarrheal strategies  anti-EGFR  anti-EGFR therapy for metastatic colorectal cancer  anti-HER2 therapy  anti-HER2 therapy for MBC  anti-Hu  anti-humaan T-lymfocyt immunoglobuline  anti-PD-(L)1 for advanced NSCLC  anti-PD-(L)1 monotherapy resistant metastatic melanoma  anti-PD-(L)1 therapy  anti-PD-1  anti-PD-1 antibodies plus RT  anti-PD-1 immunotherapy for MSS solid tumors  anti-PD-1 L1  anti-PD-1 monotherapy  anti-PD-1 PD-L1 based regimes in advanced solid tumors  anti-PD-1 related pneumonitis  anti-PD-1 therapy  anti-PD-1 therapy for advanced melanoma  anti-PD-1 therapy for solid tumors  anti-PD-1 vs anti-PD-L1 for cancer  anti-PD1 with or without anti-CTLA4  anti-programmed cell death 1 therapy  Anti-T-lymfocten globuline  anti-thymocyte globulin  anti-TNF for steroid refractory toxicity  anti-VEGF therapie  anti-VGEF therapie  antiangiogenese  antibiotic use and risk of colorectal cancer  antibiotics  antibodies  antibody-drug-conjugates  anticoagulants and breast cancer survival  anticoagulatie  antihypertensive drugs  antiogeneseresistentie  antioxidant supplements  antioxidanten  antioxidants  antithymocyte globulin  antithymocytenglobuline  antitumor-werkzaamheid van bisfosfonaten  antiviral treatment  anus squameus celcarcinoom  anuscarcinoom  anuskanker  AO AOA  apalutamide  apalutamide for nmCRPC  apalutamide versus placebo for nmCRPC  apatinib  apatinib after failure of chemotherapy  apatinib plus oral etoposide  apatinib plus pemetrexed-platinum chemotherapy  APBI versus WBI  aPC  APHINITY trial 6-year follow-up  APHINITY-studie  API-AI  apixaban  APL  APL in older patients  APOLLO study  APOLLO trial  apoptose  appendixcarcinoom  aprepitant  APT trial  AR expression in breast cancer  AR-expression  AR-remming  AR-V7  ARAMIS study  ARCAD  ARCAD database individual patients analysis  ARCAD-NADEGE cohort study  ARCAGE-studie  aRCC  ARCHER 1050  ARCHER 1050-studie  ARCHES study  ARCTIC study  ARIC-studie  ARIEL3-studie  ARIs for prostate cancer  Aristotle study  ARMD  aRMS  aromatase inhibitors  aromatase inibitor-induced adverse effects  aromataseremmer  aromataseremmers  array comparative genomic hybridization  ARROW study  ARRY-380  arseentrioxide  arsenicum  ARST1321 study  ART  ART-gerichte behandeling  arterial thromboembolism preceding cancer diagnosis  artificial intelligence  artificial intelligence algorithms  ARTIS study  ARTIST 2 study  ARTIST 2 trial  artralgie  ARTSCAN III study  ARv567es  AS04-adjuvanted HPV-16 18 vaccine  ASCC  ASCEMBL study  ASCEND study  ASCEND-2  ASCEND-3 final results  ASCEND-5  ASCEND-5 studie  ASCENT study  ASCENT trial  asciminib  asciminib versus bosutinib  ascites  ASCO  ASCO 2016  ASCT  ASCT versus maintenance chemotherapy consolidation  ASH 2015  Ashkenazi Jewish ancestry  ASILs  asparaginase-associated pancreatitis  ASPECCT  AspECT study  ASPIRE-studie  aspirin  aspirin NSAID use  aspirin use  aspirin use and CRC risk in older adults  aspirine  aspirine NSAIDs  aspirineprofylaxe  ASPREE study  ASPS  assessment of lung cancer risk  assessment of screening mammograms  Assisted reproduction  assisted reproductive technology  associatie diabetes en kanker  association between Alzheimer disease and cancer  association between PFS and QOL  association between previous infection and cancer risk  association of adjuvant chemotherapy with overall survival  association of age with efficacy of immunotherapy  association of BMI with efficacy of ICIs  association of breast cancer risk with type 2 diabetes and metformin use  association of coffee intake and survival  association of ctDNA and CTCs after NAC with disease recurrence  association of cutaneous toxic effects with outcomes  association of depression and anxiety with mortality  association of fatigue and outcomes in advanced cancer  association of fiber intake and breast cancer incidence  association of hearing impairment with neurocognition  association of HPV status with survival  association of intensity and duration of alcohol use and risk of head and neck cancer  association of intrinsic subtype with PFS  association of marital status with cancer-specific survival  association of measurable residual disease with DFS and OS  association of MHT with breast cancer subtypes  association of molecular characteristics with OS benefit  association of neoadjuvant chemotherapy with survival  association of neuronal autoantibodies and cognitive impairment  association of obesity with outcomes of breast cancer subtypes  association of obesity with survival outcomes in patients with cancer  association of pCR with outcomes in breast cancer  association of PD-L1 expression status with efficacy of PD-1 PD-L1 inhibitors  association of performance status with survival  association of periodontal disease and edentulism with cancer mortality  association of physical activity with survival  association of procedure volume and in-house mortality  association of race and socioeconomic factors with OS  association of recent oncologic treatment with mortality  association of RRSO with breast cancer risk  association of sarcopenia with short-term outcomes  association of time-to-treatment initiation and survival  association of use of PET-CT with mortality  association with cancer risk  association with hepatic malignancy  association with lung cancer risk  association with other types of tumors  association with site-specific cancers  association with survival  association with type of treatment  associations of irAEs with clinical outcomes  associations with prostate cancer risk  associations with season of birth  AST  astma  ASTRO 2015  ASTRO 2016  asunercept  asymptomatic brain metastases  asymptomatic early-stage CLL  asymptomatic mCRPC  asymptomatic WM  ASyMS  AT RT  ATBC Study  ATC  ATE  ATEMPT trial  atezolizumab  atezolizumab for urothelial carcinoma  atezolizumab plus bevacizumab  atezolizumab plus nab-paclitaxel  atezolizumab with or without bevacizumab  atezolizumab with or without CMB305  atezolizumab-vemurafenib-cobimetinib  ATG  ATL  ATLANTIC-studie  ATM  ATM mutations in cancer  ATOM study  ATOM trial  atopic dermatitis  atopic eczema and cancer risk  atopie  ATR-blockers  atrial fibrillation  atriumfibrilleren  ATRTs  ATTRACTION-2 studie  ATTRACTION-3 study  atypical breast lesions  atypical bronchopulmonary carcinoids  atypical chronic myeloid leukemia  atypical squamous cell of undetermined signifance  atypical squamous cells of undetermined significance  atypisch meningioom  atypische ductale hyperplasie  atypische hyperplasie  Atypische teratoïde rhabdoïde tumor  atypische teratoïde rhabdoïde tumoren  AUGMENT study  AURA  AURA studies  AURA-studie  AURA-substudie  AURA2  AURA3  AURA3 overall survival analysis  AURA3 study  AURA3-studie  AURELIA  AURELIA-studie  AURELIA-substudie  Aurora A  aurora kinase A inhibition  Australian Melanoma Family Study  auto-immuunziekten  autofagie  autoHCT  autoHSCT  autoimmune disease  autologe stamceltransplantatie  autologous stem cell transplantation  AVAglio  avapritinib  AVAST-M study  AVAST-M trial  AVAST-M trial analysis  avastin  avelumab  avelumab maintenance  avelumab plus axitinib  avelumab versus chemotherapy maintenance  average risk B-ALL in children  AVERT study  AVERT trial  avoiding peg-filgrastim  avoiding unnessecary surgery  axi-cel  axi-cel in the non-trial setting  axicabtagene ciloleucel  axillaire lymfeklierdissectie  axillaire radiotherapie  axillaire status  axillaire ultrasound  axillary dissection  axillary response  axillary surgery and nodal irradiation  axitinib  axitinib plus pembrolizumab  axitinib versus observation  AYA cancer  AYA cancer survivors  AYA-maligniteiten  AYAs  AYAs versus older adults  AZ9291  AZA-MDS-003 study  azacitidine  AZD4547  B-43 trial  B-ALL in CAYAs  B-cel activering  B-cel lymfoom  B-cel maligniteiten  B-cel precursor-ALL  B-cell ALL resistant to CD19 immunotherapy  B-cell lymphoma  B-cell malignancies  B-cell non-Hodgkin lymphoma  B-cellymfoom  B-precursos ALL  B-progenitor acute lymphoblastic leukemia  baarmoederhalskanker  BALLET-studie  BAP1 pathogenic variant carriers  bariatric surgery  bariatric surgery in French obese patients  bariatrische chirurgie  Barrett esophagus  Barrett slokdarm  Barrett-slokdarm  Barrett's esophagus  Barrett's slokdarm  Barrett’s oesophagus  basaalcelcarcinoom  basal-like mammacarcinoom  Baselga  baseline factors associated with response  baseline metabolic tumor volume as predictive and prognostic biomarker  basline plasma tumor mutational burden  bassi  BAT  BAY1436032  bb2121  BBB  BBD  BBD-BC  BCBM  BCC  BCCs  BCCSS  BCG  BCG vaccination in childhood  BCG-unresponsive non-muscle-invasive bladder cancer  BCIN+  BCIS  Bcl-2  BCL2 expression  BCMA-targeted CAR-T cell therapy for MM  BCNU  BCP-ALL  BCRA-mutated advanced breast cancer  BCS  BCS for N2 N3 disease  BCS versus mastectomy after neoadjuvant chemotherapy  BCS versus mastectomy for DCIS  BCT versus mastectomie  BCT vs MAST  BEACON CRC study  BEACON-studie subgroep-analyse  BEAT Cancer interventie  BEBYP-studie  Beckwith-Wiedemann syndrome  BECOME randomized trial  beeld-geleide brachytherapie  beeldvorming  beenmergevaluatie  beha  belangenconflicten  belantamab mafodotin  belinostat  BELIS study  BELLE-2 studie  BELLINI trial  BELOB  belotecan versus topotecan  belumosudil  bempegaldesleukin plus nivolumab  bendamustine  bendamustine plus dexamethasone  benign biopsy rate  benign ovarian tumor  benign ovarian tumors  benign solid tumors  benigne borstziekte  benzeen  benzodiazepine  BEP  berberine versus placebo for the prevention of recurrence of colorectal adenoma  BERIL-1  bestraling  BET inhibitor RO6870810  beta-arrestin-1  BETA-Text  bètablokkers  between-hospital variation  bevaciumzab  bevacizumab  bevacizumab and platinum-based combinations  bevacizumab biosimilar  bevacizumab plus chemotherapy  bevacizumab preconditionering voor chemotherapie  bevacizumab-resistant high-grade glioma  BEVZ92  BFORE-studie  BGJ398  bhatia  BI-ALCL  BIA ALCL  biallelic pathogenic CHEK2 variants  BIDOC-studie  BIG 1-01  BIG 1-98  BIG 1-98 trial analysis  bijnierschorscarcinoom  bijniertumoren  bijwerkingen  bilateral breast cancer  bilaterale risicoreducerende mastectomie  BILCAP study  BILCAP-studie  biliary tract cancer  BIND-014  Bing-Neel syndrome  binimetinib  binimetinib for NRAS-mutated cancers  bintrafusp alfa  biochemical recurrence of prostate cancer  biochemically detected nonadherence to adjuvant tamoxifen  biochemisch recidief  biologic subtype  biological aging  biological disease-modifying antirheumatic drugs  biologische beschikbaarheid  biomarker  biomarker voor respons op bevacizumab  biomarker-driven therapies  biomarkeranalyse ASPECCT-studie  biomarkers  biomarkers for nivolumab efficacy  biomarkers for surveillance  biomarkers of breast cancer risk  biomarkers of response to ICIs  biopsie schildwachtklier  bipolar androgen therapy  BIRC3 mutations  BIRCH-studie  birinapant  birth defects  birth order  BIS versus circumference assesements  bisfosfonaat  bisfosfonaten  bispecific CAR-T cell targeting both CD19 and CD22  bisphosphonate use and breast cancer risk among women with DCIS  bisphosphonates and risk of cancers  blaascarcinoom  blaaskanker  black race  black versus nonblack men  black versus white patients  black versus white women  Black Women's Health Study  Black Women’s Health Study  bladder cancer  bladder cancer in postmenopausal women  bladder cancer risk  bladder cancer VI-RADS score  BLC2001 study  bleeding after ACS  bleeding risk  BLEND study  bleomycin-related pulmonary toxicity  bleomycine  blinatumomab  blinded double reading  bloedgluocse  bloeding  bloedkanker  bloedlipiden  bloedtest colorectaalcarcinoom  blood arsenic levels  blood cholesterol  blood markers of oxidative stress  Blood or Marrow Transplant Survivor Study-2  blood pressure  blood tests  blood triglycerides  blood tumor mutational burden  blood-based test for the detection of multiple cancer types  bloodstream infections  bloodstream infections after curative-intent radiotherapy  BLOOM study  BLU-667  BM  BMD  BMI  BMI and outcomes of systemic therapy for metastatic melanoma  BMM  BMT  BMT CTN 1501 study  BNT162b2 vaccination in patients undergoing treatment for cancer  BO  body composition  body composition and cardiovascular events  body fat  body fat distribution  body fat mass  body fat percentage  body mass index  body mass index and risk of second cancer  body shape trajectory  Boekel  BOLERO-1  BOLERO-2  bone loss in younger breast cancer patients  bone marrow biopsy  bone marrow plasma cell level  bone marrow versus blood stem cell graft  bone metabolism  bone metastases  bone modifying agents  bone sarcoma survivors  bone-metastatic castration-resistant prostate cancer  bone-only metastasis  bone-targeted agents  borderline ovarian tumor  borderline ovariumtumor  borderline resectable or locally advanced unresectable pancreatic cancer  borderline resectable pancreatic cancer  Borealis-1 studie  Borealis-2 studie  borstbiopsie  borstchirurgie  borstdichtheid  borstimplantaat  borstkanker  borstkanker bij mannen  borstkankerpreventie  borstkankerscreening  borstkankerscreening oudere vrouwen  borstkankersterfte  borstparende chirurgie  borstreconstructie  borstreconstructie na mastectomie  borstsparende chirurgie  borsttomosynthese  borstvoeding  bortezomib  bortezomib plus chemotherapy  bortezomib plus rituximab maintenance  BOSS cohort  BOSTON study  bot-SPNs  boteffect  botmetastasen  botmetastasen van mammacarcinoom  botmetastasering  botmicrometastasen  botox  botpijn  botsarcoom  bovenste-luchtwegkanker  BP-RMS  BPDCN  BPH  BPM  BPs  BR  BRAC1 2-mutation  brachytherapie  brachytherapy for glioblastoma  BRAF  BRAF 594 en 596 mutaties  BRAF 600 wild type melanoom  BRAF HER2 MET RET-alterations  BRAF mutation  BRAF non-V600-mutant mCRC  BRAF plus MEK inhibition  BRAF plus MEK inhibitors  BRAF V600-mutated mNSCLC  BRAF V600-mutated NSCLC  BRAF V600E  BRAF V600E mCRC  BRAF V600E mutated CRC  BRAF V600E-mutated biliary tract cancer  BRAF V600E-mutated CRC  BRAF wild-type advanced melanoma  BRAF-genfusies  BRAF-mutant mCRC  BRAF-mutant melanoma  BRAF-mutant mNSCLC  BRAF-mutated malignancies  BRAF-mutated melanoma  BRAF-remmer  BRAF-remmers  BRAF-remming  BRAF-V600 mutation-positive melanoma  BRAF-V600 or BRAF-nonV600 mutated NSCLC  BRAF-V600E  BRAF-V600E mutated tumors  BRAF-V600E mutation  BRAF-wt advanced melanoma  brain cancer  brain imaging  brain metastases  brain metastases from melanoma  brain metastases in older patients  brain metastases nivolumab plus ipilimumab  brain metastases or leptomeningeal disease  brain metastasis  brain tumors  brain volume  brain-metastatic lung cancer  brainstem metastases  BRCA  BRCA mutation carriers with breast cancer  BRCA mutational status  BRCA-defective tumors  BRCA-mutatie  BRCA-related cancer  BRCA1  BRCA1 2 germline mutations  BRCA1 2 mtuation. risk of contralateral disease  BRCA1 2 mutation  BRCA1 2 mutation carriers  BRCA1 2 mutations  BRCA1 2 mutations and endometrial cancer  BRCA1 2 variants  BRCA1 2-mutatie  BRCA1 2-mutaties  BRCA1 2-mutations  BRCA1 2-negative Chinese breast cancer patients  BRCA1 and BRCA2 mutations  BRCA1 mutation  BRCA1- or BRCA2-mutated breast cancer  BRCA1-mutatie  BRCA1-versus BRCA2-altered mCRPC  BRCA2  BRCA2-associated breast cancer  BRCA2-mutaties  breast and lung cancer mortality in women  breast and prostate cancer  breast angiosarcoma  breast cancer  breast cancer –related lymphedema  breast cancer and other cancers  breast cancer bone metastasis  breast cancer brain metastases  breast cancer brain metastasis  breast cancer chemotherapy  breast cancer diagnosis  breast cancer family history  breast cancer in childhood cancer survivors  breast cancer in high-risk women  breast cancer in men  breast cancer in young women  breast cancer incidence before age 40  Breast Cancer Index  breast cancer leptomeningeal disease  breast cancer lymph node metastases  breast cancer metastases  breast cancer metastatic recurrence  breast cancer molecular subtypes  breast cancer mortality  breast cancer mortality by comorbidty and age  breast cancer mortality rates in U.S. women  breast cancer outcomes  breast cancer ovarium cancer predisposition genes  breast cancer patients  breast cancer preventive effects of anastrozole  breast cancer radiotherapy planning CT scans  breast cancer rate after oophorectomy in the general population  breast cancer recurrence  breast cancer risk  breast cancer risk after age 60  breast cancer risk estimation model  breast cancer risk in women ≥50 years  breast cancer screening  breast cancer screening among women with dense breasts  breast cancer screening in average-risk women  breast cancer subtype  breast cancer subtype incidence  breast cancer subtypes  breast cancer surgery  breast cancer survival  breast cancer survivors  breast cancer survivorship  breast cancer treated in neoadjuvant setting  breast cancer-related fatigue  breast cancer-related lymphedema  breast cancer-specific mortality  breast cancer-specific survival  breast compression  breast conservation  breast consevation versus mastectomy  breast desmoid tumor management in France  breast ductal carcinoma in situ  breast intraepithelial neoplasia recurrence  breast milk paclitaxel excretion  breast MRI versus digital tomosynthesis  breast non-invasive disease  breast symptoms  breast-conserving surgery  breast-conserving therapy  breast-conserving therapy in women over 70  breastfeeding  brentuximab vedotin  brentuximab vedotin and risk-adapted node radiation  brentuximab verdotin  brigatinib  BrighTNess study  BRIM-3 studie  BRIM7 study  BRIM8-studie  BRIs  British Childhood Cancer Survivor Study  Broad-based genomic sequencing  BROCADE3 trial  bronchopulmonary carcinoids  BRPC  BRRM  BRUIN study  bruton's tyrosine kinase  BTC  BTCRC-GU14-003 study  BTK  BTK inhibition  BTK inhibitor therapy  burden of pancreatic cancer in Europe between 1990 and 2019  Burkitt lymphoma  Burkitt's lymfoom  busulfan plus fludarabine  busulfan plus melphalan conditioning  BV  BV plus AVD  BVD-523  BYLieve study cohort A  C SCANS studie  C-486  C-ALCL  C-ETACs as hallmarks of cancer  C-ion RT  C-reactive protein  C-TASK FORCE studie  CA-125  CA180-226 studie  CA19-9  CA209-003 studie  CA209-003 trial  CA301 study  CABARET-studie  cabazitaxel  cabazitaxel plus carboplatin  cabazitaxel versus abiraterone or enzalutamide  CABONE study  CABOSUN  cabozantanib  cabozantinib  cabozantinib plus ADT  cabozantinib plus nivolumab with or without ipilimumab  cabozantinib versus everolimus  cachexia  CAD  CADC  CADM1 MAL-methylering  cadmium and lead in erythrocytes  cafeïne  caffeïne  CAG-repeat  CAIRO3  calcitonin receptor-like  calcium  calcium and magnesium intake  calcium supplementation  calciuminname  calculated tumor area  CALGB 40601 follow-up  CALGB 40903 study  CALGB 50604  CALGB 80803  CALGB 89803-studie  CALGB Alliance 140503  CALGB SWOG 80405 study  CALGB SWOG 80702 post hoc analysis  CALGB SWOG 80702 study  CALOR-studie  caloric restriction  CAM  CameL study  camrelizumab  camrelizumab plus apatinib  camrelizumab plus apatinib for advanced cervical cancer  camrelizumab plus chemotherapy  camrelizumab plus gemcitabine plus oxaliplatin  camrelizumab plus GVD chemotherapy  camrelizumab with or without decitabine  cancer  cancer burden in patients with sleep apnea  cancer clinical trial participants  cancer deaths due to delays in diagnosis in England  cancer detection rate  cancer diagnoses and survival rise as 65-year-olds become Medicare-eligible  cancer diagnosis  cancer diagnosis during adolescence  cancer diagnosis in primary care  cancer driver genes  cancer drugs approved based on response rate  cancer history  cancer immunotherapy trials  cancer in older adults  cancer in solid organ transplantation recipients  cancer incidence  cancer incidence among children and young adults by single year of age  cancer incidence and mortality  cancer incidence and spectrum in children  cancer incidence and survival in older adults  cancer mortality  cancer mortality in Europe  cancer of unknown primary  Cancer of unknown rimary  cancer outcomes  cancer patients  cancer patients and matched norm population perceived care and well-being  cancer patients treated with anticoagulation  cancer prevalence  cancer prevalence in medieval Cambridge (UK)  cancer prevention  cancer recurrence  cancer risk  cancer risk after hematuria diagnosis  cancer risk in children  cancer risk in children and adolescents  cancer risk in individuals with major birth defects  cancer risk in women  cancer risks  cancer screening  cancer screening in people with mental illness  cancer spectrum  cancer surgical procedures  cancer survival in Germany  cancer survivors  cancer susceptibility genes  cancer-associated venous thromboembolism  cancer-related cognitive impairment  cancer-related fatigue  cancer-specific mortality  cancer-testis antigens  cancers with MUC16-variants  CANDOR study  canine lung cancer detection  cannabigerol  cannabis  cannabis use and lung cancer susceptibilty  CanSNET-studie  CANTO prospective cohort study  CANTO trial  CAO ARO AIO-04 study  CAO ARO AIO-04 trial post hoc analysis  CAP-studie  capecitabine  capecitabine maintenance after first-line induction chemotherapy  capecitabine versus observation  CAPITAL study  capivaserib for AKT1 E17K-mutated tumors  capivasertib  capivasertib for tumors with AKT mutations  capmatinib  CAPP-Seq  CAPP2 study  CAPRI-GOIM  CAPRICE  CAPTAIN-1st study  CAR T cell therapy  CAR T-cell therapy  CAR T-cell therapy for relapsed refractory large B-cell lymphoma  CAR T-cellen voor solide tumoren  CAR T-cells for B-cell lymphoma  CAR T-celtherapie  CAR-HEMATOTOX model  CAR-T celtherapie  CAR-T-cell therapy in patients with advanced B-cell cancers and HBV-infection  CAR-transduced natural killer cells  CAR19 22 T-cell therapy  Caravaggio study  carbazitaxel  carbon ion RT  carboplatin  carboplatin dose capping  carboplatin plus nab-paclitaxel  carboplatin plus pemetrexed  carboplatin with radiotherapy  carboplatin-etoposide with or without atezolizumab  carboplatin-paclitaxel with or without trastuzumab  carboplatine  carcinoïd tumoren  CARD study  cardiac events  cardiac impact of cytokine release syndrome  cardiac outcomes  cardiac safety  cardiale disfunctie  cardiale toxiciteit  cardiale veiligheid  cardiometabolic risk factors and survival after cancer  cardiopulmonary complications  cardiorespiratorische fitheid  cardiorespiratory fitness  cardiotoxiciteit  cardiotoxiciteit anthracylines  cardiotoxiciteit chemotherapie  cardiotoxicity  cardiotoxicity of doxorubicin  cardiovasculair risico  cardiovasculaire toxiciteit  cardiovascular adverse events  cardiovascular disease  cardiovascular disease risk  cardiovascular diseasse  cardiovascular events  cardiovascular fitness and muscular strength  cardiovascular mortality  cardiovascular outocmes  cardiovascular risk  cardiovascular risk factors  cardiovascular toxicity  carfilzomib  carfilzomib for myeloma  carfilzomib-bendamustine-dexamethasone  carfilzomib-lenalidomide-dexamethasone-daratumumab  CARG tool  CARMENA study  CARMENA-studie  carmustine  Carolina Breast Cancer Study  carotenoïden  carpaal-tunnelsyndroom  CARRIERS consortium  CARTITUDE-1 study  CARTS study  CARTTAS study  cascade genetic testing  CASPIAN study  CASPIAN study follow-up  CASPS study  CASR  CASSINI study  CASSIOPEIA study  CASTOR and POLLUX age subgroup analysis  CASTOR subgroup analysis  castratieresistent prostaatcarcinoom  castration-resistant prostate cancer  CATCH  CATCH program  catch-up HPV-vaccination  CATNON study  CATNON-studie  catumaxomab  cause of death  cause-specific mortality  cause-specific mortality after initial chemotherapy  causes of death  causes of death after breast cancer diagnosis  causes of death among Finnish women with breast cancer  CBC  CBC prediction  CBC risk  CBC-risico  CBCSG010 study  CBTRUS  CBTS  cc mRCC  CC-223  CC-486  ccA and ccB molecular subtypes  CCEC  CCNE1 expression  CCR7  ccRCC  ccRCC brain metastases  CCRT  CCRT with or without nimotuzumab  CCSS  CD103+ immune cells  CD19 CAR-T cell therapy  CD19 CAR-T cell therapy in children and young adults  CD19-positive lymphoid tumors  CD22-directed CAR T-cell therapy  CD4  CD4+ percentage  CD45-targeted antibody-radionuclide conjugate  CD47 blockade plus rituximab  CD8+ T cell infiltration  CDG  CDH1 mutation carriers  CDK12-mutated prostate cancer  CDK4 6 inhibition  CDK4 6 inhibitor plus AI  CDK4 6 inhibitors  CDK4 6-remming  CDKN2A alterations in solid tumors  CDKN2A homozygous deletion  CDKN2C  CDS  CDX-110  CDX2  CEA  CEA-specifieke T-cel respons  cediranib  CEGT  celecoxib  CELESTIAL trial  cell nest size  cell-free circulating tumor DNA variant allele frequency  cell-free DNA multicancer early detection test  cell-free Epstein-Barr virus DNA  cell-free urine  cellulaire immuuntherapie  cellular immune activation  CelTIL score  CelTIL-score  celvrij circulerend tumor DNA  cemiplab versus investigator’s choice chemotherapy  cemiplimab  central adiposity  central adiposity and risk of subsequent breast cancer by menopause status  centrale adipositas  ceralasertib (AZD6738)  cerebellopontine angle tumors  cerebrospinal fluid microRNA signatures  cerebrospinal fluid tumor DNA genotyping  cerebrospinale vloeistof  ceritinib  cervical cancer  cervical cancer and precancer risk  cervical cancer incidence  cervical cancer screening  cervical cancer survivors  cervical chordomas  cervical dysplasia after HPV vaccination  cervical HPV-testing  cervical neoplasia  cervical screening  cervicale glandulaire neoplasie  cervicale intra-epitheliale neoplasie graad 3  cervicale intraepitheliale neoplasie  cervicale-slokdarmkanker  cervixcarcinoom  cervixcarcinoomscreening  cervixconisatie  cervixkanker  cervixkankerscreening  cervixlaesies  CESM  CeTeG NOA-09 study  CETSA  cetuximab  cetuximab-IRDye800  cetuximab-related infusion reactions  cetuximab-resistant recurrent metastatic HNSCC  cetuximab-resistentie  CEVOREM trial  CF-WBI  cfDNA  cfDNA genotyping  cfDNA methylation signatures  CGC  cGVHD  ch  CHAARTED-analyse  CHAARTED-studie  change in PD-L1 expression  change in serum uric acid level  change of breast cancer subtype during neoadjuvant chemotherapy  changes in length and complexity of oncology guidelines since 1996  changes in taste and smell of food  changes of diet after cancer diagnosis  characteristics and outcomes  characteristics in young versus old patients  Charlson-score  ChcekMate 066 five-year results  CHD  CheckMate 012  CheckMate 016-studie  CheckMate 017 and 057 trials  CheckMate 017 en 057  CheckMate 017 en CheckMate 057  CheckMate 017-studie  CheckMate 025  CheckMate 026-studie  CheckMate 032 study  CheckMate 037  CheckMate 040  CheckMate 040 study  CheckMate 064  CheckMate 066  CheckMate 066 study  CheckMate 067  CheckMate 067 five-year survival  CheckMate 069  CheckMate 069 066 en 067  CheckMate 141  CheckMate 141-studie  CheckMate 142  CheckMate 143 study  CheckMate 153  CheckMate 204  CheckMate 204 study  CheckMate 205 study  CheckMate 214  CheckMate 214 long-term follow-up  CheckMate 214 study  CheckMate 227 part 1 three-year update  CheckMate 227 study  CheckMate 227-studie  CheckMate 238 four-year results  CheckMate 238-studie  CheckMate 274  CheckMate 275  CheckMate 358 trial  CheckMate 370-studie  CheckMate 384 study  CheckMate 436 study  CheckMate 511 trial  CheckMate 568  CheckMate 577 study  CheckMate 648 study  CheckMate 649  CheckMate 743 trial  CheckMate 816 trial  CheckMate 817  CheckMate 9ER study  CheckMate 9ER trial  CheckMate 9LA study  CheckMate-032 study  CheckMate-142  checkpoint blockade  checkpoint blockade immunotherapy  checkpoint inhibitor therapy  checkpoint inhibitor-resistant metastatic melanoma  checkpoint inhibitors for various types of melanoma  checkpoint kinases  CHEK2 1100delC  CHEK2 germline pathogenic variants  CHEK2-mutaties  CHEK2*1100delC  chemerin plasma concentration  chemobrain  chemoimmunotherapy  chemopreventie mammacarcinoom  chemopreventie van mammacarcinoom  chemoprevention of CRC  chemoprevention of recurrence  chemoprevention with low-dose aspirin  chemoradiotherapie  chemoradiotherapy  chemoradiotherapy versus radiotherapy  chemoradiotherapy with proton versus photon therapy  chemorefractory metastatic colorectal cancer  Chemoresistentie  chemosensitizatie  chemotherapie  chemotherapie tijdens zwangerschap  chemotherapie-geïnduceerd ovariumfalen  chemotherapie-geïnduceerd POF  chemotherapie-geïnduceerde febriele neutropenie  chemotherapie-geïnduceerde misselijkheid en braken  chemotherapy  chemotherapy adherence  chemotherapy after colorectal cancer liver metastasectomy  chemotherapy alone versus combined modality therapy  chemotherapy and ICU admission in last phase of life  chemotherapy benefit  chemotherapy demands  chemotherapy for breast and prostate cancer  chemotherapy for childhood cancer  chemotherapy for CRC  chemotherapy for early-stage breast cancer in older women  chemotherapy free treatment  chemotherapy plus atezolizumab for NSCLC  chemotherapy plus immunotherapy  chemotherapy plus ponatinib  chemotherapy regimens  chemotherapy response  chemotherapy response score  chemotherapy timing in pregnancy  chemotherapy versus observation  chemotherapy with bevacizumab or temsirolimus  chemotherapy with or without cetuximab  chemotherapy with or without pembrolizumab  chemotherapy with versus without bevacizumab  chemotherapy-associated cognitive fatigue and evening physical fatigue  chemotherapy-free treatment  chemotherapy-induced alopecia  chemotherapy-induced amenorrhea  chemotherapy-induced cardiotoxicity  chemotherapy-induced nausea and vomiting  chemotherapy-induced neutropenia in adult NSCLC-patients  chemotherapy-induced peripheral neuropathy  chemotherapy-induced thrombocytopenia  chemotherapy-ineligible HL patients  chemotherapy-naïve non-squamous NSCLC  chemotherapy-related amenorrhea  chemotherapy-related cognitive impairment  chemotherapy-related hematological toxicity  chemotherapy-related vomiting in children and adolescents  chest radiation for childhood cancer  chest-irradiated cancer survivors  CHF  CHHiP-studie  child self-report versus caregiver report  childbearing potential  childbirth  childhood ALL  childhood ALL survivors  childhood AML  childhood and adolescent ALL in The Netherlands 1990-2015  childhood and AYA cancer survivors  childhood B-ALL  childhood brain tumors  childhood cancer  childhood cancer survival in immigrants  Childhood Cancer Survivor Study  childhood cancer survivors  childhood leukemia  childhood leukemia and lymphoma survivors  childhood leukemia risk  childhood leukemia; maternal hormonal contraception use  childhood nasopharyngeal carcinoma  childhood ovarian non-seminomatous germ cell tumors  children  children and adolescents with cancer  children and AYAs with cancer  children with cancer  Children’s Oncology Group  Children’s Oncology Group AALL0434 study  Children’s Oncology Group study  Children’s Oncology Group Study AALL03N1  chimeric antigen receptor  Chinese Alliance for Research in Thymomas database  CHIP  chirurgie  cHL  cHL after PD-1 blockade monotherapy  cHL in young patients  choice between first-line endocrine versus chemotherapy  cholangiocarcinoma  cholangiocarcinoom  cholecystitis  chondrosarcoma  chondrosarcoom  CHOP  CHOP with or without alemtuzumab  chordoma  chordoom  chromische lymfocytische leukemie  chromocolonoscopy versus white-light colonoscopy  chromosoom 21  chromosoominstabiliteit  chromothripisis  chronic comorbidities  chronic health conditions  chronic irAEs  chronic lymphocytic leukemia  chronic musculosketal pain in cancer survivors  chronic myeloid leukemia  chronic myelomonocytic leukemia  chronic neutrophilic leukemia  chronic pain  chronic phase CML  chronical medical conditions and late effects in survivors  chronisch graft-versus-host disease  chronische fase CML  Chronische fase-CML  chronische lymfatische leukemie  chronische lymfocytische leukemie  chronische lymfoide leukemie  chronische myelomonocytische leukemie  Chronos-1  CHRONOS-1 study two-year follow-up  CHRONOS-3 study  chubb  chyleuze ascites  CIA  cigarette type  cilengitide  cilta-cel  CIMBA  CIMP  CIN  CIN 3  CIN2 3  CIN2+ detection  CINP  CINV  CIO  CIOD  CIPN  circadiaan ritme  circulating breast cancer risk factors in normal weight postmenopausal women  circulating DNA  circulating HPV DNA  circulating immune cells  circulating levels of specific lipid groups  circulating sex hormone levels  circulating tumor cells  circulating tumor DNA  circulerend DNA  circulerend tumor-DNA  circulerende tumorcellen  circulerende tumorcellen; detectie nieuwe mutaties  circulerende vetzuren  CIRT  CIRT for unresectable pelvic bone sarcoma  CISIG  cisplatin  cisplatin and fluorouracil versus carboplatin and paclitaxel  cisplatin for cancer in children  cisplatin-induced hearing loss in children and AYAs  cisplatin-ineligible operable high-risk UC  cisplatine  CITN-10 study  citrusfruit  cixutumumab  cladribine  CLAP study  ClarIDHy study  CLARITY study  CLASS02 trial  classic and variant hairy cell leukemia  CLASSICAL-Lung clinical trial  claudine 18.2  CLEAR  clear cell renal cell carcinoma  CLEAR trial  CLEOPATRA study final results  Clevers  clinical and genetic risk factors  clinical and genomic risk  clinical benefit of genomicprofiling  clinical calculator for prediction of recurrence  clinical characteristics  clinical characteristics and outcomes  clinical features  clinical features for prediction of survival  clinical meaningful outcomes  clinical outcomes  clinical outcomes and prognostic factors  clinical prognostic stage group system  clinical stage I gastric cancer  clinical stage I nonseminoma  clinical stage I NSCLC  Clinical Treatment Score at 5 years  clinical trial enrollment  clinical trial evidence  clinical trial participation  clinical trials  clinical utility of qPCR plasma EGFR mutation detection in advanced lung cancer  clinical value  clinically N2 non-small cell lung cancer  clinically node-positive breast cancer  clinicogenomic classifier  CLL  CLL 2007 SA-studie  CLL in patients intolerant to BTK inhibitor or PI3K inhibitor  CLL in younger patients  CLL resistant to venetoclax  CLL SLL  CLL therapies after venetoclax discontinuation  CLL with coexisting conditions  CLL-IPI  CLL10  CLL14 trial  CLL2-BAG study  CLLM1-studie  CLM  CLND  clofarabine  clofarabine plus total body irradiation conditioning  CLOG1302-studie  clomid  clomifeen  clomifeencitraat  Clozel  CLUE II cohort  CME  CML  CML after ABL kinase inhibitor failure  CML in chronic phase  CML-BP  CML-CP  CML-studie IV  CMM  CMML  CMS risk  CMSs  CMV  CMV viremia after hematopoietic stem cell transplant  CMV-viremie  CN-AML  CNAs  CNBSS  CNS disease control with cranial radiotherapy and ICIs versus chemotherapy  CNS efficacy  CNS lymphoma  CNS metastases  CNS metastases of breast ancer  CNS metastasis  CNS NGGCTs  CNS response  CNS tumors in children  CNS-DLBCL  CNS-lymfoom  CNS-metastasen  CNS-recidief HER2-tumoren  CNS-tumoren  CNS-tumoren; impact van behandelcentrum  CNV signature  co-occuring MET amplification  co-occuring NOTCH and HR mutations  CO.26 study  cobas  cobimetinib  cobimetinib plus vemurafenib  COBRA study  COBRA-score  coBRIM-studie  cochlear radiation dose  CodeBreaK100 trial  codon 12 13 versus codon 61 mutation  coffee intake  COG AALL0434  COG AALL0622-studie  COG AALL0932 study  COG AALL1331 study  COG AAML0631-studie  COG ARAR0331 study  COG AREN0533-studie  COG trial ACNS0333  COG-studie AAML0531  COG-studie AREN0532  cognitief functioneren  cognitieve disfunctie  cognitieve klachten  cognitieve veranderingen na chemotherapie  cognition  cognition after endocrine versus chemoendocrine therapy  cognitive and neurobehavioral impairment  cognitive performance  cohabitation and breast cancer risk  COIN colorectal trial  colectomie  colitis-associated CRC risk prediction  collider stratification bias  COLOFOL-studie  Cologuard  colon cancer  colon cancer drug metabolism  Colon Cancer Family Registry  colon cancer peritoneal recurrence  colon cancer risk  colon cancer surgery  colon surgery  colon-NET  coloncarcinogenese  coloncarcinoom  colonkanker  colonoscopie  colonoscopy-based CRC screening  colorectaakanker  colorectaaladenomen  colorectaaladenoom  colorectaalcarcinoom  colorectaalkanker  colorectaalkankerscreening  colorectaalneoplasie  colorectaalpoliepen  colorectal  colorectal adenomas  colorectal cancer  colorectal cancer incidence in Americans approaching screening age  colorectal cancer lever metastasis  colorectal cancer molecular subtypes  colorectal cancer mortality  colorectal cancer precursors  colorectal cancer risk  colorectal cancer screening  colorectal carcinogenesis  colorectal liver metastases  colorectale chirurgie  colorectale levermetastasen  colorectale neoplasie  coloscopie  COLUMBA study  COLUMBUS trial  COMBI-AD studie  COMBI-AD study  COMBI-d studie  COMBI-MB studie  COMBI-v  CombiDT  combination of HAI and systemic chemotherapy  combination of HDAC and mTOR inhibition  combination of osimertinib and bevacizumab  combined analysis of N9831 and NSABP B-31  combined BRAF- and MEK-inhibition plus PD-1 blockade  combined CTLA-4 and PD-1 inhibition  combined effect of breast density and BMI  combined lifestyle factors  combined modality treatment  combined nivolumab and bevacizumab  combined PD-1 blockade and VEGF inhibition  combined-modality therapy  commercial gene expression tests  common cancers  common medications  CoMMpass study  community jury  comorbiditeiten  comorbidities  comparative safety of ICIs  comparison between men and women  comparison Hong Kong and USA  comparison of 5-aza and HSCT  comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing HSCT  comparison of clinical studies and real-world outcomes  comparison of first-line treatments  comparison of five guidlelines  comparison of PD-L1 protein expression between primary and metastic lesions  comparison of systemic treatments  comparison of three MIBG regimens  comparison of two induction therapies  comparison of two RT fractionation schedules  COMPASS study  complementaire en alternatieve behandelingen  complementary and alternative medications  complementary medicine  complete mesocolic excision  complete remission with vismodegib  complete response to neoadjuvant CRT  COMPLETE study  completion of chemotherapy for breast cancer  complex gastrointestinal cancer surgery  complex karyotype  complication rate and outcomes  complication risk  complications after surgery for colorectal cancer  COMPOSE-studies  composite GRFS and CRFS outcomes  compromised immune microenvironment  computationele pathologie  computer-assisted colorectal adenoma detection  Computer-geassisteerde chirurgie  conclusions of publcations  concomitant mutations  concomitant use  CONCORD-2  CONCORD-3  concurrent capecitabine and stereotactic radiation  concurrent chemoradiotherapy  conditional immune toxicity rate  conditional local recurrence risk  conditional recurrence-free survival  conditional survival  conditional survival after five recurrence-free years  conditional survival after resection  conditionele ziektevrije overleving  conditioning after autoHCT  CONDOR trial  congenital heart disease  congestive heart failure  conjunctival melanoma  CONKO-004  connexine 30  consecutive mammography screening examinations  consensus molecular subtypes  conservative management  CONSIGN  consistent physical activity  consolidation radiotherapy  consolidation with WBRT or stem-cell transplantation  consoliderende radiotherapie  Consomic Xenograft Model  constitutional mismatch repair deficiency syndrome  contemporary hormonal contraception  contemporary lenalidomide-based regimens  contemporary radiation therapy for ESFHL  CONTESSA 2 study  continuation of screening after age 70 years  continuous growth model  continuous lenalidomide maintenance for MM  continuous tumor-size-based end points  continuous versus 1-year nivolumab  continuous versus intermittent dosing of dabrafenb-trametinib  CONTINUUM-studie  contralateraal mammacarcinoom  contralateral breast cancer  contralaterale borstkanker  contralaterale mastectomie  contralaterale profylactische mastectomie  convalescent plasma therapy  conventional versus moderate hypofractionated RT  conversion surgery  CONVERT-studie  CONVINCE-studie  copanlisib  copanlisib plus gemcitabine  COPD  COPD and lung cancer  copy number alteration screening  copy number loss  coronary artery calcifications  corpus uteri cancer  correlation between surrogate end points and overall survival  correlation of CTCs or DTCs with Oncotype DX recurrence score  correlation with overall survival  corticosteroid refractory ICI-induced enterocolitis  corticosteroïden  corticosteroids  COSMIC-311 study  COSMOS trial  cost-effective global care for cancer in children  cost-effectiveness  cost-effectiveness of CAR T-cell therapy  cost-effectiveness of intraoperative MRI  cost-effectiveness of lung cancer screening  cost-effectiveness of nivolumab-ipilimumab combination therapy  cost-effectiveness of prostate RT  cost-effectiveness of surveillance  Costa RIca  Costa Rica HPV Vaccine Trial  cotinine  COVID-19  COVID-19 first wave  COVID-19 hospitalized patients  Covid-19 hospitalized patients with lymphoma  COVID-19 in patients with hematological malignancies  COVID-19 in patients with thoracic malignancies  COVID-19 incidence and mortality  COVID-19 mortality in patients with various cancers  COVID-19 mRNA vaccine  COVID-19 outcomes  COVID-19 pandemic  COVID-19 severity and outcomes in patients with cancer  COVID-19-infected cancer patients  COVIDSurg Collaborative  coxibs  CP-CML  CP-genen  CPA use  CpG-B  CPI-613  CPIs  CPM  CPPT  CPX-351  CRA  craniopharyngioma in adults  craniotomie  CRBSI  crc  CRC detection  CRC diagnosis  CRC in Taiwan  CRC incidence  CRC incidence and mortality after polypectomy  CRC incidence and mortality after snigle negative screening colonoscopy  CRC incidence in Canada  CRC intrinsic subtypes  CRC liver metastases  CRC prognosis  CRC risk  CRC risk following polypectomy  CRC risk in Lynch syndrome  CRC screening in European countries  CRC stage distribution  CRC survival  CRC survivors  CRC with asymptomatic synchronous metastases  CRC with ERBB2 amplification overexpression  CRC with high tumor mutaional burden  CRC-biomarkers  CRC-diagnose  CRC-risico  CRC-screening  CRCD  CREATE-studie  crenigacestat  CRF  cribriform groeipatroon  CRICKET trial  crizotinb  crizotinib  crizotinib-resistant ALK-positive NSCLC  CRLM  CRLX101  CRN  Crohn’s disease  CROSS  CROSS trial ten-year outcomes  crossover or pembrolizumab rechallenge after recurrence  CROWN study  CROWN Trial  CRP  CRP flare-response  CRP-niveau  CRPC  CRPC with bone metastases  CRS  CRS HIPEC  CRS-207  CRS-HIPEC  CRS-HIPEC cost effectiveness  CRT  CRT for esophageal cancer  CRT versus CT  CRT with cisplatin versus cetuximab  cryoablation for lung metastases  CSCC  cSCC risk after diagnosis actinic keratosis  CSCCs  CSF penetration of anti-PD-1 antibodies  CSM  CT  CT examinations  CT lung cancer screening  CT-based biomarkers  CT-longkankerscreening  CT-P10  CT-P6 versus trastuzumab  CT-screening longkanker  cT1-2N0 breast cancer  cT1T2No OTSCC  CTCAE  CTCL  CTCs  CTCs and early relapse  ctDNA  ctDNA after neoadjuvant chemotherapy  ctDNA alterations  ctDNA analysis  ctDNA analysis to direct therapy  ctDNA and risk of progression after long-term response  ctDNA as biomarker of response to palbociclib-fulvestrant  ctDNA as response indicator  ctDNA markers for early progression  ctDNA mutations  ctDNA predicts response and prognosis  ctDNA reflects response and survival  ctHPVDNA monitoring in recurrence surveillance  CTL019 for pediatric B-ALL  CTLA-4  CTLA-4 blokkade  CTLC  CTONG1104 study  CTP  CTS5 risk score  CUDC-907  CUETO  cumulative GRAS score  cumulative incidence of CVD  CUP  curatie  curative intent treatment for bladder cancer  curative-intent resection  current or former smoking  cutaan squameus celcarcinoom  cutaan squameus celcarcinoom van hoofd en hals  cutaan T-cel lymfoom  cutane bijwerkingen  cutaneous adverse events  cutaneous BCC  cutaneous HNSCC with regional lymph node metastasis  cutaneous malignant melanoma  cutaneous melanoma  cutaneous squamous cell carcinoma  cutaneous toxicities  cutaneous toxicity  CUX1-ALK rearrangement  CVD  CVD risk  CVD risk after GnRH agonists versus GnRH antagonists  CVD risk factors  CVD risk factors and colorectal cancer  CVSS-studie  CXB  CXCL8-CXCR1 2 axis  CXM  cycline D1  cyclofosfamide  cyclophosphamide  cyclophosphamide for prevention of aGVHD  cyclophosphamide-bortezomib-dexamethasone  cyclophosphamide-free chemotherapy for ovarian protection  CYP2D6 genotype  CYP3A  cyproteronacetaat  cyramza  cystectomie  cytarabine  CYTO-CHIP study  cytogenetically defined high-risk multiple myeloma  cytogenetisch normaal AML  cytokine-induced killer cell therapy  cytokines  cytology testing  cytoreductive surgery  Cytosponge-trefoil factor 3  D-2-hydroxyglutaraat  D-index-guided early antifugal therapy  D-Rd  D-Rd versus Rd  D-VCd  D-Vd versus Vd  D-VMP  D-VTd versus VTd for newly diagnosed multiple myeloma  DA-EPOCH-R versus R-CHOP  dabrafenib  dabrafenib plus trametinib  dabrefenib plus trametinib  dacarbazine for metastatic melanoma  dacomitinib  DADI  DAFI  daily aspirin  dairy intake during adolescence and risk of colorectal adenoma  DALLT cohort  daratumumab  daratumumab-based treatment  darm-microbioom  darm-stamcellen  darmflora  darmkanker  darolutamide  DARPin drug candidate MP0250  DART S1609 neuroendocrine cohort  DART SWOG 1609  DART-studie  dasatinib  dasatinib plus blinatumomab  dasatinib versus imatinib  DASCERN randomized study  DATA-studie  David A. Karnofsky Memorial Award and Lecture  davoli  DAWN-studie  DAWT  DBCG 07-READ studie  DBCG HYPO trial  DBMS  DC-CIK  DCd with or without P  DCE-MRI  DCF chemotherapy  DCIS  DCIS adjacent to IBC  DCIS and early stage HR-positive breast cancer  DCIS and node-negative breast cancer  DCIS before age 50 years  DCIS grading  DCOG-LATER cohort  DCOG-LATER cohort study  DCOG-LATER studie  dd-chemotherapie  DDCT  DDR gene aberrations  DDR gene mutations  de novo metastatic nasopharyngeal carcinoma  de novo metastatic prostate cancer  de novo stage IV HER2-positive MBC  De-ESCALaTE HPV study  de-escalation of axillary surgery  de-escalation of TKIs  death from unintentional injury among cancer patients  Debio 1143 plus high-dose cisplatin CRT  Debio0932  Decipher  decision support system  decitabine  decitabine plus camrelizumab  dedifferentiated chordoma  deep learning  deep learning model  deep molecular response  deepening of response after completing therapy  defactinib  deficient mismatch repair stage III colon cancer  definitive radiotherapy  definitive stereotactic body radiotherapy  degarelix  DEL  delay of cancer surgery  delayed hearing loss  delayed immune-related adverse events  delayed surgical treatment  delirium  dementia  Denemarken  denosumab  denosumab or zoledronic acid in cancer patients  dense breast tissue  dentaal trauma  depatux-M  depressie  depression  depression and suicidal ideation  depth of response  dermatofibrosarcoma protuberans  desmoïd  desmoid tumors  DESMOPAZ study  DESTINY study  DESTINY-Breast01 study  DESTINY-CRC01 trial  DESTINY-Gastric01 study  DESTINY-studie  detectie  Detectie borstkanker  detectie colorectaalkanker  detecting genomic biomarkers in plasma versus tissue  detection advanced neoplasia  detection bias  detection early-stage OPSCC  detection of circulating tumor DNA after surgery for nmCRC  detection of CTCs during follow-up  detection of invasion of detrusor muscle  detection of microsatellite instability  detection of mutations in ctDNA  detection of non-index lesions  detection of prostate cancer  detection of relapse  determinants of breast cancer risk  determinants of optimal adjuvant therapy  determinants of outcomes  determinants of survival  determinants of tumor cell PD-L1 expression  dexamethason  dexanethasone  dexrazoxane  DFCI 11-001 study  DFP-10917  DFS  DHA  DHAP  DHL  DHL and THL  diabetes  diabetes and cancer risk  diabetes mellitus  diagnose longcarcinoom  diagnosis and treatment  diagnostic low-dose ionizing radiation in youth  diagnsotic performance of feacal immunochemical test  DICER1 pathogenic variants  diet qualiity  diet quality  dietary carbohydrate quality and human health  dietary carbohydrates  dietary fiber  dietary fiber and yogurt  dietary intake  dietary intake of antioxidants  dietary modification and breast cancer mortality  dietary polyunsaturated fat  dietary supplement use  dietary supplement use during chemotherapy  differences in treatment outcomes  different cancer types  differential activity of PARP inhibitors  differential ribosome measurements of codon reading  differentiated thyroid cancer  difficult patients  diffuse large B cell lymphoma  diffuse large B-cell lymphoma  diffuse large B-cell lymphoma-specific mortality  Diffuse optical spectroscopic imaging  diffuse type TGCT  diffuse-type giant cell tumor  diffusion-weighted MRI  diffuus grootcellig B-cel lymfoom  diffuus intrinsiek ponsglioom  difluoromethylornithine maintenance  digestive tract cancer  digital breast tomosynthesis  digital breast tomosythesis  digital screening mammografie  DigniCap  digoxine  DII  DIPG  DIPG patients ≥ 10 years of age  DIPG-BATS studie  direct-acting antivirals  discontinuation imatinib for CML in children  discontinuation of anti-PD-1 antibody therapy  discontinuation of first-line dasatinib for CML  discontinuation of immune suppression  discontinuation of TKIs for de novo CP-CML  discontinuous SBRT  disease progression in cancer patients  disease trajectories and mortality after breast cancer  disease-free survival  diseases and deaths in middle-aged adults  disontinuation of trastuzumab  disparities by race ethnicity and age  disruption of FIT-screening programmes  distal cholangiocarcinoma  distal rectal cancer  distale pancreatectomie  distant disease-specific survival  distant metastasis of salivary gland cancer  distant metastatic breast cancer  distant recurrence of breast cancer  distant versus supraclavicular lymph node metastases  distress  Distress Thermometer  DLBCL  DLBCL survivors  DMFS  dMMR CC  dMMR PDAC  DN  DNA damage immune response  DNA Damage Immune Response signatrue  DNA damage repair mutations  DNA promoter-hypermethylering  DNA repair gene aberrations. platinum-base chemotherapy  DNA-methylering  DNA-test  DNA-thioguanine concentration  DNMT3A-mutatie  docetaxel  docetaxel-cyclophosphamide for breast cancer  documentaire  doelgerichte behandeling  donor clonal hematopoiesis  donor-derived expanded NK-cells to prevent relapse  DoR  DOREMY study  dormancy-genen  dose dense doxorubicin-cyclophosphamide and-paclitaxel  dose optimization  dose reduction of preoperative RT  dose-adjusted EPOCH-R  dose-dense adjuvant chemotherapy plus trastuzumab  dose-dense versus standard chemotherapy  dosisescalatie  DOSISPHERE-01 study  dostarlimab  DOT1L  double expressor DLBCL  DOVIGIST-studie  doxorubicin delivery from ultrasound-triggered liposomes  doxorubicin plus pembrolizumab  doxorubicine  DPP-4 inhibition for aGVHD proylaxis  DPYD genotyping  DPYD*2A variant carrying cancer patients  DREAM study  DREAMM-2 study  droge mond  droplet digital PCR  DRRD  drug response predictor  drug-drug interactions  drye eye syndrome  DSMM XI-studie  DSRCT  DSTP30865  dt-GCT  DTC  DTCs  DTX3 copy number in breast cancer  ductaal carcinoom in situ  ductal carcinoma in situ  DUD  dunne-darmadenocarcinoom  dunne-darmneoplasie  DUO Crossover Extension Study  DUO study  duration of adjuvant trastuzumab  duration of response  durvalumab  durvalumab for solid tumors in HIV-1 infected patients  durvalumab or placebo after CRT for stage III NSCLC  durvalumab plus chemotherapy  durvalumab plus olaparib plus cediranib  durvalumab with or without stereotactic body radiotherapy  durvalumab with or without tremelimumab  durvalumab-cisplatin-pemetrexed  DURVAST study  dutasteride  Dutch Bone Metastasis Study  Dutch MINDACT cohort analyis  duvelisib  DYNAMIC study  dynamics of ctDNA  DYNAMO study  DYPD genotyping  dysfagie  dyslipidemia  dyspnoe  e-sigaretten  E1609 study  E1912 study  E2F8  E3805-studie  E3A06 study  E3N  E3N cohort  E4  E5103 study  E75  EA  EAC  EADC  EAGLE study  early and locally advanced breast cancer  early AYAs  early breast cancer  early breast cancer or ductal carcinoma in situ  early cancer surveillance  early detection and monitoring progression of gastric cancer  early diagnosis  early discontinuation of endocrine therapy  early donor identification  early experience  early HER2-positive breast cancer  early interdisicplinary supportive care  early melanoma recurrence despite adjuvant anti-PD-1 therapy  early metabolic response  early mortality  early noninvasive detection of response  early onset CRC  early onset female cancer survivors  early palliative care use  early phase ICI-trials  early prediction of chemoradiotherapy-induced cardiotoxicity  early prediction of response  early predictors of pathologic complete response to neoadjuvant therapy  early recurrence  early relapse detection  early stage breast cancer  early stage breast cancer in older women  early stage breast cancer outcome  early stage ER-positive breast cancer  early stage ER-positive breast cancer in older women  early stage prostate cancer  early stage TNBC  early thymic precursor acuut lymfoblastische leukemie  early thymic precursor-like phenotype ALL  early TNBC  early trastuzumab interruption  early triple-negative breast cancer  early-life alcohol intake  early-onset colorectal cancer  early-onset colorectal cancer among women  early-onset CRC  early-onset familial breast cancer  early-onset pancreas cancer  early-onset pancreatic cancer  early-onset severe infections  early-stage breast cancer  early-stage breast cancer in elderly patients  early-stage breast cancer in the elderly  early-stage breast cancer recurrence  early-stage cancers  early-stage cervical cancer  early-stage cutaneous T-cell lymphoma  early-stage endometrial cancer  early-stage HER2-positive breast cancer  early-stage Hodgkin lymphoma  early-stage HR-positive breast cancer  early-stage lung cancer  early-stage non-small cell lung cancer  early-stage non-small lung cancer  early-stage NSCLC  early-stage oropharyngeal squamous cell carcinoma  early-stage pediatric HL  early-stage unfavorable classic Hodgkin lymphoma  early-stage unfavorable HL  EBCC-12 postponed  EBRT for localized prostate cancer  EBV  EC  ECD  Echelon-1 studie  ECHELON-1 study  ECHELON-2 study  ECHO-202 KEYNOTE-037  ECOG PS  ECOG PS 2  ECOG-ACRIN 2511 study  ECOG-ACRIN 5508 study  ECOG-ACRIN E1412 study  ECOG-ACRIN E1609 study analysis  ECOG-ACRIN E1912 study  ECOG-PS  economic evaluation  ECX)  Edinburgh Pain Assessment and management Tool  educational level  één-maands mortaliteit  eenarmige versus gerandomiseerde fase 2-studies  eerdere kanker  EF-14  effect modifiers of low-dose tamoxifen  effect on early cancer detection  effectivity and safety of BNT162b2 vaccine in patients undergoing treatment for cancer  effects of GVHD on long-term outcomes  efficacy of BNT162b2 mRNA vaccine in patients with CLL  efficacy of immunotherapy  efficacy of medications for reduction of risk of primary breast cancer in women  EFVPTC  EGFR  EGFR amplification  EGFR amplified glioblastoma  EGFR copy number gain  EGFR inhibition resistance  EGFR mutated advanced non-small cell lung cancer  EGFR mutated NSCLC  EGFR mutation-positive advanced NSCLC  EGFR mutation-positive MET-amplified NSCLC after EGFR TKIs  EGFR mutation-positive NSCLC with leptomeningeal metastases  EGFR T790M  EGFR T790M-positive advanced NSCLC with leptomeningeal metastases  EGFR T790M-positive NSCLC  EGFR T790M-positive NSCLC in elderly patients  EGFR therapy resistant NSCLC  EGFR-amplified recurrent glioblastoma  EGFR-blokkade  EGFR-mutant and MET-amplified NSCLC  EGFR-mutant lung adenocarcinoma  EGFR-mutant lung cancer  EGFR-mutant non-small cell lung cancer  EGFR-mutant NSCLC  EGFR-mutant NSCLC with liver metastases  EGFR-mutated advanced non-small cell lung cancer  EGFR-mutated advanced non-small-cell lung cancer  EGFR-mutated advanced NSCLC  EGFR-mutated lung adenocarcinoma  EGFR-mutated non-small cell lung cancer  EGFR-mutated NSCLC  EGFR-mutated NSCLC in elderly or frail patients  EGFR-mutatie  EGFR-mutaties  EGFR-TKI  EGFR-TKIs  EGFR-TKIs for stage IIIB IV EGFR-mutant NSCLC  EGFR+ and ALK+ NSCLC  EHCC  eHealth support  eierstokkanker  eiwitbiomarkers  elacestrant (RAD1901)  ELCC 2017  elderly cancer patients  elderly HR-positive breast cancer patients  elderly patients  elderly patients with advanced non-small cell lung cancer  electric power morcellation  electronic nose  electroporated plasmid IL-12  ELEVATE TN study  elevated vitamin B12 levels  ELIANA study QOL analysis  Eliasof  ELOQUENT-3 study  elotuzumab  ELRP  ELSA  eltrombopag  ELTS-score  emactuzumab  EMBRACA study  EMBRACA-studie  EMBRACE-I study  EMBRACE-studie  embryonale hersentumoren  EMD  emergency department use and unplanned hospitalization  EMERGING-CTONG 1103 study  emesis  emetogenic chemotherapy in pediatric patients  EMILIA  EMN09 study  emotionele uitputting  EMPIRE-1 study  EMPOWER-Lung 1 trial  EMT  EMVI  encorafenib  encorafenib plus binimetinib  ENCORE-601 study  end-of-life care  end-of-life zorg  ENDEAVOR-studie  ENDOANGEL system  endocriene behandeling  endocriene effecten  endocriene therapie  endocrine deficiency  endocrine diseases  endocrine resistance  endocrine therapies  endocrine therapy  endocrine therapy adherence  endocrine therapy for breast cancer  endocrine therapy resistance  endocrine treatment  endocrine treatment versus chemotherapy  endocrine-responsive lobular carcinoma of the breast  endometrial ancer  endometrial cancer  endometrial cancer risk  endometrial cancer surgery  endometrial cancer survival  endometrioïd endometriumcarcinoom  endometrioïd epitheliaal ovariumcarcinoom  endometrium-adenocarcinoom  endometriumcarcinoom  endometriumkanker  EndoPredict  endoscopic or open resection  endoscopic surgery versus intensity-modulated radiotherapy  endotheliaal ovariumcarcinoom  ENDS  ENDURANCE trial  energetic capacity  ENESTfreedom  ENESTfreedom trial  enfortumab vedotin  ENGOT-OV16 NOVA study  ENGOT-OV16 NOVA trial  ENHANCE 1 study  enhanced recovery after surgery  enhancer of zeste homolog 2  ENITEC consortium  ENKTL  ENLIVEN study  ENOC  enocrafnib  ensartinib  entecavir  enterovirus  enthusiasm hypothesis  entospletinib  entrectinib  Environmental Quality Index  enzalutamide  enzalutamide for castration-resistant prostate cancer  enzalutamide plus trastuzumab  enzalutamide versus bicalutamide  ENZAMET study  enzastaurine  EOC  EOPM  EORTC  EORTC 10995  EORTC 1325 Keynote-054 studie  EORTC 1325 KEYNOTE-054 study  EORTC 1325 KEYNOTE-054 trial  EORTC 1325-MG KEYNOTE-054 3-year follow-up  EORTC 18071  EORTC 22922 10925 study  EORTC 22922 10925-studie  EORTC 22952-26001 trial exploratory analysis  EORTC 26101 analysis  EORTC study 22033-26033  EORTC-62092  EPA  epacadostat  EpCAM-positieve tumoren  ependymoom  epertinib  EPHOS-B  epi-drugs  EPIC  EPIC cohort  EPIC-analyse  EPIC-NL  EPICAP-studie  epichaperome-targeted positron emission tomography for tumor imaging  epidemiology and outcomes  epidural use  epidurale metastasen  epigenetic age acceleration  epigenetic editing  epigenetische stabiliteit  epigenetische veranderingen  epilepsy risk factors  epirubicin  epitheliaal ovariumcarcinoom  epithelial ovarian cancer  epithelial ovarian cancer risk  epithelial ovarian cancer survivors  epithelial ovarian carcinoma  Epitopes-HPV02 ancillary study  Epitopes-HPV02 study  EPOC  EPOC1706 study. advanced gastric cancer  eprenetapopt (APR-246) plus azacitidine  eprenetapopt plus azacitidine  EPSILoN  Epstein-Barr virus-geïnduceerde lymfoproliferatieve ziekte  EQoL-MDS  ER positive breast cancer  ER status  ER status and breast cancer survival  ER- en PR-testen  ER-negatief mammacarcinoom  ER-negatieve borstkanker  ER-negatieve tumoren  ER-positief HER2-negatief gevorderd mammacarcinoom  ER-positief mammacarcinoom  ER-positieve borstkanker  ER-positive advanced breast cancer  ER-positive advanced breast cancer after aromatase inhibitor failure  ER-positive breast cancer  ER-positive early-stage breast cancer  ER-positive HER2 negative breast cancer  ER-positive HER2-negative breast cancer  ER-positive HER2-negative breast cancer in elderly patients  ER-positive HER2-negative MBC  ER-positive HER2-negative primary breast cancer  ER-positive node-positive breast cancer in elderly patients with comorbidities  ER+ HER2-  ER+ HER2- BC  ER+ HER2- breast cancer  ERA 223 study  eRAPID intervention  ERAS  ERBB2 HER2-positive metastatic breast cancer  ERBB2 mutations in solid tumors  ERBB2 plasma copy number  erdafitinib  Erdheim-Chester disease  erfelijke borst- en eierstokkanker  erfelijke syndromen  erfelijkheid  ERG- and PTEN-defined prostate cancer  eribulin  eribulin plus everolimus  eribulin plus pembrolizumab  eribulin with or without pembrolizumab  eribuline  ErkentNIS  erlotinib  erlotinib for advanced EGFR-mutated NSCLC  ersatzdroge  Erβ1  Erβ2  ES-NSCLC  ES-SCLC  ES-SCLC after platinum-based chemotherapy  ESAS-scores  ESCC  ESCC detection by microRNA profiling  ESCORT study  ESD  ESGC  ESHAP  eSMART study  ESMO  esomeprazole  esophageal adenocarcinoma  esophageal and esophagogastric junction adenocarcinoma  esophageal and GEJ adenocarcinoma  esophageal cancer  esophageal squamous cell carcinom  esophageal squamous cell carcinoma  esophagogastric cancer surgery  ESPAC-4 secondary analysis  ESR1 mutations  ESR1 mutations in CTCs and ctDNA  ESR1-amplificatie  essential thrombocythenia and polycythemia vera  estetrol  ESTHER cohort study  esthesioneuroblastoom  esthetische uitkomst  estimated projection of US cancer incidence and deaths to 2040  estimating risk of pancreatic cancer in the general population  estradiol levels  estrogen monotherapy  ET  ET outcomes  ET with versus without CDK4 6 inhibitors  etirinotecan pegol  etnische diversiteit  ETP-ALL LBL  ETS  EU-regelgeving  EURECCA  Euro-E.W.I.N.G.99  Euro-Ski  EURO-SKI studie  EUROCARE-5  European cancer mortality  European Code against Cancer  Europese kankermortaliteit  EURTAC  EUTOS  EV-101 study  EV-201 study  EV-201 trial  EV-301 study  EV-assay  evaluation of adjuvant chemotherapy after neoadjuvant FOLFIRINOX  evaluation of hematuria  EVAN study  event order  everolimus  everolimus plus exemestane for postmenopausal HR+ HER2- advanced breast cancer  everolimus plus letrozole and metformin  everolimus plus octreotide  everolimus plus pazopanib  everyday clinical practice  EVIDENCE study  evofosfamide  Ewing and Ewing-like sarcoma in adults  Ewing sarcoma  Ewing sarcoom  Ewing-2008  ex vivo IFNγ production  exceptional responder  EXCITE-studie  exemestaan  exemestaan plus everolimus  exemestane with or without enzalutaimde  exemstaan  exercise intervention in cancer patients  exercise versus usual care  exhaled breath tests  exogenous hormone use  exome sequencing-based screening  exosomal lncRNA-GC1  exosomen  expansie van fase 1-studie PCD4989g  explaining risk factors  Exploratieve analyse MARQUEE-studie  exposoom  exposure to occupational carcinogens in 195 countries  expressie stromagenen in CRC  EXPRESSION III-studie  expression of biomarkers  expression of insulin-like growth factor-1 receptor on CTCs  extended endocrine benefit  extended follow-up of PALOMA-2 study  EXteNET  ExteNET-studie  extension of aromatase inhibitor therapy  extensive stage  extensive stage small cell lung cancer  extensive-stage small cell lung cancer  extensive-stage small-cell lung cancer  external beam radiation therapy  external validation of risk calculators  extracapsular extension in sentinel node  extracorporeal photopheresis  extracranial chondrosarcoma  extracranial oligometastasis  extracranial oligometastatic breast cancer  extrahepatisch cholangiocarcinoom  extrameningeal primary SFT  extranodal natural killer T-cell lymphoma  extranodale extensie  extrapleural pneumonectomy  extrauterine disease  EZH2  FACE  facial nerve function  facial-aging app  facility volume  facilty volume and mortality  factors affecting sentinel node metastasis  factors associated with duration of diagnostic interval  factors associated with risk of body image-related distress  factors associated with risk of progression  factors associated with vomiting control  factors influencing multidisciplinary tumor board recommendations  factors predicting invasive breast cancer recurrence  FAKTION study  FALCON  fall and fracture risk  false positive FIT  familair mammacarcinoom  familiaal colorectaalcarcinoom  familiaal risico  familiaire adenomateuze polyposis  familiaire adenomateuze popyposis  familial adenomatous polyposis  familial and hereditary cancer syndromes  familial platelet disorder  familiale adenomateuze polyposis  familiegeschiedenis  familiegeschiedenis prostaatkanker  family history  family history of breast cancer  family history of cancer  family history of OC and BC  family history-based screening  FaMRIsc study  fase 2-studie BOLERO-4  fase 2-studie BOLERO-6  fase 2-studie KEYNOTE-224  Fase 2-studie SWOG S0801  fase 3- studie DREAM  fase 3-studie AURA3  fase 3-studie BrighTNess  fase 3-studie COLUMBUS  Fase 3-studie CRITICS  fase 3-studie ETNA  fase 3-studie FATA-GIM3  fase 3-studie GEC-ESTRO  Fase 3-studie KEYNOTE-045  fase 3-studie METEOR  Fase 3-studie MONALEESA-3  fase 3-studie MONALEESA-7  fase 3-studie NETTER-1  Fase 3-studie PERSEPHONE  fase 3-studie PRODRIGE 9  Fase 3-studie SAKK 75 08  Fase 3-studie SWOG S9921  fase 3-studie TROG 05.01  fase 3-studies  FAST study  FAST-Foward noninferiority phase 3 study  fatal ICI-associated toxic effects  fatalisme  fatigue  fatigue in cancer patients  favorable histology Wilms tumor  favorable-risk AML in patients younger than 60 years  FCR  FCT  FDA approval of novel cancer therapies between 2000 and 2016  FDA oncology drug approvals in 2018  FDA-approved novel oncology drugs  FDG-PET  FDG-PET CT  FDG-PET scanning  feasibility  febriele neutropenie  fecal and plasma short-chain fatty acdis  fecale immunochemische test  female and male breast cancer. global trends 1990-2017  female breast cancer risk  fentanyl  fentanyl sublinguale spray  fenylketonurie hyperfenylalaninemie  fermented dairy foods  fertiliteitspreservatie  fertility drugs  fertility preservation  fertility treatment  fertility-sparing surgery  FGFR pathway alterations  FGFRs  FH02 study  FHWT  FIA  FIGHTDIGO-studie  FIGO score 5 or 6 gestational trophoblastic neoplasia  fijne motoriek  fijnstof  FIL-HD0801 study  Final OS results from SOLO2 study  final overall survival analysis of IMpassion130  Finale analyse FIRST-studie  finale analyse van GOG 240-studie  finale overlevingsresultaten van KEYNOTE-006  financial links  financiële toxiciteit  finasteride  fine-needle biopsy  FinXX-studie  FIR-studie  FIRE-3  FIRE-SCLC Cohort Study  firefighters  FIRES  first line therapy  first relapse B-ALL in children and AYAs  first-degree relatives of pancreas cancer patients  First-iGAP study  first-line abiraterone-prednisone for mCRPC with bone metastases  first-line apatinib plus gefitinib  first-line atezolizumab  first-line atezolizumab plus chemotherapy  first-line avelumab for mMCC  first-line azacitidine plus venetoclax  first-line bavacizumab plus trebananib without chemotherapy  first-line BV plus nivolumab  first-line carboplatin versus cisplatin  first-line carboplatin-paclitaxel with or without bevacizumab  first-line cemiplimab  first-line CHOP or R-CHOP  first-line cladribine with concurrent or delayed rituximab  first-line CLL treatment  first-line DADI trial  first-line donafenib versus sorafenib  first-line dose-dense early postoperative intraperitoneal chemotherapy  first-line everolimus plus bevacizumab  first-line FOLFIRINOX  first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel  first-line gemcitabine-trastuzumab-erlotinib combination  first-line ibrutinib plus venetoclax  first-line ibrutinib-venetoclax versus chlorambucil-obinutuzumab  first-line ICI  first-line ICIs with or without chemotherapy  first-line ipatasertib plus paclitaxel for advanced TNBC  first-line lorlatinib versus crizotinib  first-line mCRC  first-line mFOLFOX6 plus bevacizumab versus cetuximab  first-line nivolumab plus cabozantinib for advanced RCC  first-line NSCLC treatment  first-line osimertinib  first-line pazopanib  first-line pembrolizumab  first-line pembrolizumab for advanced NSCLC with low PD-L1 expression  first-line pembrolizumab monotherapy  first-line pembrolizumab plus R-CHOP  first-line quavonlimab (anti-CTLA-4) plus pembrolizumab  first-line R-CODOX-M R-IVAC chemotherapy  first-line radioembolization plus chemotherapy  first-line selinexor plus R-CHOP  first-line SRS versus WBRT  first-line sunitinib  first-line tebentafusp versus investigator’s choice  first-line therapies  first-line tislelizumab plus chemotherapy  first-line TKIs  first-line TPEx versus EXTREME  first-line trastuzumab  first-line treatment  first-line treatment options  first-line Tumor Treating Fields plus chemotherapy  first-line venetoclax-obinutuzumab versus chlorambucil-obinutuzumab  first-line versus second line daratumumab  first-relapse rhabdomyosarcoma  FIRSTANA-studie  fistula  FIT  FIT cohort  FIT screening  FIT-detection of advanced colorectal neoplasia  FIT-screening  fitheid  fitness  five miRNA-model  five versus two years adjuvant zoledronate  five-miRNA based classifier  five-year analysis  five-year follow-up of CPX-351 versus 7+3 cytabine and daunorubicin  five-year outcome  five-year outcomes  five-year outcomes with cobimetinib plus vemurafenib  five-year PROs  five-year survival outcomes  five-year survivors of adolescent and young adult cancer  five-year survivors of chldhood cancer  fixed duration of venetoclax-rituximab  fixed-duration MRD-guided approach  FKBPL  FL  FLAME trial  FLAURA study  FLAURA-studie  flavonoïden  flexibele sigmoïdoscopie  flexibele-sigmoïdoscopie  FLIPPER trial  Florence Trial long-term results  FLOT4 study  FLOT4-studie  flow cytometry status  FLT3-internal tandem duplication mutated AML  FLT3-ITD AML  FLT3-ITD positive AML  fluciclovine versus PSMA PET-CT  fludarabine  FLUOGLIO-studie  fluoropyrimidine therapy  fluoropyrimidines  fluoroscopie  fluorouracil-leucovorin  fluzoparib  FLYER study  FNMTC  focal adhesion kinase  focal boost  FOCUS-cohort  FOCUS4-N trial  Fol-BRITe study  FOLFIRI  FOLFIRI plus cetuximab or bevacizumab  FOLFIRINOX  FOLFIRINOX and chemoradiotherapy  FOLFIRINOX salvage treatment  FOLFOX  FOLFOX4  FOLFOXIRI  FOLFOXIRI plus panitumumab  FOLFOXIRI-bevacizumab versus doublets-bevacizumab  foliumzuur  FOLL05-studie  folliculair lymfoom  follicular and other CD20+ non-Hodgkin lymphoma  follicular lymphoma  follow-up after discontinuation  follow-up after treatment cessation  Follow-up analyse van CheckMate 067-studie  follow-up analyse van JFMC34-0601  follow-up van overlevers  food insecurity in cancer survivors  forego medical care  formaldehyde  FOrMAT-studie  FoRT trial  FORUM study  fosaprepitant  fosaprepitant meglumine  fotofarmacologie  four-factor prognostic model  FOXA1-expressie  FOXA2  FOXC1  FP with or without oxaliplatin  FPD AML  fractionated gamma knife radiosurgery  fractionated stereotactic radiosurgery  fractionated stereotactic radiotherapy  fractionation schedule of CCTRT  fracturen  fractures  fractuurrisico  fragiele ouderen  fragiliteit  fragmentation of surgery and chemotherapy  frailty and neurocognitive decline  frequency and outcomes of brain metastases  frequent cystoscopy  FRESCO study  fresolimumab  front-line fludarabine-cyclophosphamide-rituximab  front-line ibrutinib for CLL patient populations not included in RESONATE-2  frontline dasatinib  frontline hyper-CVAD plus ofatumumab  frontline hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab  frontline targeted therapy plus low-intensity chemotherapy  frontline therapy for AML in elderly patients  frontline treatment for pediatric AML  frontline treatments  fruit  fruit and vegetable consumption  fruquintinib  FSRT  FSS versus RS  FTD versus HD-MA  FTL3-mutatie  FUJI cohort  fulvestrant  fulvestrant plus palbociclib  fulvestrant versus AIs  functional outcomes  furmonertinib  FUS-ERG and RUNX1-CBFA2T3  fusion gene  Fusobacterium nucleatum  future cancer risk  fysieke activiteit  G-CSF support  G-CSFs  g-NETs  G84E  gain-of-function mutatie  gait speed  galactography  galblaascarcinoom  GALEN study  galeterone  gallium-68 labelled PSMA-11 PET  GALLIUM-studie  galunisertib  galwegcarcinoom  gamma knife radiosurgery  ganglioside vaccine for high-risk neuroblastoma  ganglioside-monosialic acid  ganitumab  GARD  garlic  gastric adenocarcinoma  gastric cancer  gastric cancer family history  gastric cancer risk  gastric cancer with synchronous peritoneal metastases  gastric gastroesophageal junction AC  gastric gastroesophageal junction adenocarcinoma  gastric or gastro-esophageal junction cancer  gastric or gastroesophageal junction adenocarcinoma  gastric or gastroesophageal junction cancer  gastric or GEJ adenocarcinoma  gastritis  gastro-intestinale mucositis  gastro-intestinale stromale tumoren  gastro-oesofagaal adenomcarcinoom  gastroenteropancreatic neuroendocrine tumors  gastroesophageal adenocarcinoma  gastroesophageal cancer  gastroesophageal reflux disease  gastrointestinal bleeding  gastrointestinal stromal tumor  gastrointestinal stromal tumors  gastroïntestinale kanker  gastroïntestinale stromale tumoren  Gattelli  GAUDI  GBC  GBCA  GBM  GBM in elderly patients  GBS  GBSM  GBV-C  GC  GC GEJC  GC1008  GC4419  GCA  GCC  GCT  GCTB  GCTs  GD  GDP  GEC  gedatolisib plus paclitaxel and carboplatin  GeDDiS-studie  gedifferentieerd schildkliercarcinoom  gedissemineerde tumorcellen  gefitinib  gefitinib alone or with chemotherapy  gefitinib continuation after progression  GEICAM 2003-11_CIBOMA 2004-01 study  GEICAM 2010-04 study  gelokaliseerd prostaatcarcinoom  GEM  GEM-1402 study  gemcitabine  gemcitabine plus adavosertib  gemcitabine plus cisplatin induction chemotherapy  gemcitabine with or without berzosertib  gemcitabine-eribulin combination  gemcitabine-trastuzumab-pertuzumab after pertuzumab-based therapy  gemcitabineresistentie  gemetastaseerd mammacarcinoom  gemetastaseerd melanoom  gemetastaseerde borstkanker  gemetastaseerde borstkanker; trastuzumab  gemetastaseerde colorectaalkanker  gemtuzumab ozogamicin  gemtuzumab ozogamicine  GEN501 and SIRIUS final results  gender differences  gene expression profiles  gene expression profiling assay  gene variants and subsequent neoplasms  gene variants associated with increased cancer risk  geneesmiddelinteracties  Generations Study  genetic and clinical predictors  genetic factors  genetic prognostic and predictive factors  genetic testing  genetically defined renal tumors  genetically proxied inhibition of HMG-CoA reductase  genexpressie  genito-urinaire maligniteiten  genmethylering  genome sequencing  genome-edited donor-derived anti-CD19 CAR T cells for pediatric and adult B- ALL  genome-wide association study  genome-wide diet-gene interaction  genome-wide variants  genomic alterations  genomic analysis in NRG Oncology RTOG 9802  genomic biomarkers predicting anti-PD-(L)1 response  genomic classification and clinical outcome  genomic correlates  genomic correlates of progression or response  genomic determinants of clinical outcomes  genomic identification of HRD  genomic profiling  genomic profiling of prostate cancers from met with African and European ancestry  genomics and outcomes  genotoxic pks E. coli  genotyping lung adenocarcinoma  GENUINE trial  genvarianten  GEOMETRY mono-1 study  GEP-NETs  GeparNuevo analysis  GeparNuevo study  GeparOcto secondary analysis  GeparQuattro-studie  GeparSepto  GeparSepto long-term outcomes  GeparSixto trial  gepegyleerd liposomaal doxorubicine  geptanolimab  geptanolimab (GB226)  gerandomiseerde fase 2-studie PrE0102  GERD treatment  Gerecke  geriatirc patients  geriatric assessment impairments  geriatric comanagement  Geriatric Prognostic Indicator  germ cell tumors  germline BARD1 gene variants  germline BRCA PALB2 mutation  germline BRCA pathogenic variant  germline BRCA PVs and ovarian reserve  germline BRCA-mutated metastatic pancreatic cancer  germline BRCA1 2 mutation  germline BRCA1 2 pathogenic variants  germline BRCA2 mutations  germline genetic testing  germline mutaties  germline mutations  germline mutations in DNA repair genes  germline PALB2 pathogenic variants  germline pathogenic variants in 28 genes  germline predisposition gene mutations  germline variant status  germline variants in DNA repair genes  germline variants in natural killer cells  geserreerde poliepen  geslachtshormonen  gestation and birthweight of offspring  gestationele trofoblasttumor  GETNE-TRASGU study  GETUG-AFU 16 study 112-months follow-up  gevorderd cervixcarcinoom  gevorderd maag-adenocarcinoom  gevorderd melanoom  gevorderd niercelcarcinoom  gevorderde borstkanker  gevorderde maagkanker  geweichtsverlies  gezondheidsutiliteitsindex  gFOBT  GFR  GFR; niercelcarcinoom; urotheelcarcinoom  GHSG HD13-15 trials  GHSG HD17 study  GI adverse events  giant-cell tumor of bone  gilteritinib  GIMEMA-MMY-3006 trail  GIST  GISTs  GK-SRS with or without EGFR-TKIs  GKRS  GKRS for BMs of non-pulmonary primary tumors  GLARIUS-studie  glasdegib  GLASS study  Gleason score 9-10 prostate cancer  glembatumumab vedotin  glioblastoma  glioblastoma in poor perfomance status patients  glioblastoma multiforme  glioblastoma recurrence  glioblastoma with methylated MGMT promoter  glioblastoom  glioma  glioma risk  gliomas  gliomen  glioom  glitazonen  global burden of breast cancer  Global Burden of Cancer  global burden of cancer attributable to infections in 2018  global burden of cancer in 2020 attributable to alcohol consumption  Global Burden of Disease Study  global expanded access program  global incidence and mortality trends  global pediatric cancer care  global retinoblastoma presentation analysis by national income level  global trends  glofitamab  glottic squamous cell carcinoma  GLOW study  glucocorticoid treatment  glucocorticoid-refractory cGVHD  glucose lowering drugs  GLUT-  GLUT-14  glutathion-S-transferase P1  glycaan-gerelateerde genen  glypicaan-1  GM-CSF  GMMG-MM5 trial  GNCC  GnHRa  GnRH-agonist  GO  GO30140 study  GOG-0213 studie  GOG-0213 study  GOG-0218 final OS-analysis  GOG-0218 studie  GOG-0277  Golestan Cohort Study  gonadotropine  Google Translate  GORTEC 2007-01 studie  GORTEC 2014-01 TPExtreme study  gosereline  GOYA-studie  GP-led versus surgeon-led colon cancer survivorship care  grade 2 oligodendroglioma  graft failure  graft versus host disease  graft-versus-host disease  graft-versus-host disease prophylaxis  grain consumption and dietary fiber intake  GRASPA  GRECCAR 2-studie  GREEN study subgroup analysis  GRIFFIN study  grijpkrachtverlies  grip strength  groeicurves naevi  groeisnelheid  groenten  groentenconsumptie  grootcellig granulair lymfocytaire leukemie  grootcellig neuro-endocrien longcarcinoom  grootte van lymfekliermetastasen  gross total versus subtotal resection  gross-total resection  grote-korrel lymfocyten leukemie  growth hormone deficiency  growth rate of untreated hemangioblastomas  growth rates  GSK2857916  GTT  GU-toxiciteit  guadecitabine  guanylaatcyclase  GVAX pancreas  GVHD  GVHD prevention after haploidentical HCT  GVHD prophylaxis  GWAS  Gxplore-002 study  Gxplore-005 study  gynecological brain metastases  gynecologische maligniteiten  H. pylori  HA-WBRT + SIB for brain metastases  HA-WBRT + SIB versus conventional WBRT  haarverlies  hafnium oxide nanoparticle  HAI  HAIC  hairy cell leukemia  hairy-cell leukemie  hallmarks of cancer  HALO 202-studie  Ham-Wasserman lecture  Hamilton Fairley Award  hand-voet huidreacties  hand-voet syndroom  hand-voetsyndroom  HannaH study final analysis  haplo versus UD transplantation  haplo-HSCT  haplo-HSCT versus chemotherapy  haplo-identieke HSCT  haplo-SCT  haploidentical versus unrelated cord blood transplantation  haploidentical versus unrelated SCT  haploidentical; sibling; matched unrelated donor  HART  hartfalen  hartfalen na auto-HCT  HBOC  HBOT in breast cancer patients  HBV-related HCC  HBV-related HCC risk  HBV-vaccinatie  HC  hcc  HCC expressing CD147  HCC in HBV- or HCV-infected patients  HCC overall survival  HCC with portal vein tumor thrombus  HCMV reactivation during radiochemotherapy  HCT  HCV  HD 0607 trial  HD IL-2  HD12 study  HD16 trial  HD18-studie  HD9 study  HDAC inhibition  HDCT plus PBSCT  HDL-cholesterol level and risk of hematologic malignancy  HDR-brachytherapie  head and neck cancer  head and neck cancer risk after hematologic cancer  head and neck cancer surgery during COVID-19 pandemic  head and neck procedures  head and neck squamous cell carcinoma  head en neck cancer  Head Start III  health care use  health literacy  health maintenance practices  Health Professionals Follow-up Study  health promotion among cancer survivors  health-related quality of life  healthy immigrant effect  healthy lifestyle  healthy older adults  heart failure  heavily pretreated HR-positive HER2-negative metastatic breast cancer  heavily pretreated MBC  heavy smokers  hedgehog-signaalroute  heldercellig niercelcarcinoom  heldercellig ovariumcarcinoom  Helicobacter pylori  Helicobacter pylori treatment  HELIOS study  hematologic cancers and COVID-19  hematologic malignancies in older patients  hematologic malignant neoplasms  hematologische maligniteiten  hematopoietic cell transplantation  hematopoietic score predicts outcomes  hematopoietic stem cell transplantation  hematopoietic stem cell transplation  hematopoïetische celtransplantatie  hemispheric-specific clinical presentation  hemochromatosis HFE p.C282Y homozygosity  hemorrhagic cystitis following allotransplantation  HEPAR PluS study  hepatectomy in academic versus community cancer center  hepatic artery infusion pump chemotherapy  hepatitis B virus infection  hepatitis B-virus  hepatitis C  hepatocallular carcinoma  hepatocellulair carcinoom  hepatocellular carcinoma  hepatocellular carcinoma with portal vein invasion  hepatospleen T-cel lymfoom  hepatotoxiciteit  hepatotoxicity  HER2  HER2 amplification  HER2 exon 20 insertions  HER2 expression discordance between primary and metastatic breast cancer  HER2 expression testing  HER2 peptide vaccines for prevention of breast cancer recurrence  HER2 pro-oncogene signalering  HER2-amplified mCRC  HER2-directed therapies  HER2-expressie  HER2-expressing cancers  HER2-expressing mCRC  HER2-gedreven NSCLC  HER2-HER3 dimerization  HER2-low-positive breast cancer  HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy  HER2-mutant lung cancer  HER2-mutant metastatic cervical cancer  HER2-negatief mammacarcinoom  HER2-negatieve borstkanker  HER2-negatieve MBC  HER2-negative  HER2-negative BC  HER2-negative breast cancer  HER2-negative MBC  HER2-negative metastatic breast cancer  HER2-negative tumors  HER2-overexpressing breast cancer  HER2-positief mammacarcinoom  HER2-positief metastatisch mammacarcinoom  HER2-positieve borstkanker  HER2-positieve vroege borstkanker  HER2-positive ABC  HER2-positive ABC MBC  HER2-positive advanced breast cancer  HER2-positive and AR-positive advanced breast cancer  HER2-positive and biopsy-proven node-positive breast cancer  HER2-positive breast cancer  HER2-positive breast cancer brain metastases  HER2-positive breast cancer neoadjuvant lapatinib plus trastuzumab  HER2-positive breast cancer survivors  HER2-positive breast cancer with brain metastases  HER2-positive EAC  HER2-positive early breast cancer  HER2-positive early breast cancer in elderly  HER2-positive esophagogastric cancer  HER2-positive gastric cancer  HER2-positive gastro-esophageal adenocarcinoma  HER2-positive localized breast cancer  HER2-positive MBC  HER2-positive metastatic breast cancer  HER2-positive metastatic breast cancer after ≥ 2 HER2-directed regimens  HER2-positive salivary duct carcinoma  HER2-scoringsysteem  HER2-screening  HER2-targeted CAR T cell therapy  HER2-targeted therapies  HER2-targeted therapy  HER2+ BC  HER2+ breast cancer  HER2CLIMB  HER2CLIMB randomized phase 2 study  HER2CLIMB study exploratory analyses  HER2DX model  HER3-mutant mammacarcinoom  HERA  herb and supplement use  HERBY-studie  herceptin  herceptin-biosimilar  herceptine  Heritage  HERO study  heropname  herpes zoster after autologous stem cell tranplantation  hersenmetastasen  hersenmetastasen mammacarcinoom  hersenmetastasering  hersenmicrobloedingen  hersentumoren  Heterocephalus glaber  heterogeneity between SEER counties  HF-WBI  HFSRT  HGG  HGS OC  HGSOC  HIDAC versus IDAC consolidation  hidradenitis suppurativa  HIFU  high hereditary breast cancer risk  high PD-L1 expressing NSCLC  high risk early breast cancer  high risk locally advanced rectal cancer  high risk melanoma  high risk of colorectal peritoneal metastasis  high RS  high sensitivity C reactive protein  high versus low dose lenalidomide maintenance after transplantation  high-dose chemotherapy  high-dose chemotherapy and 3D conformal radiation  high-dose cyproterone acetate  high-dose intensity-modulated chemoradiotherapy  high-dose versus standard-dose twice daily thoracic RT  high-dose-rate brachytherapy  high-grade and low-grade glioma  high-grade brainstem gliomas  high-grade glioma  high-grade gliomas in children  high-grade osteosarcoma of the extremities  high-grade prostate cancer  high-intensity focused ultrasound  high-intermediate and high risk early stage EC  high-mobility group box 1  High-molecular-mass hyaluronan  high-PD-L1 expressing NSCLC with brain metastases  high-risk ALL in children  high-risk AML  high-risk AML in remission  high-risk breast cancer  high-risk cancer surgery  high-risk DLBLC  high-risk early breast cancer  high-risk EBC  high-risk endometrial cancer  high-risk extremity trunk STS  high-risk features  high-risk first-relapse B-ALL in children  high-risk HNC patients  high-risk localized gastrointestinal stromal tumor  high-risk locally advanced rectal cancer  high-risk low-grade glioma  high-risk luminal breast cancer  high-risk lymphoma  high-risk mature B-cell non-Hodgkin’s lymphoma in children  high-risk medulloblastoma in children  high-risk melanoma  high-risk mNSCLC  high-risk neuroblastoma  high-risk oral squamous cell carcinoma  high-risk pediatric HL  high-risk prostate cancer  high-risk resected melanoma  high-risk rhabdomyosarcoma  high-risk smoldering multiple myeloma  high-risk soft tissue sarcoma  high-risk stage 2 colon cancer  high-risk uveal melanoma  HIIT  HiLo trial  HIPEC  HIPEC + CS  histologic regression  histological biomarkers  histologically rare triple-negative breast cancers  histologische regressie  histology-tailored versus standard neoadjuvant chemotherapy  histopathologic features  history of use of statins and COX-2 inhibitors  HIV  HIV AIDS  HIV infection  HIV infection in elderly patients  HIV RNA  HIV-associated Kaposi sarcoma  HIV-infection  HL  HL diagnosis during pregnancy  HL-behandeling  HLA antigen mismatch  HLA-matched or alternative donors  HLA-mismatched unrelated donor HCT  HMAs for high-risk MDS or AML  HMIE versus open esophagectomy  hMPV  HMR 2.0  HNC  HNCs  HNSCC  HNSCC surgery  Hodgkin and non-Hodgkin lymphoma  Hodgkin lymfoom  Hodgkin lymphoma  Hodgkin lymphoma in children and adolescents  Hodgkin lymphoma survivors  Hodgkin's lymfoom  Hodgkin’s lymphoma  hofd-hals Merkel celcarcinoom  hoge dosering chemotherapie  Hokusai VTE-Cancer studie  holmium-166 after lutetium-177-dotatate  home administration of trastuzumab  homeobox B13  homocysteïne  homologous recombination deficiency  hoofd hals squameus celcarcinoom  hoofd halscarcinoom  hoofd halskanker  hoofd-hals melanoom  hoofd-hals squameus celcarcinoom  hoofd-halscarcinoom  hoofd-halskanker  hoofdhuidkoeling  hoog-risico B-ALL  hoog-risico cervixcarcinoom  hoog-risico CML  hoog-risico melanoom  hooggradig sereus ovariumcarcinoom  horizontale transfer  hormonal therapy  hormonal therapy resistance  hormone-modulating breast cancer therapy  hormone-naïve metastatic prostate cancer  hormoonreceptor positieve borstkanker  hormoontherapie  hospital volume  hospitalisatie  hospitalization  hospitalization after adolescent and young adult cancer  hospitalized patients with active cancer  hot flashes  HOVON 105 ALLG NHL 24  HOVON 105 study  Hovon 143 study  How Long studie  HP SCC  HPC-SFT  HPD  HPTC  HPV  HPV ctDNA  HPV DNA in penile cancer and intraepithelial neoplasia  HPV DNA persistence  HPV load and genotype analysis  HPV status  HPV types  HPV types 16 18 in cervical precancers  HPV vaccination  HPV vaccine  HPV-16 18 vaccin  HPV-associated epithelial cancers  HPV-associated malignancies  HPV-associated oropharyngeal carcinoma  HPV-associated oropharyngeal squamous cell carcinoma  HPV-FOCAL trial  HPV-infectie  HPV-negative HNSCC  HPV-orofarynxcarcinoom  HPV-positive oropharyngeal cancer  HPV-positive oropharyngeal squamous cell cancer  HPV-related OPSCC  HPV-typen  HPV-vaccinatie  HPV+OPSCC  HPV16 18-positive advanced cervical cancer  HPV16-related cancerISA101  HR-deficiëntie  HR-NB  HR-NBL1 SIOPEN study  HR-NL81 SIOPEN  HR-positief mammacarcinoom  HR-positief metastatisch mammacarcinoom  HR-positive advanced breast cancer  HR-positive advanced postmenopausal breast cancer  HR-positive breast cancer  HR-positive breast cancer brain metastases  HR-positive early-stage breast cancer  HR-positive HER2 negative metastatic breast cancer  HR-positive HER2-negative advanced breast cancer  HR-positive HER2-negative advanced or metastatic breast cancer  HR-positive HER2-negative early breast cancer  HR-positive HER2-negative metastatic breast cancer  HR-positive HER2-negative metastatic breast cancer in older women  HR-positive HER2-positive advanced breast cancer  HR-positive metastatic breast cancer  HR-status  HR+ HER2- breast cancer  HR+ HER2- MBC  HR+ HER2- vroeg-stadium mammacarcinoom  HR+ HER2+ breast cancer  HR+ MBC  HRBOC  HRQoL  HRQOL in prostate cancer  HRT  HRT and breast cancer risk  HRT versus CRT  hs-cTnT  HSC  HSCT  HSCT-bijwerkingen  Hsp70  HT  hTERT-DCs  hu3F8  huCART19  huidkanker  huidkankerscreening  huidmaligniteit  huidneoplasmen  huisartsenzorg  humaan papillomavirus  human equilibrative nucleoside transporter 1  human readers versus machine-learning algorithms  hybrid minimally invasive esophagectomy  hyperbaric oxygen therapy  hypercalcaemia of malignancy  hypercalcemie  hyperemesis gravidarum  hyperleukocytosis  hyperprogressive disease  hyperproliferatie van stamcellen  hypertensie  hypertension  hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery  hyperthermische intraperitoneale chemoperfusie  hypervascular intracranial tumors  HYPO-RT-PC study  hypodiploid ALL in children  hypofarynxcarcinoom  hypofractionated adjuvant radiotherapy  hypofractionated breast RT for 1 week versus 3 weeks  hypofractionated IMRT  hypofractionated postmastectomy radiotherapy  hypofractionated RT  hypofractionated SRS  hypofractionated SRT to the resection cavity  hypofractionated stereotactic radiotherapy  hypofractionated stereotactic radiotherapy after surgery for brain metastases  hypofractionated versus conventional RT  hypofractionated versus conventionally fractionated RT  hypofractionated versus conventionally fractionated whole-breast irradiation  hypomethylating agents  hyponatremie  HYPOR  HYPRO  I CARE trial  I-131 labelled metuximab  i-ALCL  I-SPY 2 trial  I-SPY2 three-year follow-up analysis  iAMP21  IARC  IBC  IBCSG 23-01 trial  IBD  IBIS II  IBIS-I  IBIS-II trial 10 year follow-up  IBM Watson  IBR  ibrutinib  ibrutinib discontinuation  ibrutinib for CLL  ibrutinib plus fludarabine  ibrutinib plus palbociclib  ibrutinib plus venetoclax  ibrutinib versus ofatumamab  ibrutinib with or without ublituximab  ibrutinib-obinutuzumab-venetoclax combination  ibuprofen  ICARIA-MM study  ICARIA-MM subgroep analysis  ICB  ICBP SURVMARK-2 study  ICC  ICI dosing strategy  ICI for GBM  ICI therapy  ICI therapy in IBD patients  ICI treatment  ICI-associated neurotoxicities  ICI-induced autoimmunity  ICI-related multisystem immune-related adverse events  ICI-related myocarditis  ICIs  ICIs for advanced cSCCs  ICIs for advanced non-small cell lung cancer  ICIs for advanced NSCLC  ICIs for advanced NSCLC in clinical practice  ICIs for aNSCLC  ICIs for cancer  ICIs for lung cancer or malignant melanoma  ICIs for melanoma  ICIs for melanoma in patients with preexisting autoimmune disease  ICIs for metastatic cancer  ICIs for metastatic cancers in solid organ transplant recipients  ICIs for metastatic melanoma. early prediction of pseudoprogression  ICIs for metastatic renal and urothelial cancer  ICIs for MSI-H metastatic colorectal cancer  ICIs for non-small cell lung cancer  ICIs for NSCLC  ICIs for solid malignancies  ICIs plus chemotherapy  ICLL-07 FILO trial  ICLL07 FILO study  ICON6-studie  ICON8 study  ICON8-studie  ICPi  ICU-opname  idarubicine plus cytarabine plus nivolumab  iddEPC-studie  ide-cel  IDEA collaboration  IDEA-collaboration  idelalisib  IDH mutation  IDH wildtype glioblastoma  IDH-mutant lower-grade glioma and glioblastoma  IDH1 IDH2-mutant solid tumors  IDH1-expressie  IDH1-mutant solid tumors  idiopathische membraneuze nefropathie  idiopatische MCD  Idylla  IELSG-19 studie  IELSG32-studie  IES  IFD  IFG  IFM 2009  IFN-onderhoudsbehandeling  IFRT  IGBT  IGF-1  IGF-1R expressie  IGF2-AS  IgM MGUS  IGT  IHCA  IHCC  IHGV mutational status  IIIA-N2 NSCLC  ijzersuppletie  IKFZ1-deletie  IKFZ1-deletion  IKZF1-deletie  IL-12 plasmid transfection  IL-6  IL-8  ILC  illness perception and outcomes in cancer  iLLUMINATE study  image-guided intensity modulated radiation therapy  Imaging  imaging surveillance  imaging-based prostate cancer screening  IMAJEM-studie  imatinib  imatinib after other multi-kinase inbitors  iMATRIX study  IMbrave 150 study  IMbrave150  IMbrave150 study  IMD  imetelstat  IMiDs  imiquimod  immediate vs deferred cytoreductive nephrectomy  IMmotion 151 trial  IMmotion 151-studie  IMmotion151 trial  immune checkpoint blockade  immune checkpoint inbition for cancer  immune checkpoint inhibition  immune checkpoint inhibition for unresectable HCC  Immune Checkpoint Inhibitor  immune checkpoint inhibitor associated acute kidney injury  immune checkpoint inhibitor for NSCLC  immune checkpoint inhibitor induced pituitary dysfunction  immune checkpoint inhibitor rechallenge after irAE  immune checkpoint inhibitor therapy  immune checkpoint inhibitor trials  immune checkpoint inhibitor-induced colitis  immune checkpoint inhibitor-mediated diarrhea and colitis  immune checkpoint inhibitors  immune checkpoint inhibitors for metastatic cutaneous melanoma  immune health  immune infiltration  immune markers of nivolumab response  immune microenvironment  immune response  immune status  immune-mediated diarrhea and colitis  immune-related adverse events  immune-related adverse events and efficacy of avelumab  immune-related meningitis  immune-related pneumonitis  IMMUNED study  immunocheckpoint blockade  immunochemottherapy  immunocompromised cancer patients  immunoglobuline lichte-keten amyloïdose  immunologically quiescent melanoma  immunophenotyping of TILs and PBLs  Immunoscore  immunosuppressive therapy for management of MDS  immunotherapy  immunotherapy after surgery of the primary tumor  immunotherapy for advanced non-small cell lung cancer  immunotherapy for advanced stage cancer  immunotherapy for EGFR ALK wild-type advanced NSCLC  immunotherapy for melanoma  immunotherapy for NSCLC  immunotherapy plus stereotactic radiotherapy  immunotherapy rechallenge  immunotherapy-related pruritus  immutherapy  immuuncheckpointremmers  immuunrespons  immuunsuppressie  immuuntherapie  IMPAC  IMPACT  impact of adjuvant regimes  impact of adjuvant therapies on outcomes  impact of advances in treatment  impact of age  impact of age and frailty  impact of age at diagnosis on survival  impact of age on melanoma response to bevacizumab  impact of age on outcomes  impact of alcohol and smoking and FRP  impact of antibiotics  impact of antiviral therapy for chronic hepatitis C  impact of asparaginase discontinuation on outcome  impact of attending surgeon  impact of baseline body mass index  impact of biopsy frequncy on metastasis and mortality  impact of bone metastases  impact of BRAF V600E K mutation status  impact of breast cancer treatment on employment  impact of breast screening programme on mortality in England  impact of calcium channel blocker use  impact of centralization within hospital systems  impact of cisplatin-based chemotherapy on risk of metachronous contralateral disease  impact of concomitant PPIs on survival  impact of concurrent dexamethasone on clinical benefit  impact of conditioning intensity  impact of COVID-19 pandemic  impact of cumulative exposure to premenopausal obesity  impact of detailed family history  impact of diet  impact of disease stage  impact of EGFR mutation and ALK rearrangement  impact of epigenetics on association of aspirin use with mortality after breast cancer  impact of ER status on survival  impact of facility caseload  impact of follow-up time  impact of germline BRCA1 or BRCA2 or PALB2 mutation on platinum response  impact of germline mutations  impact of high TMB on response rates  impact of HIV infection  impact of hormone receptor status  impact of imaging intensity on survival after systemic therapy  impact of low-dose aspirin  impact of lower airway dysbiosis on progression  impact of metabolic syndrome  impact of moderate-to-vigorous intensity physical activity  impact of molecular subtypes on incidence and prognosis of CNS metastases  impact of optimizing diagnostic workup and reducing time to treatment  impact of overweignt and obesity  impact of patient age  impact of poverty  impact of pre-existing CVD on mortality  impact of pregnancy on genomic landscape  impact of primary tumor surgery  impact of prior CT or RT on efficacy of durvalumab for NSCLC  impact of prior or concurrent antibiotic therapy  impact of prior ruxolitinib  impact of prior therapy  impact of probiotics use  impact of race ethnicity  impact of race on outcomes  impact of race on outcomes of definitive RT  impact of radiation facility volume  impact of screening  impact of screening on OPE diagnosis  impact of solid cancer on in-hospital mortality  impact of stewardship program  impact of subtype on axillary pCR to neoadjuvant therapy  impact of subtype on GKS outcomes  impact of surveillance  impact of treatment modality on performance of prognostic factors  impact of tumor size and high-risk features on chemotherapy benefit  impact on breast cancer incidence and mortality  impact on breast cancer risk  impact on COVID-19 survival  impact on CRC incidence and mortality  impact on diagnosis and initial treatment of breast cancer in The Netherlands  impact on Dutch lung cancer care  impact on functional age and mortality  impact on long-term risk of morbidity  impact on memory  impact on metastatic behavior and outcome  impact on OC risk in African American and White women  impact on outcome  impact on outcomes  impact on outcomes of durvalumab for NSCLC  impact on recurrence and survival  impact on sexual function  impact on short-term mortality  impact on survival  impact on survival and recommended treatment intensity  IMPACT program  Impact van timing van adjuvante chemotherapie voor vroeg-stadium mammacarcinoom  IMPACT-studie  IMPACT2  IMpassion031 trial  IMpassion130 study  IMpassion130 study updated results  IMpassion130 trial  IMPATTO study  implications of minimal residual disease detection  IMPORT LOW study  IMpower010 study  IMpower110 study  IMpower130 trial  IMpower132 trial  IMpower133 Study  IMpower133 updated analyses  IMpower150 final overall survival analyses  IMpower150 study  IMpower150 trial safety and PROs  IMpower150-studie  IMPRESS-studie  IMPROVE study  IMPT  IMRT  IMRT alone  IMspire150 trial  IMT  IMvigor130 study  IMvigor211-studie  in situ mammacarcinoom  in utero chemotherapy exposure  in-hospital mortality  incidence  incidence and mortality in England  incidence and mortality of second primary cancers  incidence and outcomes  incidence and outcomes of lung cancer  incidence and predictors of diabetes mellitus  incidence and survival among solid organ transplant recipients  incidence and survival in the USA 1973-2015  incidence of and mortality from malignancies after CIN treatment  incidence of cancer diagnoses  incidence of hypothyroidism  incidence of pneumonitis  incidence of relapse  incidence of T790M mutation in cfDNA  incidence of thyroid cancer in WTC-exposed rescue workers  incidence of vulvar precancerous lesions and cancer  incidence of young adult cancers in Canada  incidence trends  incidence trends of breast cancer molecular subtypes by age and race in the US  incident cancer  incident cancer risk  incident cardiovascular events  incident type 2 diabetes duration  incidental pulmonary embolism in cancer patients  incidentally detected lung nodules  incidentally found pediatric brain tumors  incidentie  incidentie mammacarcinoom USA  incomplete pregnanacy  increased α-fetoprotein  increasing dose intensity of chemotherapy  INDAR  independence  indeterminate pulmonary nodules  individual oncogenic HPV types  individual patient-level analysis  individual patient-level data meta-analysis  individualised axitinib regimen  indolent lymfoom  indolent mammacarcinoom  indoor tanning  Indoor tanning industry  indoximod plus pembrolizumab  inductie-chemoradiatie  inductiechemotherapie  induction chemotherapy  induction chemotherapy for AML  infants  infectie  infigratinib  inflammatie  inflammation  inflammation cascade  Inflammatoir mammacarcinoom  inflammatoire voeding  inflammatory bowel disease  Inflammatory breast cancer  inflammatory markers  infliximab  influenza vaccination  influenza vaccine effectiveness among cancer patients  influenzavaccinatie  infradiaphragmatic disease  inhaled corticosteroids  INHANCE-consortium  iNHL  iniparib  INITIATE study  iNNOVATE  iNNOVATE-studie  innovations in therapy  InnovaTV 201 study  innovaTV 204 study  INO-VATE studie  inoperable endometrial cancer  inoperable pancreatic cancer  inotuzumab ozogamicin  inpatient versus outpatient administration  INSIGHT-studie  inspanning  Institute of Cancer Research  insulin resistance  insulin-like growth factor  insulin-like growth factor -1  insulinemie  insulineresistentie  intake of one-carbon metabolism-related micronutrients  intake of whole grains and dietary fiber  INTEGRATE  integrated palliative and oncology care  INTELLANCE 2 study  intellectual functioning  intellectual outcomes  INTENS-studie  intense androgen deprivation before prostatectomy  intensieve chemotherapie  intensity of diagnostic evaluation  intensity-modulated proton therapy versus intensity-modulated radiation therapy  intensity-modulated radiation therapy  intensive therapy  inter- and intra-laboratory variation  InterAAct  Intergroup Exemestane Study  interim OS analysis of MONARCH 2  interim PET  interim PET CT predicts PFS  intermediate endpoints  intermediate recurrence score  intermediate- or high-risk GIST  intermediate-risk AML  intermediate-risk prostate cancer  intermediate-stage hepatocellular carcinoma  intermittent nivolumab  intermittent versus continous PEG-asparaginase  intermitterende claudicatie  internal mammary and medial supraclavicular irradiation  International Breast Cancer Intervention Study I  International Childhood Cancer Cohort Consortium  International Male BC Program  International Prognostic Index  International Prognostic Score  international variation in radiation dose  internet-steunprogramma's  interruption or noncompletion of chemoradiotherapy  interstitial lung disease induced by HER2-targeting therapy for MBC  interval breast cancer  interval cancers  interval versus screening-detected breast cancers  interval-compressed VDC IE-chemotherapy  intervalcarcinomen  intervals to diagnosis  intra-tumor heterogeniteit  intra-tumoral genomic heterogeneity in rectal cancer  intracraniaal ependymoom  intracranial meningioma  intracranial metastatic disease  intractable serous ascites  intraductal papillary mucinous neoplasms  intraductale papillaire mucineuze neoplasie  intraductale papillaire mucineuze neoplasmen  intrahepatic cholangiocarcinoma  intrahepatic cholangiocarcinoma risk  intrahepatisch cholangiocarcinoom  intraoperative peritoneal lavage  intrapatient heterogeneity in enzalutamide response  intraperitoneale chemotherapie  intrathecal pemetrexed  intratumoral F. nucleatum  intratumoral PVSRIPO  intratumorale genetische heterogeniteit  intratumorale genoomdiversiteit  intrauterine devices  intravenous high-dose methotrexate based therapy  intravitale microscopie  intrinsic subtype analysis of BOLERO-2  intrinsiek subtype  intrinsieke subtypes  intrinsieke subtypes mammacarcinoom  invasieve borstkanker  invasive breast cancer  invasive cervical cancer  invasive ductal carcinoma of the breast  invasive fungal infections  invasive lobular carinoma of the breast  invasive melanoma  invasve breast cancer and breast cancer mortality after screen-detected DCIS  INVICTUS trial  invloed behandelcentrum op overleving  involvement of dentists  IO plus bosutinib  ioniserende straling  iontoforese  IORT  IOTA5 study  IP1-PROSTAGRAM study  ipatasertib  ipatasertib plus abiraterone and prednisolone  IPATential150 trial  IPD meta-analysis  IPH4102  ipilimumab  ipilimumab plus nivolumab  ipilimumab versus pembrolizumab  ipilimumab with or without anti-PD-1  IPMN  ipsilateral axillary lymph node reactivity on imaging  ipsilateral breast event  IPTT  irAEs  IRd  IRE  irinotecan  irinotecan dose  irinotecan plus cetuximab with or without vemurafenib  IRIS  isatuximab  isatuximab fixed-volume infusion  iscocitraatdehydrogenase  isocitraatdehydrogenaseremmer  isocitrate dehydrogenase 1-mutated glioma  isocitrate dehydrogenase wild-type glioblastoma in young adults  isoflavone intake  isolated breast pain  isolated synchronous colorectal peritoneal metastases  isotretinoin  Italiaanse cultuur  ITOMIC-001 studie  IV versus IP chemotherapy plus bevacizumab  IVC filters  IVF  IVIG for HG  ivosidenib  ivosidenib plus azacitidine  IVY study  IWDD  ixazomib  ixazomib maintenance  ixazomib of placebo toegevoegd aan lenalidomide-dexamethason  J-ALEX studie  J-FAPP Study IV  JACC-studie  JACCRO CC-08 study  JACCRO GC-07 study  JACOB study  JAKARTA-2 studie  jandus  Janus Cohort  JAVELIN Bladder 100 study  JAVELIN Lung 200 study  JAVELIN Merkel 200 study  JAVELIN Merkel 200-studie deel B  JAVELIN ovarian cancer cohort  JAVELIN Renal 100-studie  JAVELIN Renal 101 study  JAVELIN Renal 101 trial second interim analysis  JAVELIN Solid Tumor studie  JAVELIN Solid Tumor study mUC cohort two-year follow-up  JAVELIN Solid Tumor Study NSCLC cohort  JAVELIN Solid Tumor trial  JAVELIN Solid Tumor trial mesothelioma cohort  JCOG0203 trial  JCOG0504-studie  JCOG0910-studie  JCOG0912 study  JCOG1001-studie  JCOG1007 study  JFMC37-0801 study  JGO  job-exposure matrices  jodium-131  joint replacement. B-cell neoplasms  JPHC nested case-control study  JULIET trial  JULIET-studie  JVDL study  KAMILLA exploratory analysis  kanker  kanker bij kinderen  kanker-immunotherapie  kankerchirurgie  kankerincidentie  kankermortaliteit  kankermortaliteit 2015  kankerpijn  kankerrisico  kankerrrisico  kankersterfte  kankersubtypes  KARISMA study  KARMA study  KATE2 study  KATHERINE phase 3 study  KATHERINE study  katheter  KC  KDD  KdD versus Kd  keratinocytcarcinoom  keratinocyte carcinoma  Keratinocyte Carcinoma Chemoprevention Trial  keratinocyte carcinomas  kerncentrales  ketotifen  KEYNOTE-001  KEYNOTE-001 (secundaire analyse)  KEYNOTE-001 study  KEYNOTE-006 study  KEYNOTE-010  KEYNOTE-010 study  KEYNOTE-012  KEYNOTE-013 and -170  KEYNOTE-017 study  KEYNOTE-020  KEYNOTE-021  KEYNOTE-021 cohort G  KEYNOTE-021 study  KEYNOTE-022 study  KEYNOTE-024  KEYNOTE-024 five-year outcomes  KEYNOTE-028  KEYNOTE-028 and -158  KEYNOTE-028 and -158 pooled analysis  KEYNOTE-028 and -158 studies  KEYNOTE-028 studie  KEYNOTE-028 study  KEYNOTE-029  KEYNOTE-029 cohort C  KEYNOTE-029 Part 1B long-term follow-up  KEYNOTE-029 studie  KEYNOTE-040 study  KEYNOTE-040 study HRQOL analysis  KEYNOTE-042 study  KEYNOTE-045  KEYNOTE-048 study  KEYNOTE-052 long-term oucomes  KEYNOTE-052 studie  KEYNOTE-055  KEYNOTE-057  KEYNOTE-059 studie  KEYNOTE-061 exploratory analysis  KEYNOTE-061 studie  KEYNOTE-062 phase 3 study  KEYNOTE-086 cohort A  KEYNOTE-086 cohort B  KEYNOTE-087  KEYNOTE-100 study  KEYNOTE-119 trial  KEYNOTE-146 study  KEYNOTE-158 study  KEYNOTE-164  KEYNOTE-164 studie cohort B  KEYNOTE-177 health-related quality of life analysis  KEYNOTE-177 study  KEYNOTE-180 study  KEYNOTE-181  KEYNOTE-181 study  KEYNOTE-189 studie  KEYNOTE-189 study  KEYNOTE-189 trial final analysis  KEYNOTE-199 study  KEYNOTE-204 trial  KEYNOTE-240 study  KEYNOTE-355  KEYNOTE-355 trial  KEYNOTE-407  KEYNOTE-407 final analysis  KEYNOTE-407 study  KEYNOTE-426 extended follow-up  KEYNOTE-426 study  KEYNOTE-427 cohort B  KEYNOTE-427 study cohort A  KEYNOTE-427 study cohort B  KEYNOTE-522 study  KEYNOTE-564 trial  KEYNOTE-598  KEYNOTE-604  KEYNOTE-629 study  KEYNOTE-799 trial  Khorana-score  Ki-67  Ki67  kidney cancer  kidney function and cancer risk  kidney stones and risk of RCC and UTUC  kidney transplant recipients  kiemceltumor  kiemceltumoren  kinaseremmers  kinderkanker  KIT  klachten aromataseremmers  KLASS-01 studie  KLASS-02-RCT  klassiek Hodgkin lymfoom  klein lymfocytair lymfoom  kleincellig longcarcinoom  kleincellig prostaatcarcinoom  kleincellige longkanker  kliernegatief mammacarcinoom  klierpositief mammacarcinoom  KMT2A-rearranged ALL in infants  Know Your Tumor registry trial  KO-TIP-001 trial  koffie  koffieconsumptie  kosten behandeling HER2-positief MBC  kosten van gezondheidszorg  kosteneffectiviteit hematologische middelen  kosteneffectiviteit screening  KP-BSI  KRAS  KRAS G12C mutation  KRAS mutation  KRAS variant status  KRAS wild-type mCRC  KRAS-G12C mutant NSCLC  KRAS-mutatie  KRAS-mutaties  KRd versus VRd for newly diagnosed multiple myeloma  KRISTINE study  KRISTINE-studie  KRYSTAL -1 study  KRYSTAL-1 study  KS  KSHV-transmissie  KTE-X19 CAR T-cell therapy  kwaliteit van leven  L-COSY  L-MIND study  LA-CSCC  LA-ESCC  LA-HNSCC  LA-NSCLC  laag-moleculairgewicht heparine  laag-vet voeding  laaggradig glioom  laaggradig niet-spierinvasief urotheelcarcinoom  laaggradig sereus ovarium- of peritoneaal carcinoom  laat recidief coloncarcinoom  LABC  labeled sodium fluoride PET CT  laboratory prognostic scores  LACE-Bio studies  LACE-Bio-II study  LACE-studie  LAcSCC  LADG  LADG versus ODG  LAFA-studie  LAHNC  LAM  LAM-SA 2007 study  LAMIS  LAN  Lancet Haematology  Lange-termijn analyse van SBG 2004-1 studie  lange-termijn follow-up van KEYNOTE-001  lange-termijn uitkomsten GeparQuinto  langerhanscel histiocytose  LAP07  LAPA and BRPA  LAPACT study  laparoscopic versus open distal gastrectomy  laparoscopic versus open gastrectomy  laparoscopic versus open pancreatoduodenectomy  laparoscopic versus open resection  laparoscopic versus open surgery  laparoscopic versus open total gastrectomy  laparoscopie  laparoscopische chirurgie  laparoscopische hysterectomie  laparoscopische ingreep  laparoscopische resectie  lapatinib  LAPC  LAPC mPC with associated pain  LAPC-1 trial  LARC  large B-cell lymphoma  large brain metastases  large skull base meningiomas  larotrectinib  laryngectomy  laryngectomy outcomes  larynxcarcinoom  larynxkanker  larynxpreservatie  Lasker Award  late bone marrow relapse of B-cell ALL in children  late cardiac adverse events  late distant recurrence  late lower cranial neuropathy  late mortaliteit  late mortality in the North American CCSS versus the UK BCCSS  late outcomes  late radiation toxicity  late recurrence  late recurrence after liver resection  late toxicity of moderately hypofractionated PBT versus IMRT  late-onset anorectal disease  Lateral Node Study  LATITUDE study  LATITUDE-studie  LAVC  lazertinib  LBCL  LC  LCH  LCL161  LCNEC  LCS-6 KRAS  LDCT lung cancer screening  LDH response as prognostic biomarker  LE  LEA-studie  LEBS  leefstijl  leefstijl-geassocieerde maligniteit  leefstijlfactoren  leefstijlinterventies  leeftijd  left anterior descending coronary artery radiation dose  left lung cancer  left ventricular global longitudinal strain  leighl  leiomyomatose  leiomyosarcoom  leisure-time physical activity  lenalidomide  lenalidomide maintenance  lenalidomide maintenance after autologous hematopoietic stem cell transplantation  lenalidomide maintenance versus observation  lenalidomide plus rituximab  lenalidomide with or without EPO alfa  lenvatinib  lenvatinib plus pembrolizumab  lenvatinib plus pembrolizumab or everolimus versus sunitinib  lenvatinib plus pembrolizumab salvage therapy  leptomeningeal disease  leptomeningeal disease in metastatic melanoma patients  leptomeningeal disease recurrence  leptomeningeal metastases  leptomeningeal metastases from EGFR-mutant NSCLC  leptomeningeal metastases from NSCLC  leptomeningeale ziekte  letrozol  letrozole  letrozole for early breast cancer  letrozole maintenance therapy  letrozole with or without bevacizumab  leucine-rich repeating G-protein-coupled receptor 5  leukapheresis  leukemia  leukemia cutis  leukemie  leukemie in kinderen  leukocyt-telomeerlengte  leukocytenattractie  leukocytosis  leumie  levensverwachting  levercarcinoom  levercelcarcinoom  levercelkanker  leverfunctie  leverkanker  levermetastasen  levofloxacin prophylaxis of infection  Leydig cell function  LFS  LGG  LGG before one year of age  LGSC  LGSOC  Li-Fraumeni syndrome  Li-Fraumeni syndroom  liberal versus restrictive thresholds  LIBRETTO-001 study  lichaamsgewicht  lichaamslengte  lichaamsomvang  lichaamsvet  lichaamsvetgehalte  lichte keten-geassocieerd Fanconi syndroom  lidocaïne  lieu  lifastuzumab vedotin  life expectancy free from major chronic diseases  life expectancy of adult survivors of childhood cancer diagnosed between 1970 and 1999  lifestyle  lifestyle factors  lifestyle factors and risk of MPN  lifestyle intervention  lifileucel  lifirafenib  ligating veins first versus arteries first  light-chain amyloidosis  limited stage small-cell lung cancer  limited-stage diffuse large B-cell lymphoma  limited-stage small cell lung cancer  LINC00472  lincRNA  linked color imaging  linsitinib  lip-SCC  LIPI  lipophilic statin use  lipophilic statins  liposarcoom  lipoxygenases  liquid biopsy  liquid biopt tracking in surveillance  liquide biopten  liso-cel  Listeria expressing mesothelin  LITT  liver cancer  liver cancer mortality  Liver Cancer Pooling Project  liver cancer risk  liver metastatic breast cancer  liver or lung oligometastatic CRC  liver resection for malignancy  liver surgery for primary liver cancer  liver transplant for HCC  liver transplantation after tumor downstaging  liver-directed local therapy  living donors  LLPCa  LM  LMB-2  LMR  LNC-PATH score  lncRNAs  lobaplatin versus cisplatin non-inferiority trial  lobectomie  lobectomy  lobulair carcinoom in situ  lobulair mammacarcinoom  lobular breast cancer  local consolidative therapy  local control  local failure  local recurrence  local recurrence after transanal TME  local therapy  localized bone or soft tissue sarcoma  localized GIST  localized high-risk prostate cancer  localized OPSCC  localized pancreatic cancer  localized PCa  localized PDAC  localized prostate cancer  localized renal cell carcinoma  localized small bowel adenocarcinoma  localized versus advanced stage  localizing recurrent prostate cancer  locally advanced BCC  locally advanced BCC after HHI  locally advanced bladder cancer  locally advanced breast cancer  locally advanced cancer  locally advanced cervical cancer  locally advanced ESCC  locally advanced esophageal cancer  locally advanced esophageal squamous cell carcinoma  locally advanced esophagogastric adenocarcinoma  locally advanced G GEJ adenocarcinoma  locally advanced gastric cancer  locally advanced head and neck squamous cell carcinoma  locally advanced HER2-negative breast cancer  locally advanced intrahepatic cholangiocarcinoma  locally advanced large cell neuroendocrine carcinoma of the lung  locally advanced laryngeal cancer  locally advanced lung cancer  locally advanced non-small cell lung cancer  locally advanced NSCLC  locally advanced or metastatic melanoma  locally advanced or metastatic non-squamous NSCLC  locally advanced or metastatic sarcoma  locally advanced or recurrent metastatic cSCC  locally advanced pancreatic cancer  locally advanced pancreatic cander  locally advanced pancreatic neuroendocrine tumors  locally advanced prostate cancer  locally advanced rectal cancer  locally advanced squamous cell lung cancer  locally recurrent brain metastases  locally recurrent breast cancer  locally recurrent NPC  locally recurrent or metastatic HER2-positive breast cancer  locally recurrent pancreatic cancer after resection  locatie  locatie van overlijden  locoregionaal recidief  locoregional progression during neoadjuvant systemic therapy  locoregional recurrence  locoregional recurrence of breast cancer  Locoregional recurrent rhabdomyosarcome  locoregionale behandeling  locoregionally advanced HNSCC  locoregionally advanced NPC  locoregionally advanced resectable CSCC-HN  LOGICA trial  LOH  lokaaal-gevorderd rectumcarcinoom  lokaal gevorderd prostaatcarcinoom  lokaal gevorderd rectumcarcinoom  lokaal recidiverend mammacarcinoom  lokaal-gevorderd hoofd-halscarcinoom  lokaal-gevorderd metastatisch mammacarcinoom  lokaal-gevorderd rectumcarcinoom  lomustine  lomustine plus temozolomide  loncastuximab tesirine  Long Island Breast Cancer Study Project  long-term antiandrogen therapy  long-term cancer risk  long-term cause-specific mortality  long-term cerebrovascular changes  long-term consequences  long-term CRC risk  long-term CRC risk after screen detected adenoma  long-term disease-free breast cancer survivors  long-term follow-up  long-term follow-up BIG 1-98 trial  long-term follow-up KEYNOTE-012  long-term follow-up of CD19-CAR T-cell therapy  long-term health outcomes  long-term IHD risk  long-term impact  long-term mental health service utilization  long-term neurocognitive and psychosocial outcomes  long-term OPC survivors  long-term outcomes  long-term outcomes in Poland  long-term responders  long-term results  long-term results OlympiAD study  long-term risk of endocrine and metabolic diseases  long-term risk of hospitalization  long-term risk of infections  long-term somatic disease risk  long-term survival  long-term survivors NHL  long-term survivors of advanced melanoma treated with checkpoint inhibitor  long-term survivors of childhood cancer  long-term survivors of cisplatin for testicular cancer  long-term survivors of IDH-wildtype glioblastoma  long-term survivos of childhood cancer  long-term thyroid cancer risk  longadenocarcinoom  longcarcinoom  longer intervals after negative low-dose CT result  longfunctie  longitudinal analysis of fatigue and anxiety and quality of life  longitudinal analysis of HRQOL  longkanker  longkanker-screening  longkankerchirurgie  longkankerscreening  longmetastasen  LORELEI study  lorlatinib  lorlatinib after second-generation ALK TKI  lorlatinib versus crizotinib  loss of CEACAM1-expression  loss of heterozygosity 1p and 16q  loss of life expectancy  LOTIS-2 study  LOTUS trial  LOTUS-studie  low cT3 4 rectal cancer  low dose radioiodine ablation  low grade and anaplastic glioma  low grade glioma  low-dose aspirin  low-dose aspirin use  low-dose bisphosponates or denosumab  low-dose erlotinib  low-dose metronomic versus conventional chemotherapy  low-dose tamoxifen  low-dose tamoxifen for mammographic density reduction  low-grade glioma  low-grade glioma in children  low-grade upper tract urothelial carcinoma  low-intensity chemotherapy  low-intensity regimens  Low-PV study  low-risk BD-IPMNs  low-risk CRC symptoms  low-risk prostate cancer  low-risk PTC  low-volume mHSPC  lower extremity lymphedema  lower-risk MDS  lower-risk myelodysplastic syndromes  LP  LPHL  LPL  LPPG  LPS  LR-HL  LRBC  LRC  LRR  LS  LS SCLC  LS-SCLC  LSCC  LTL  LTLD  Lu-177 for metastatic castration-resistant prostate cancer  LUAD  LUME-Meso studie  luminal B  luminal B breast cancer  lumpectomy for early breast cancer  LUN 14-179 study  LUNA-studie  lung adenocarcinoma  lung adenocarcinoma brain metastases  lung adenocarcinoma with CNS metastases  lung and colorectal cancer  lung cancer  lung cancer incidence in young women versus young men in 40 coutnries  lung cancer mortality  lung cancer resection  lung cancer risk  lung cancer screening  lung cancer screening efficacy  lung cancer surgery  lung cancer survival  lung cancer survivors  lung nodule progression to cancer  lung squamous cell carcinoma  Lung-MAP SWOG S1400  LUNGSTAR  LuPSMA  LuPSMA-studie  lurbinectedin  lurbinectedine  luspatercept  lutathera  lutetium-177 PSMA-617 versus cabazitaxel  lutetium-177-PSMA-616  lutetium-177-PSMA-617  LUX-Lung 8 trial  LUX-Lung3; LUX-Lung6  LV-V5  LY3039478  LY3127804 with or without ramucirumab  lycopeen  LYM-3002  LYM-3002 study  LyMa-101 study  lymfadenectomie  lymfekliermetastasen  lymfeklierpositiviteit  lymfoblastisch non-Hodgkin lymfoom  lymfocyten  lymfocyteninfiltratie  lymfoedeem  lymfoïde neoplasie  lymfoom  lymph node burden  lymph node macrometastases  lymph node metastasis  lymph node ratio  lymphadenectomy  lymphatic versus hematogneous dissemination  lymphaticovenous anastomosis  lymphedema  lymphocyte doubling time in CLL  lymphoid blast phase of CML  lymphoma  lymphoma patients aged ≥85 years  Lymphome Malin de Burkitt chemotherapy  lymphopenia  lymphoscintigraphy  Lynch syndrome  Lynch syndrome associated cancers  lynch syndroom  Lynch syndrooom  LYRA study  M-trap  MA.17R  MA.17R-studie  MA.27  maag maag-slokdarmovergangkanker  maag-slokdarmadenocarcinoom  maagadenocarcinoom  maagcarcinoom  maagkanker  MaBC  MabEase-studie  MABLE-studie  MACBETH-studie  machine-learning-directed clinical evaluation of RT and CRT patients  MACRO2 TTD study  MAESTRO study  Magee Equation 3  MAGIC-studie  magnesium  magnesiuminname  MAIA study  MAIA trial  main-duct intraductal papillary mucinous neoplasms  maintenance  maintenance pembrolizumab after first-line chemotherapy  maintenance rituximab  maintenance therapy  maintenance treatment  maintenance with or without pembrolizumab  maitenance chemotherapy  MAJA study  MAJA-studie  major head and neck surgery  MALDI-MS  male BRCA mutation carriers  male breast cancer  male excess risk of advanced colorectal neoplasms  male germ cell cancer treatment  male pattern baldness  male sex disease-specific mortality  MALE study  male-pattern baldness  malignant glioma  malignant melanoma  malignant mesothelioma  malignant pleural disease  malignant pleural effusion  malignant pleural mesothelioma  maligne ascites  maligne glioom  maligne pleura mesothelioom  maligne pleuraal mesothelioom  Malmö Breast Tomosynthesis Screening Trial  Malmö Diet and Cancer Study  malnutrition in older adults with gastrointestinal malignancies  MALT lymfoom  MALT-IPI  MALT-lymfoom  mamacarcinoom  mammacarcinoom  mammacarcinoom in mannen  mammacarcinoom mannen  mammacarcinoom; SABCS 2015  mammacarcinoom. lichaamsgewicht  mammacarcinoomscreening  mammacarcinooom  mammacarcionoom  mammacarcioon  MammaPrint  MammaPrint-assay  mammografie  mammografiescreening  mammographic microcalcifications and breast cancer risk  mammographic surveillance in young women  mammography  mammography breast cancer screening in high-risk males  mammography screening  MAN  management and outcomes  managing oral complications of oral cavity and oropharyngeal cancer  MANHATTAN trial  mannen  Mannuci  mantelcellymfoom  mantle cell lymphoma  MAPS IFCT-GFPC-0701 study  MAPS2-studie  MARCH  margetuximab  margetuximab plus pembrolizumab  marginaal zone lymfoom  marginal zone lymphoma  MARIANNE study final results  MARIE study  MARIE-cohort  marihuana  marijuana use  marital status  marizomib  marker borstkanker  MARQUEE study  MARS mutation-adjusted risk score  masitinib  MasSpec Pen  mastectomie  mastectomy versus lumpectomy plus RT  matched sibling donor transplantation  matched sibling transplantation  matched therapy  maternal and fetal outcomes  maternal breast cancer risk  MATISSE-studie  MATRix induction  matrix metalloproteïnase-8  mature B-cell malignancies  MAVORIC study  MAVORIC-studie  MaxRP  MaxRT  MBC  MBC with high TMB  MBI  MBL  MBMs  MCC  MCC-Spain follow-up study  MCL  MCL in older patients  mCRC  mCRC extremes of survivorship  mCRC with response or stable disease with 16 weeks first line treatment  mCRPC  mCRPC in DDRmut patients  mCRPC with or without PTEN-loss  mCSPC  MD  MDS  MDS and sAML  MDS or AML  MDS-EB-1 or EB-2  MDTB  meat consumption  meat intake  mebendazol  mechanisms of resistance to BRAF-targeted therapy  MED10562  MEDALIST study  median 15.7 years follow-up  mediating factors  mediation analysis of racial disparities  medical decision-making capacity  medication interactions  medication-related osteonecrosis of the jaw  MEDIOLA study  medische marihuana  mediterrane voeding  medium-sized brain metastases  medium-throughput drug screening  MEDOCC  medullair schildkliercarcinoom  medullair thyroïdcarcinoom  medulloblastoma  medulloblastoma subgroups  medulloblastoom  meeroken  MEI  MEK- plus AKT-remming  MEK-remmers  MEK-remming  Mel-Ipi-Rx study  melanoma  melanoma brain metastases  melanoma brain metastasis  melanoma in adolescents and young adults  melanoma in children and adolescents  Melanoma Institute Australia nomogram  melanoma of unknown primary  melanoma with rare BRAF mutations  melanoom  melanoom-geassocieerde leucoderma  melanoom-mortaliteit  melanoomrisico  melatonin after lung cancer resection  melatonine  MelBase French cohort  melfalan  melflufen plus dexamethasone  melkconsumptie  men with germline BRCA1 and BRCA2 pathogenic variants  MEN1  Mendelian randomisation analysis  Mendelian randomization study  meningioma  meningioma risk factors  meningioom  menopausal hormone therapy  menopausal hormone therapy options  menopauzale hormoontherapie  mental health  mental health disorders  mental health of mothers and siblings  mental health resource use  mentale stoornis  Merkel celcarcinoom  Merkel cell carcinoma  Merkelcelcarcinoom  MESCC  mesothelin-targeted CAR T cells  mesothelioom  mestcel-neoplasmata  MET exon 14 altered lung cancer  MET exon 14-altered NSCLC  MET exon 14-mutated or MET-amplified NCSLC  MET-amplificatie  MET-driven metastatic papillary RCC  meta-analysis  meta-analysis of outcomes  meta-analysis of studies of immunotherapy for NSCLC  metabole gezondheid  metabolic dysregulation  metabolic health  metabolic syndrome  metabolic syndrome biomarkers  metabool syndroom  metachronous contralateral testicular cancer  MetaPHER study  metastase  metastasectomie  metastasering  metastasevrije overleving  metastasis sites  metastasis-directed therapy  metastasis-free interval  metastatic brain tumors  metastatic breast cancer  metastatic breast cancer in BRCA-mutated patients  metastatic breast cancer in geriatric patients  metastatic cancer  metastatic cardiophrenic lymph nodes  metastatic castration resistant prostate cancer  metastatic castration-resistant prostate cancer  metastatic castration-sensitive prostate cancer  metastatic clear cell RCC  metastatic colorectal cancer  metastatic colorectal cancer cetuximab plus FOLFOX-4  metastatic colorectal cancer in older vulnerable patients  metastatic CRC and other solid tumors with KRAS G12C mutation  metastatic EGFR-mutated NSCLC after TKI failure  metastatic endometrial cancer  metastatic esophagastric cancer  metastatic esophageal cancer  metastatic esophagogastric adenocarcinoma  metastatic esophagogastric cancer  metastatic gastric cancer  metastatic gastric or gastroesophageal junction cancer  metastatic gastric or junctional adenocarcinoma  metastatic gastrointestinal stromal tumors  metastatic gastrointestinal tract cancer  metastatic HER2-positive breast cancer  metastatic hormone sensitive prostate cancer  metastatic hormone-sensitive prostate cancer  metastatic intrahepatic cholangiocarcinoma  metastatic melanoma  metastatic melanoma after ICIs and targeted agents  metastatic melanoma and NSCLC  metastatic Merkel cell carcinoma  metastatic MSI-H dMMR CRC  metastatic mucosal melanoma  metastatic nasopharyngeal carcinoma  metastatic non-small cell lung cancer  metastatic non-squamous NSCLC  metastatic nonseminomatous germ cell tumors  metastatic nonsquamous NSCLC  metastatic osteosarcoma  metastatic pancreatic adenocarcinoma  metastatic pancreatic cancer  metastatic pancreatic ductal adenocarcinoma  metastatic papillary renal cell carcinoma  metastatic papillary thyroid cancer  metastatic prostate cancer  metastatic renal cell carcinoma  metastatic seminoma  metastatic soft tissue sarcoma in patients aged 60 years or older  metastatic spinal canal compression  metastatic squamous cell carcinoma of head and neck  metastatic squamous NSCLC  metastatic triple-negative breast cancer  metastatic urothelial carcinoma  metastatic uveal melanoma  metastatisch castratieresistent prostaatcarcinoom  metastatisch cervixcarcinoom  metastatisch colorectaalcarcinoom  metastatisch colorectaalkanker  metastatisch colorrectaalcarcinoom  metastatisch heldercellig niercelcarcinoom  metastatisch maagcarcinoom  metastatisch mammacarcinoom  metastatisch melanoom  metastatisch niercelcarcinoom  metastatisch niet-castratieresistent prostaatcarcinoom  metastatisch pancreas ductaal adenocarcinoom  metastatisch pancreascarcinoom  metastatisch PDAC  metastatisch potentieel  metastatisch prostaatcarcinoom  metastatisch squameus celcarcinoom van hoofd en hals  metastatische borstkanker  metastatische botziekte  metastatische castratieresistente prostaatkanker  metastatische colorectaalkanker  metastatische niet-kleincellige longkanker  metastatische prostaatkanker  metastatische triple-negative borstkanker  METEOR  METEOR-studie  METex14-positive pulmonary sarcomatoid carcinomas and other NSCLC-subtypes  metformin  metformin plus CRT  metformin plus irinotecan  metformin use  metformine  methionine  methotrexate neurotoxicity  metronome chemotherapie  metronomic eribulin  metronomic methotrexate-celecoxib-erlotinib  metronomic oral vinorelbine plus trastuzumab  METROS study  MF  mFOLFOX6  mGCT  mGEA after progression on ICI  MGMT promoter methylation  MGPT  MGUS  MHD  mHNSCC  mHSPC  MHSs  MHT  MIBC  MIC-1  microductectomy  microRNA-203  microRNA-371a-3p test  microRNA-classifier  microRNAs  microsatelliet-instabiele kanker  microsatellite instability  microsatellite instability-high gastric or gastroesphageal junction cancer  microsatellite instability-high mCRC  microsatellite-instability-high advanced CRC  microwave ablation  middel-heupomtrekverhouding  middelomtrek  middelomvang  middle low rectum versus left-sided colon  middle-aged and older adults  midgut NETs  migraine  migratie naar hersenparenchym  MILD trial  MILES-3  MILES-4  Miller-Payne score  million women study  MILO ENGOT-ov11 study  MILS  MIMOSA-1 study  MINDACT  mindfulness  mindfulness-based cognitive therapy  mini-mental state examination  minimal residual disease  minimally invasive robotic surgery  minimally invasive versus open radical hysterectomy  minimally invasive versus open surgery  mipsagargin  MIPSS70  miR-126  miR-190b  miR-34  miR-345  miR-506  mirdametinib (PD-0325901)  miRNA  miRNAs  MIRO trial  MIRO-studie  mismatch repair deficient small bowel adenocarcinoma  mismatch repair status  Mitchell  MITCI-studie  MITO-8 studie  MITO-9 study  mitomycin C  mitosesnelheid  mitotische activiteitsindex  mitoxantrone  MIUC  mivebresib with or without venetoclax  MK-2206  MK-3475  MK-4166 with or without pembrolizumab  MK-6482  MLBO  MM  MM and AL amyloidosis  MM-302  mMCC  MMR  MMR-D noncolorectal cancers  MMR-deficiency  MMR-deficiëntie  MMRd  MMSE  mNPC  mNSCLC  mNSCLC in patients aged 80 years and over  mNSCLC with PD-L1 TPS≥50%  mNSCLCwith PD-L1 tumor proportion score ≥ 50%  MNTX  mode of detection  mode of progression  model for predicting acute complications after surgery for breast cancer  moderately hypofractionated helical IMRT  moderately hypofractionated IMRT  modern chemotherapy  modern treatments for newly diagnosed lymphoma  modifiable risk factors for early ET discontinuation  mogamulizumab  Mohs micrographic surgery for T1a-T2a invasive melanoma  Mohs surgery versus wide margin excision  moleculaire subtypen  moleculaire tumormarkers  molecular analysis  molecular classification  molecular markers of prognosis  molecular markers of recurrence  molecular pahtological subtypes and pathways  molecular profiling  molecular profiling for assessment of distant metastasis risk  molecular recurrence  molecular relapse detection  molecular risk stratification  molecular subtype  molecular subtypes  molecular subtypes of breast cancer  Molina  MONALEESA studies exploratory analysis  MONALEESA-2 studie  MONALEESA-3 OS analysis  MONALEESA-3 overall survival analysis  MONALEESA-7 studie  MONALEESA-7 trial  MONARCH 1  MONARCH 1-studie  MONARCH 2 study  MONARCH 2-studie  MONARCH 3-studie  monarchE study  monarcHER trial  mondholte squameus celcarcinoom  mondholtecarcinoom  mondhygiëne  mondkanker  monoclonal antibody combined with induction chemotherapy  monoklonale B-cel lymfocytose  montelukast and rupatadine premedication  Moore-criteria  MOR202  morcellatie  mortaliteit  mortaliteit colorectaalcarcinoom  mortaliteit na kankerdiagnose  mortality  mortality after breast cancer  mortality and chronic health conditions  mortality and overall survival trends  mortality as function of age  mortality due to cancer treatment delay  mortality from unrelated causes  mortality prediction by Oncotype DX  mortality risk  mortality trends  mortalteit  MOSAIC  MOSAIC trial post hoc analysis  moxetumomab pasudotox  mPCa  mPDAC  MplBC  MPM  MPN  MPNs  MPNs treated during pregnancy  MPR  mRCC  mRCC histologic varants  MRCLS  MRD dynamics  MRD-status  MRD-stratified treatment  mRECIST objecte response  MRI  MRI background parenchymal enhancement  MRI of ultrasonography for prostate concer screening  MRI plus targeted biopsy versus systematic biopsy alone  MRI staging of breast camcer  MRI versus conventional endoscopy  MRI-FIRST study  MRI-guided adaptive brachytherapy  MRI-guided biopsy to verify pCR  MRI-guided or standard biopsy  MRI-screening  MRI-screening mammacarcinoom  MRI-targeted versus systematic versus combined biopsy  MS2010 study  MSC  mSCLC  MSE  MSG-carcinomen  MSI  MSI-CRC  MSI-H dMMR gastrointestinal tumors  MSI-H dMMR mCRC  MSI-H mCRPC  MSLCs  MSLT-II studie  mss CRC  MT-GCT  MTC  mtDNA  MTH1-remmers  MTL-CEBPA  mTNBC  mTOR-remmer  mTOR-remmers  mUC  mUC and other genitourinary tumors  mUC in patients with renal insufficiency or mixed variant histology  mUC progressing after chemotherapy and ICIs  MUC16 mutations  mucosaal melanoom  mucosalaesies  mucositis  mucositispijn  mulitpel myeloom  Müllerian carcinoom  multi-antigen targeted T cells  multi-cancer detection and localization  multi-gen panel testing HBOC  multidisciplinary salvage treatment  multidrugresistentie  Multiethnic Cohort  multigene testing for all patients  multikinase inhibitors  multimodal therapy  multimodality management  multinational post registration study of nivolumab  multipel myeloom  multipel myeloom. KTd  multipele endocriene neoplasie  multiple brain metastases  multiple foci of microinvasion  multiple myeloma  multiple myeloma refractory to CD38 MoABs  multiple myeloma survival  multiple primary melanoma incidence  multiple sclerosis  MULTOMAB study  MURANO study  MURANO study 4-year results  MURANO-studie  muscle mass  muscle radiodensity  muscle-invasive bladder cancer  musculoskeletal burden  mutatiescreening  mutatievolgorde  mutation burden  mutation clearance  mutation profiling  mutation status and prognosis  mutation-enhanced prognostic system  mutational profile  mutational signature in colorectal cancer  mutations in cancer-associated genes  mutations in cancer-related genes  mutations in homologous recombination-related genes  mutp53 proteins  muziektherapie  MVAC  MVI  MVPA  MYC  MYC deregulated cancers  MYC rearrangement and translocation partner  Myc-remming  MYCN  mycobacterial infections  mycosis fungoides  myelodysplasie  myelodysplastic syndrome  myelodysplastic syndromes refractory to hypomethylating agents  myelodysplastisch syndroom  myelodysplastisch syndroom myeloproliferatieve neoplasmen  myelodysplastische syndromen  myelofibrose  myelofibrosis  myeloid cancers  myeloid malignancies  myeloïde neoplasie  myeloma  Myeloma X trial  Myeloma XI study  myeloom  myelopreservation with trilaciclib  myeloproliferatieve neoplasmen  myelosuppression with chemotherapy for extensive-stage SCLC  MYL-14010  myocarditis  myomectomie  MyPathway study  MyPathway-studie  MYSTIC study  myxoid liposarcoma  MZL  n-3 fatty acids  N-cadherine  N1087-studie  N2-3 breast cancer  N3 stage IIIB NSCLC in elderly patients  NA-PHER2 studie  Naakte molrat  nab-paclitaxel  nab-paclitaxel plus gemcitabine  nab-paclitaxel plus gemcitabine plus cisplatin  nab-paclitaxel versus paclitaxel  nabiximols oromucosal spray  NABON Breast Cancer Audit  NAC  nachtarbeid  NACT  NACT and IDS with or without HIPEC  NACT versus PCS  NACT-induced immune microenvironment changes  NADIM study  nadofaragene firadenovec  naevi  NALA study  NALA study health-related quality of life analysis  NALA trial  nanoparticles  nanotechnologie  NAPOLI-1 study  NAS  nasofarynxcarcinoom  nasopharyngeal cancer  nasopharyngeal carcinoma  nasopharyngeal carcinoma early detection  National Breast and Cervical Cancer Early Detection Program  National Cancer Data Base  National Cancer Database analysis  National Institute for Health and Care Excellence  National Lung Cancer Screening Trial secondary analysis  natriumthiosulfaat  natural history and prognostic factors  natural killer  natural killer T-cel lymfoom  NAVIGATOR trial  NBTXR3  NC-6004  NCCN-richtlijnen  NCDB analysis of immunotherapy in resected stage III melanoma  NCDB analysis of use of mastectomy for DCIS in young women  NCGA  NCGC  NCI 8628  NCI-CONNECT  NCI-Maryland Case Control Study  NCI-MATCH study  NCI-MATCH subprotocol EAY131-Y  NCI-MATCH trial  NCI-Match Trial E131-Y  NCI-MATCH trial subprotocol H  NCI9673  NCIC CTG MA.27-studie  NCM  NCSLC  NCTN study S1001  ND- or R R-AML  NDMM  NDMM in transplant-ineligible patients  near real-time intraoperative brain tumor diagnosis  NEC study  NECC  necitumumab  nectin-4-positive solid tumors  negative colonoscopy  negative for intraepithelial lesions or maligancy  negative thyroid biopsy  NEJ009 study  nelarabine  nelfinavir plus chemoradiotherapy  nelfinavir with concurrent chemoradiotherapy  NELM  NELSON study  NELSON-studie  NEMO  NENs  neoadjuvant and adjuvant chemotherapy  neoadjuvant and adjuvant pembrolizumab  neoadjuvant anti-HER2 therapy for HER2-positive breast cancer  neoadjuvant apatinib plus chemotherapy  neoadjuvant aspirine  neoadjuvant atezolizumab  neoadjuvant atzolizumab plus chemotherapy  neoadjuvant bevacizumab  neoadjuvant CAPOX plus radiotherapy  neoadjuvant carboplatin plus docetaxel  neoadjuvant carboplatin with or without anthracycline  neoadjuvant chemoradiation  neoadjuvant chemoradiotherapy  neoadjuvant chemotherapie  neoadjuvant chemotherapy  neoadjuvant chemotherapy for breast cancer  neoadjuvant chemotherapy for early breast cancer  neoadjuvant chemotherapy for ovarian cancer  neoadjuvant chemotherapy plus durvalumab  neoadjuvant chemotherapy plus nivolumab  neoadjuvant CRT  neoadjuvant CRT plus atezolizumab  neoadjuvant CRT versus CT  neoadjuvant CRT with UGT1A1 status guided irinotecan dose  neoadjuvant dual checkpoint blockade  neoadjuvant durvalumab  neoadjuvant endocrine therapy  neoadjuvant endocrine versus chemotherapy  neoadjuvant erlotinib  neoadjuvant FOLFIRINOX  neoadjuvant FOLFIRINOX or gemcitabine plus nab-paclitaxel  neoadjuvant gemcitabine plus S-1  neoadjuvant ICI  neoadjuvant immune checkpoint blockade  neoadjuvant immunoradiotherapy  neoadjuvant immunotherapy  neoadjuvant lapatinib plus trastuzumab without chemotherapy  neoadjuvant larotrectinib  neoadjuvant mFOLFIRINOX and postoperative gemcitabine  neoadjuvant nab-paclitaxel  neoadjuvant nivolumab  neoadjuvant nivolumab plus chemotherapy  neoadjuvant nivolumab plus ipilimumab  neoadjuvant nivolumab with or without ipilimumab  neoadjuvant pembrolizumab  neoadjuvant pembrolizumab plus HDI  neoadjuvant pertuzumab  neoadjuvant plus adjuvant erlotinib  neoadjuvant radiotherapy  neoadjuvant ribociclib-letrozole versus chemotherapy  neoadjuvant SABRT  neoadjuvant single or dual HER2 blockade  neoadjuvant sintilimab  neoadjuvant systemic therapy  neoadjuvant T-DM1  neoadjuvant T-DM1 plus lapatinib plus paclitaxel  neoadjuvant talazoparib  neoadjuvant TCHP  neoadjuvant therapy  neoadjuvant therapy for breast cancer  neoadjuvant trastuzumab emtansine plus pertuzumab  neoadjuvant trastuzumab plus pertuzumab  neoadjuvant treatment  neoadjuvant zoledronic acid  neoadjuvant-treated breast cancer  neoadjuvante chemotherapie  neoadjuvante CRT  neoadjvuant systemic therapy  NeoALTTO  NeoCombi study  neonatal inflammatory markers  neonatal phototherapy  NeoPAL study  NeoPalAna  neoplasm detection in upper gastrintestinal tract  neoplasm risk  neopterine  NeoSTOP study  NEOZOTAC trial  nephrectomy  nephrotoxicity  neratinib  neratinib for HER2-positive breast cancer  nercelcarcinoom  NET  NET liver metastases  NET versus NACT  NETs  network meta-analysis of first-line treatments  network meta-analysis of regimens  network meta-analysis of treatments  neurale invasie  neuro-endocrien carcinoom  neuro-endocriene neoplasmen  neuro-endocriene tumoren  neuroblastoma  neuroblastoom  neurocognitie  neurocognition  neurocognitive function  neurocognitive problems  neurodegenerative outcomes  neuroendocrine prostate cancer  neuroeondocriene tumoren  neurofibromatose  neurofibromatose 1  neurofibromatosis type 1  neurofibromatosis type 1-related plexiform neurofibromas  neurologic disorders  neuropathie  neuropsychiatric functioning  neuropsychological outcomes  neutrofiel lymfocyt-ratio  neutrofiel-lymfocyt ratio  neutropenie  neutrophil to lymphocyte ratio  neutrophilia  never-smoker lung adenocarcinoma patients  New EPOC trial  new treatment options  new-generation BCR-ABL TKIs versus imatinib for CML  newly diagnosed AML in elderly patients  newly diagnosed AML with IDH1-mutation in elderly patients  newly diagnosed APL  newly diagnosed average-risk medulloblastoma in children  newly diagnosed cancer patients  newly diagnosed CML  newly diagnosed DLBCL  newly diagnosed early NK T cell lymphoma  newly diagnosed endometrial cancer  newly diagnosed glioblastoma  newly diagnosed low-burden metastatic prostate cancer  newly diagnosed multipel myeloma  newly diagnosed multiple myeloma  newly diagnosed multiple myeloma in frail patients  newly diagnosed multiple myeloma in transplant-ineligible patients  newly diagnosed or relapsed multiple myeloma  newly diagnosed stage III IV ovarian cancer in vulnerable patients  newly diagnosed stage IV squamous cell lung cancer  newly diagnosed T-ALL  newly diagnosed transplant-ineligible multiple myeloma  newly-diagnosed multiple myeloma  next-generation BRAF inhibitor PLX8394  next-generation flow cytometry for assessing measurable residual disease  next-generation sequencing  next-generation sequencing detected MET amplification  next-generation sequencing of ctDNA  NF1  NF1 mutations  NF1-related PNs  NF106 trial  NF2  NFκB  NGS  NHANES III analysis  nHL  NHL in AYAs  NHL subtypes in Sweden 2000-2016  NHL-001 study  NHS  NIBIT-MESO-1 studie  nice-or-naughty theorie  NICHE study  nicotine  niercarcinoom  niercelcarcinoom  niercelkanker  nierfunctie  niet-cervicale anogenitale maligniteit  niet-chirurgische behandeling  niet-invasief prenataal testen  niet-kelincellig longcarcinoom  niet-kleincellg longcarcinoom  niet-kleincellig longcarcinoom  niet-kleincellige longkanker  niet-melanoom huidkanker  niet-seminomateus testiscarcinoom  niet-squameus niet-kleincellig longcarcinoom  nieuw logo  Nieuw-Zeeland  NIFTP  night shift work  NIH-AARP  NIH-AARP cohort  NIH-AARP Diet and Health study  NIH-AARP Diet and Health Study prospective cohort  NIH-AARP Diet and Health Study; alcohol consumption  Nijmegen breakage syndrome  NILM  NiloPeg  nilotinib  nimotuzumab  nimotuzumab plus concurrent CRT  nintedanib  nipple-sparing mastectomy  NIPPON DATA 80  niraparib  niraparib after response to chemotherapy  niraparib maintenance  niraparib plus pembrolizumab  nitraat  nitriet  NIVAHL trial  nivolumab  nivolumab and AVD  nivolumab for advanced cancer  nivolumab for metastatic renal cell carcinoma  nivolumab for NSCLC  nivolumab plus cabozantinib  nivolumab plus gemcitabine and cisplatin  nivolumab plus ipilimumab  nivolumab plus ipilimumab and radiotherapy  nivolumab plus ipilimumab for NSCLC with brain metastases  nivolumab plus ipilimumab versus sunitinib  nivolumab plus ipilimumab with or without local therapy  nivolumab plus SBRT  nivolumab versus bevacizumab  nivolumab versus nivolumab plus ipilimumab  NIVOREN study  NK  NLCS  NLPHL  NLR  NLR as prognostic factor  NMA of treatment options  nmCPRC  nmCRPC  NMIBC  nmPrCa  NMR  NMSC  NMSC-ASE  NMSIs  NNAL  no evidence of increased breast cancer risk  NO16968  NO2  NOA-07 studie  NOA-08 study  NOCCA study  nodal PTCL  node-positive breast cancer  node-positive HER2-positive breast cancer  node-positive HR-positive HER2-negative breast cancer  node-positive melanoma  node-positive vulvar cancer  node-postive HR+ HER2-breast cancer with RS≤25  nodulair lymfocyt-predominant Hodgkin lymfoom  nodular desmoplastic medulloblastoma in young children  NOM  nomogram for individualized prediction of survival  nomogram for predicting mortality  nomogram to estimate individualized overall survival  nomograms to predict outcomes  Non Core Binding Factor AML  non-adherence to aromatase inhibitors  non-alcoholic fatty liver disease  non-engineered multi-antigen specific T cells  non-germinal center B-cell DLBCL  non-germinal center B-cell like diffuus grootcellig B-cel lymfoom  non-Hodgkin lymfoom  non-Hodgkin lymphoma  non-inferioriteits fase 3-studie AXEPT  non-melanoma skin cancer  non-metastatic castration-resistant prostate cancer  non-metastatic castration-resistant prostate cancer in older men  non-muscle-invasive bladder cancer  non-muscle-invasive bladder cancer unresponsive to BCG  non-relapse mortaliteit  non-RMS soft tissue sarcoma in patients younger than 30 years  non-seminoom testikelkanker  non-small cell lung cancer  non-small cell lung cancer brain metastases  non-small cell lung cancer surgery  non-small cell lung cancer with MET exon 14 skipping mutations  non-specific symptoms and signs of cancer  non-squamous metastatic non-small cell lung cancer  non-squamous non-small cell lung cancer  non-V600 BRAF mutations  nonadherence  nonadherence to cancer screening  nonaspirin NSAIDs  noncancer mortality  noncolorectal dMMR MSI-H cancers  noncutaneous and cutaneous cancer risk  nonelderly adult cancer survivors  nonfunctioning pituitary adenomas in elderly patients  nongerminomatous malignant germ cell tumors  nonhereditary breast cancer  noninferiority phase 3 study HYPO-RT-PC  noninvasive prediction of occult peritoneal metastasis  nonmelanoma skin cancer  nonmetastatic breast cancer  nonmetastatic NPC  nonmetastatic prostate cancer  nonmetastatic retroperitoneal sarcoma  nonmetastatic unfavorable-risk prostate cancer  nonmetastic castration-resistant prostate cancer  nonoropharyngeal squamous cell carcinoma  nonpancreatic neuroendocrine tumors  nonsquamous NSCLC  nonverbale communicatie  Noorwegen  NOP10  NOPHO ALL2008 protocol  NOPHO ALL2008 study  NORCCAP-studie  Nordic BRCA2 mutation carriers  Nordic Lymphoma Group  NORDIC9 study  not previously treated mNSCLC  not transplant-eligilbe MM  notifying GPs regarding nonadherence to FIT screening  novel treatment sequences for transplant-ineligible MM patients  NOx  NPC  NPM1-gemuteerde AML  NPM1-mutated AML  NRAS-mutatie  NRAS-mutaties  NRF2 expression  NRG Oncology CC001 trial  NRG Oncology RTOG 0617 study  NRG Oncology RTOG 1203  NRG Oncology RTOG studie 0621  NRG-GY003  NSABP B-28 studie  NSABP B-31 study  NSABP B-40  NSABP B-41 neoadjuvant trial  NSABP B-42  NSABP B-42 study  NSABP FB-10 trial  NSAID  NSAID use  NSAID-gebruik  NSAIDs  NSCLC  NSCLC after EGFR TKI  NSCLC after PD-1 PD-L1 blockade  NSCLC BMs  NSCLC brain metastases  NSCLC brain metastasis  NSCLC in patients with interstitial lung disease  NSCLC in performance status 2 patients  NSCLC in postmenopausal women  NSCLC progressing on various EGFR TKIs  NSCLC refractory to second-generation ALK inhibitor  NSCLC with ALK or ROS1-rearrangement  NSCLC with brain metastases  NSCLC with high PD-L1 expression  NSCLC with uncommon EGFR mutations  NSCLC; linifanib  NSGCT  NSM  nsq NSCLC  nsq-NSCLC  nsqNSCLC  NTD-Haplo versus SUCBT  NTP  nucleaire installaties  nuclear ZEB2 expression  number of doses  Nurses' Health Study  Nurses’ Health Studies  Nurses’ Health Study  Nurses’ Health Study I and II  Nurses’ Health Study II  nursing home residents  nut consumption  nutrient intake  NutriNet-Santé cohort  NutriNet-Santé prospective cohort  NutriNet-Santé studie  NutriNet-Santé study  nutritional status  NVALT19 trial  NWAS  NWTS-5  O E incidence ratios of second malignant neoplasms  OA-MCL  OAC  OAC for AF  OAK  OAK and POPLAR trials  OAK-studie  obesitas  obesitasparadox  obesity  obesity paradox  obesity-related cancer trends  obinutuzumab  obinutuzumab plus DHAP  obinutuzumab plus lenalidomide  observation versus SABR  Observationele studie van discontinueren van TKIs voor CML in de Italiaanse klinische praktijk  obstetric and maternal outcomes  obstetric outcomes  OCC  OCCC  occult breast cancer  occulte kanker  occupational variation  OCSCC  octagenarians compared to younger patients  ocular toxicity of bortezomib  ODM-201  odontoom  ODXRS  oedeem  oesofagaal squameus celcarcinoom  oesofagastrische tumoren  oesofagectomie  oesofagogastrisch adenocarcinoom  oesofagus squameus celcarcinoom  oesofagusadenocarcinoom  oesofaguscarcinoom  oesofaguskanker  oesophageal cancer  oesophageal squmous cell carcinoma  oestradiol  oestrogeengebruik  oestrogeenreceptor  oestrogeensuppressie  ofatumumab  offspring donors versus HLA-matched siblings  offspring of survivors of childhood or adolescent CNS tumors  ofranergene obadenovec  OGC  OHERA study  Okayama Lung Cancer Study Group Trial 1404  olanzapine  olaparib  olaparib maintenance  olaparib monotherapy  olaparib plus bevacizumab maintenance  olaparib plus cetuximab and IMRT  olaparib plus durvalumab  olaparib plus temozolomide combination  olaratumab  older adults receiving cancer chemotherapy  older adults with blood cancer  older adults with cancer  older breast cancer patients with high recurrence scores  older cancer patients  olfactorisch neuroblastoom  oligometastase  oligometastatic cancer  oligometastatic cancers  oligometastatic non-small cell lung cancer  oligometastatic NSCLC  oligometastatic oligoprogressive NSCLC  oligometastatic prostate cancer  OLIVIA  olmutinib  OlympiA trial  OlympiAD-studie  OLYMPUS study  OM-CRC  omacetaxine mepesuccinate  omalizumab  omega 3-vetzuren  OMEGA offspring cohort  omission of dexamethasone  on-target adverse events  on-target ALK resistance mutations  ONC201  once weekly selinexor-bortezomib-dexamethasone  once-weekly XVd  oncolytic HSV-1 G207 immunovirotherapy  oncolytisch adenovirus  oncolytische virustherapie  oncoplastische mammoplastie  Oncoscience  Oncotype  Oncotype DX  Oncotype DX DCIS-score  ondergewicht  onderhoudstherapie  ondervoeding  onderzoeksfraude  one versus two doses of Pfizer-BioNTech vaccine for patients with cancer  one week off  ONJ  online predictor of short-term postoperative outcomes  online preview AACR Annual Meeting  ONT-380  ontstaan colorectaalkanker  ontwikkeling resistentie  oogmelanoom  Oost-Afrika  OPAS-1 study  OPC  open resectie  open versus minimally invasive surgery  operable oral and oropharyngeal cT1-T2N0 cancer  operable TNBC  opioid use  opioid use among older cancer survivors  opioid use and toxicity among cancer survivors  opioid-associated mortality in cancer survivors versus general population  opleidingsniveau  OPN  opportuniby costs of receiving palliative chemotherapy  OPSCC  opsoclonus-myoclonus ataxie syndroom  OPTIMA Prelim  optimal adjuvant trearment time  optimal neoadjuvant sequence of anthracyclines and taxanes  optimal RT regime  optimal RT strategy after breast-conserving surgery  optimal sequence of enzalutamide and abiraterone acetate plus prednisone  optimal timing of chemoradiotherap  OPTIMISMM study  optimizing chemotherapy  optimizing patient selection for cytoreductive nephrectomy  OPTION-studie  Opto-RTKs  oraal carcinoom  oraal oncogeen HPV  oral androgen signaling inhiibitos  oral arsenic trioxide  oral azacitidine  oral azacitidine maintenance  oral cancer  oral cavity or oropharyngeal squamous cell carcinoma  oral cavity squamous cell carcinoma  oral contraceptive use  oral endocrine therapy  oral health  oral hydration after cisplatin  oral mucositis after chemoradiotherapy for OCC OPCC  oral mucositis with high-dose chemotherapy and transplanation  oral S-1  orale anticonceptiva  orale contraceptiva  ORALEV study  ORATOR study  ORCA-010  ORCHARRD  orgaantransplantatie  Organ transplant recipients  organ-sparing transanal endoscopic microsurgery  organic food consumption  organische oplosmiddelen  organoids from colorectal peritoneal metastases  orgnnoïdencultures  ORIENT-1 study  ORIENT-12 study  ORIENT-32 study  ORIOLE trial  orofaryngeaal squameus celcarcinoom  orofarynx squameus celcarcinoom  orofarynxcarcinoom  oropharyngeal cancer  oropharyngeal carcinoma in older patients  oropharyngeal HPV infections  oropharyngeal squamous cell carcinoma  ORR and six months PFS as surrogate endpoints for OS  orthopedische oncologie  OS  OS impact of surgical margins larger than 1 cm  OS2006 Sarcome-09 study  OSCC  osimertinib  osimertinib 160 mg  osimertinib combination therapy  osimertinib for advanced T790M-positive and -negative NSCLC  osimertinib for NSCLC  osimertinib plus navitoclax  osimertinib plus savolitinib  OSJ  Oslo 1-studie  OSLO-COMET study  osteonecrose van de kaak  osteopenie  osteopontin  osteoporosis  osteosarcoma  osteosarcoom  ototoxiciteit van chemotherapie  OTX015  outcomes  outcomes after surgery  outcomes by prior treatment at first relapse  outcomes in cancer patients  outcomes of CRT  outcomes of patients treated with CAR T-cell therapy admitted to intensive care  outcomes of primary endocrine therapy  outcomes of rechallenge after high-grade heaptitis  outcomes of risk-reducing total gastrectomy  outcomes of surgery  outcomes of transgender cancer patients in the USA  outcomes of various RIC-NMAC conditioning regimes  outcomes without locoregional treatment  OV21 PETROC  ovarian cancer  ovarian cancer and borderline tumors  ovarian cancer in women aged 65 years and older  ovarian cancer risk  ovarian cancer survival  ovarian cancer survivors  ovarian function  ovarian function suppression  ovarian or endometrial cancer  ovarian removal at or after benign hysterectomy  ovarian stimulation  ovarian tumors  ovariëctomie  ovariumcacrinoom  ovariumcarcinoom  ovariumfunctie  ovariumfunctie-suppressie  ovariumfunctiesuppressie  ovariumkanker  ovariumtumoren  ovariumvolume  OVC  overall and specific cancer risks  overall mortality in men versus women  overall survival  overall survival trend from 2000 to 2019  overall survival-analyse van fase 3-studie ARCHER 1050  overdiagnose  overdiagnosis  overgewicht  overhospitalisatie overlevers  overlevers jeugdkanker  overlevers kinderkanker  overleving  overleving borstkanker  overleving CRC  overleving in Europa  overleving melanoom  overleving oudere patiënten  overweight  oviductcarcinoom  oxaliplatin  oxaliplatin hepatic artery infusion  oxaliplatin-based adjuvant chemotherapy  oxaliplatine  oxybutynin  p16 Ki-67 dual stain and HPV16 18 genotyping  p53  PABC  PACE-B study  PACE-studie  pachymeningeal seeding  PACIFIC study  PACIFIC study post-hoc analysis  PACIFIC trial update  PACIFIC-studie  paclitaxel  paclitaxel for breast cancer  paclitaxel- and oxaliplatin-induced peripheral neuropathy  PACMEL trial  pacmilimab for advanced or recurrent solid tumors  PACT trial  PACT-15 studie  PACT-19 study  PADT  pain and pain interference  pain in older survivors  painful spinal metastases  Painyanitikul  PAKT trial  PALB2 germline mutations  PALB2-mutatie  PALB2-mutaties  palbociclib  palbociclib combination therapy for advanced or metastatic breast cancer  palbociclib plus endocrine therapy  palliatie  palliatieve radiotherapie  PALOMA-1 TRIO-18  PALOMA-2 analyse  PALOMA-3  PALOMA-3 analysis  PALOMA-3 study  PAM50 signature  PAMELA  PAMELA-studie  pamiparib plus tislelizumab  pan-cancer noninvasive detection of MSI and high TMB  pan-RAF remmers  PANACEA study  pancreas  pancreas cancer  pancreas ductaal adenocarcinoom  pancreas-adenocarcinoom  pancreas-ductaaladenocarcinoom  pancreas-MCNs  pancreasadenocarcinoom  pancreascarcinoom  pancreaskanker  pancreatectomie  pancreatic adenocarcinoma  pancreatic cancer  pancreatic cancer risk  pancreatic cystic neoplasms  pancreatic ductal adenocarcinoma  pancreatic fistula  pancreatic head adenocarcinoma  pancreatic NETs  pancreatic neuroendocrine tumors  pancreatic or periampullary tumors  pancreatic-colorectal-stomach cancer  pancreaticoduodenectomie  pancreaticoduodenectomy  pancreaticoduodenectomy for pancreatic cancer  PANFIRE  PANFIRE-2 study  panitumumab  panitumumab versus cetuximab after bevacizumab  panobinostat  PANOPTIMOX-PRODIGE 35 trial  PANORAMA 3 study  PANTHER trial  Panther trial long-term HRQOL  PANVAC  PAOLA-1 study  PAPAGEMO trial  papillair craniofaryngioom  papillair metastatisch niercelcarcinoom  papillair schildkliercarcinoom  papillary neoplasms of the breast  papillary thyroid carcinoma aggressive variants  paraganglioma  paraneoplastisch neurologisch syndroom  parasagittal meningioma  parenthood rates and use of assisted reproductive techniques  parity  Parkinson  PARP inhibitor maintenance therapy  PARP inhibitor treatment  PARP-remmer  PARP1-expressie  partial hepatectomy versus TACE  partial prostate treatment  partial versus whole breast irradiation  particle radiation therapy  particpating in randomized breast cancer study  PAs  passief roken  PASSION trial  PASSOS Heart studie  PATCH trial program  paternity after treatment for testicular germ cell cancer  PATHFINDER study interim analysis  pathogenic germline variants  pathogenic variants in less familiar cancer susceptibily genes  pathogenic variants in RAD51C and RAD51D  pathologic fractures  pathologic stage II nonseminomatous ger cel tumors  pathological complete response  pathological nipple discharge  pathological response to neoadjuvant chemotherapy  pathologically node-negative neck  patient age and progression  patient and diagnostic intervals of sarcoma survivors  patient factors and ratio of basal cell to cutaneous squamous cell carcinoma  patient factors associated with prognosis  patient mortality after surgery on surgeon’s birthday  patient reported outcome  patient reported outcomes  patient reported symptoms  patient volume of oncologist  patient- and clinican-reported  patient- and clinician-reported symptoms during standard RT or IMRT  patient- and hospital-level risk factors  patient-collected versus clinician-collected samples  patiënt-gerapporteerde uitkomsten  patient-reported outcomes  patiëntnavigatie  patients aged 40 years or younger  patients with 4-15 brain metastases  patients with cancer and acute deep venous thrombosis  patients with COVID-19 and solid tumors  patients with hematologic malignancy and other independent cancer  patients with myelofibrosis and anemia  patients younger than 50 years  patterns and survival  patterns of invasive recurrence  patterns of recurrence  patterns of relapse  patterns of relapse after neoadjuvant chemotherapy in clinical practice  patterns of treatment and outcome in The Netherlands  PAVO study  pazopanib  pazopanib plus cetuximab  pazopanib versus doxorubicin  pazopanib with or without gemcitabine  PBC  PBL  PBSO  PBT  PBT versus IMRT  PC  PCa diagnosis  PCD  PCI  PCLO  PCNSL  PCOS  pCR  pCR after NACT  pCR and outcomes by intrinsic subtypes of breast cancer  pCR to NACT  pCR to pertuzumab and trastuzumab  PCS with or without HIPEC  PCSNL  PD-(L)1 blockade for NSCLC  PD-(L)1 inhibitors  PD-(L)1-blockade  PD-1  PD-1 Ab  PD-1 and PD-L1 checkpoint inhibitors  PD-1 and PD-L1 expression in breast cancer  PD-1 and PD-L1 inhibitos  PD-1 blockade  PD-1 blockade for melanoma  PD-1 inhibitor  PD-1 inhibitors for metastatic melanoma  PD-1 inhibitors for mNSCLC  PD-1 PD-L1 inhibitors  PD-1 PD-L1 targeting  PD-1-inhibitor therapy  PD-L1  PD-L1 expression  PD-L1 expression as predictive biomarker  PD-L1 expression as predictive biomarker for EGFR TKIs  PD-L1 negative NSCLC  PD-L1-inhibitor LY3300054  PD-L1-positive advanced NSCLC  PD-L1-positive mTNBC  PD1 inhitiors for NSCLC  PD1-based immunotherapy for melanoma  PDAC  PDGFRA D842V-mutated GIST  PDS  PDT  PEACE randomized trial  PEAK study  pediatric acute leukemia  pediatric ALL  pediatric AML  pediatric and adolescent melanocytic lesions  pediatric and youg adult cancer surivors  pediatric BRAF V600E-mutated glioma  pediatric brain tumor survivors  pediatric cerebral microbleeds  pediatric CT-related radiation exposure  pediatric ependymoma  pediatric germ cell tumors  pediatric hepatoblastoma  pediatric high-grade gliomas  pediatric high-risk medulloblastoma  pediatric locally advanced TRK fusion sarcomas  pediatric low-grade glioma  pediatric medulloblastoma  pediatric neuro-oncology  pediatric neuroblastoma  pediatric or adolescent NHL  pediatric Ph+ ALL  pediatric Ph+ CML-CP  pediatric posterior fossa tumors  pediatric R R ALL  pediatric recurrent ependymoma  pediatric recurrent or refractory CNS tumors  pediatric relapsing high-risk ALL  pediatric spinal cord low-grade glioma  pediatric thyroid cancer incidence and mortality trends  pediatric-style chemotherapy versus alloHCT  pediatrisch ALL  pediatrisch AML  pediatrisch ependymoom  pediatrisch sarcoom  pediatrische AML  pediatrische CNS-tumoren  pediatrische hersentumoren  pediatrische leukemie  pediatrische NETs  pediatrische patiënt-gerapporteerde uitkomsten  pediatrische stamceltransplantatie  PEG  PEG-IFN  pegaspargase versus calaspargase  PEGASUS  PEGASUS-D trial  pegfilgastrim  pegfilgrastim-profylaxe  pegilodecakin  peginterferon alpha-2b  pegteograstim  pelareorep  pelvic fractures and changes in bone mineral density  pelvic radiotherapy  pelvic RT versus IMRT  pembolizumab  pembolizumab plus ipilimumab  pembolizumab with bevacizumab and oral metronomic cyclophosphamide  PEMBRO-RT study  pembrolizmab  pembrolizumab  pembrolizumab activity  pembrolizumab after concurrent CRT  pembrolizumab after locally ablative therapy  pembrolizumab and concurrent CRT  pembrolizumab for advanced melanoma  pembrolizumab for advanced NSCLC  pembrolizumab for advanced prostate adenocarcinoma  pembrolizumab for previously treated mTNBC  pembrolizumab for previously treated PD-L1 positive advanced NSCLC  pembrolizumab for previously untreated  pembrolizumab for solid tumors  pembrolizumab monotherapy for aNSCLC  pembrolizumab plus axitinib  pembrolizumab plus axitinib versus sunitinib  pembrolizumab plus bevacizumab  pembrolizumab plus cetuximab  pembrolizumab plus concurrent chemoradiation  pembrolizumab plus CRT  pembrolizumab plus enzalutamide  pembrolizumab plus GX-188E DNA vaccine  pembrolizumab plus ipilimumab  pembrolizumab plus nab-paclitaxel salvage  pembrolizumab plus NACT  pembrolizumab plus RT after induction chemotherapy  pembrolizumab plus trastuzumab  pembrolizumab versus best supportive care for advanced HCC  pembrolizumab versus brentuximab vedotin  pembrolizumab versus chemotherapy  pembrolizumab versus ipilimumab  pembrolizumab with or without RT  pembrolizumab-etoposide-platinum  pemetrexed and platinum  pemetrexed for lung cancer  pemetrexed plus carboplatin  pemetrexed plus cisplatine  pemigatinib  penta-refractory MM  pepinemab plus avelumab  peptide receptor radionuclide therapy  percent ctDNA  percentage dense area  perception of cancer risk  percutaneous ablation  percutaneous cryoablation  percutaneous IRE  PerELISA neoadjuvant study  PERFECT trial  perfluarinated alkylated substances in serum  performance status ratings in pediatric cancer  pericardial disease  perifeer T-cel lymfoom  perifere neuropathie  perinatal and postnatal exposures  perinatal exposures  perinatal outcomes  periodontale ziekte  perioperative cell-free DNA dynamics  perioperative COX2 and β-adrenergic blockade  perioperative durvalumab and tremelimumab  perioperative dynamic changes in ctDNA  perioperative FLOT versus ECF ECX  perioperative radiotherapy  perioperative trastuzumab plus FLOT  peripheral neuropathy  peripheral T-cell lymphoma  peripheral T-cell lymphoma in elderly patients  perirectal hydrogel spacer  peritoneal mesothelioma  peritoneal metastases from gastric cancer  peritoneale carcinomatose index  peritoneale metastasen  PERSEPHONE trial  PERSIST-1  PERSIST-2 studie  PERSIST-5 trial  persistence of F. nucleatum  persistent acromegaly  persistent febrile neutropenia  persistent postchemotherapy alopecia  persistent radiation-induced alopecia in cancer patients  persistente pijn  personalised versus standard dosimetry  personalized ctDNA as predictive biomarker  personalized ctDNA profiling  personalized neoantigen vaccine monotherapy  PERTAIN study  pertuzumab  pertuzumab plus trastuzumab  peru  PERUSE study  pesticide exposure  PET  PET CT  PET CT for predicting PD-L1 expression  PET-adapted regimen for advanced HL  PET-CT  PET-CT staged localized follicular lymphoma  PET-guided neoadjuvant chemotherapy de-escalation  PET-guided omission of radiotherapy  PET-guided risk adapted treatment  PET-guided therapy  PET-guided treatment  PETAL-studie  PETHEMA GEM2012 study  PETra trial  peulvruchten  pevonedistat  pexidartinib  PF-05280014  PFAS in serum  PFS  PFT  PGC-1α  PGF  PGHD  PGT  PGV frequency  Ph- ALL  Ph-ALL  Ph-like ALL  Ph-negative ALL in adults  Ph-negative ALL in AYAs in first CR  Ph-negative ALL in older patients  Ph-negative CD20-positive B-cell ALL  Ph-positive ALL in adults  Ph+ ALL  phase 1 oncology trials  phase 2 ACCRU study  phase 2 adaptively randomized I-SPY2 trial  phase 2 BENEFIT trial  phase 2 CONTROL trial  phase 2 GEMCAD 1402 study  phase 2 HORIZON trial  phase 2 PEANUT study interim results  phase 2 PETREMAC study  phase 2 study JULIET  phase 3 COSMIC-311 trial  phase 3 EA1131 study  phase 3 FIRE-3 study  phase 3 JAVELIN Gastric 100 study  phase 3 KEYNOTE-062 study  phase 3 MAIA study  phase 3 monarchE study  phase 3 NEJ026 study  phase 3 RESOLVE trial  phase 3 studies supporting FDA approval of cancer drugs  phase 3 study AML08  phase 3 study COMBI-AD  phase 3 study TRAIN-2  phase 3 study TRIBE 2  phase 3 trial RADAR  phase III APROMISS study  phase III IMpower131 study  phase III POLO trial  phase III SUCCESS-A trial  Phc  pheochrmocytoma  pheochromocytoma  PHEREXA-studie  PHERGain trial  Philadelphia chromosome-negative ALL  Philadelphia-negative B-cell ALL  PHILEMON-studie  PHL86 NCI#9322 study  phlebotomy with or without ropeginterferon α-2b  PHOEBE trial  PHOENIX study  photodynamic therapy  PHP-Mel  physical activity  physical activity during adolescence  physican workforce requirements  physicians’ perspectives  PI3K inhibitors  PI3K mTOR-remming  PI3K-signalering  PI3Kδ  PIB  PICN  pictilisib  pigmented skin lesion classification  pIIIA-N2 NSCLC  pijnlijke botmetastasen  PIK3CA  PIK3CA-altered HNSCC  PIK3CA-mutated HR+ ABC  PIK3CA-mutated HR+ HER2- advanced breast cancer  PIK3CA-mutaties  pilaralisib  pilocarpine  pimasertib versus dacarbazine  pimecrolimus  pioglitazon  pirtobrutinib  pituitary macroadenomas  pituitary metastasis  PIVOT-02 study  PIVOT-studie  pixatimod plus nivolumab  PL  placebo adverse events in cancer trials  PLACOL-studie  plaque radiotherapy for uveal melanoma  plasma Epstein-Barr virus DNA  plasma exosomal miRNAs  plasma metabolomic signatures  plasma tumor gene conversions after one cycle of abiraterone acetate